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I
Abstract
Bladder cancer has the highest recurrence rate of any cancer, and as with most solid organ ma-
lignancies, early diagnosis, detection, and treatment are imperative for good clinical outcomes.
Cystoscopy is the cornerstone of bladder diagnostics for real-time visualization of the bladder
mucosa. However, it is an uncomfortable, invasive procedure, and is not without significant risk
and potential complications for the patient. Urine cytology is currently the only non-invasive
diagnostic tool available for the diagnosis of bladder cancer; this method is highly sensitive for
high grade tumours, but has low sensitivity for low grade tumours, which accounts for the ma-
jority of cases. Therefore, there exists a clinical need to develop and integrate a non-invasive,
accurate technique to assist in the diagnosis of bladder cancer.
The combination of Raman micro-spectroscopy and voided urine cytology may provide an
ideal platform to replace cystoscopy for bladder cancer diagnostics. By recording Raman spec-
tra from cells obtained from urine cytology, it is possible to analyse the spectral differences
associated with the biomolecular continuum of disease progression, as well as being able to
classify between different pathological subgroups. Previous studies to date have shown promis-
ing results in the application of Raman based urine cytology; however, there appears a high
degree of variability across experimental protocols, which is believed to have hindered the ad-
vancement of this technique into the clinic.
This thesis involves the design and building of a confocal Raman micro-spectrometer to be
utilised for the analysis of urine cytology samples, with a key emphasis on the translation of
Raman based urine cytology into the clinic. In order to achieve this, a range of traditional proto-
cols and consumables are systematically examined in terms of their compatibility with Raman
micro-spectroscopy, as well as comparing the differences between Raman micro-spectroscopy
and another form of vibrational spectroscopy for bladder and prostate cancer diagnostics. Al-
though no patient urine cytology samples are used in this thesis, simulated samples are gen-
erated using bladder and prostate cell lines along with commercially available synthetic urine.
Additional experimentation is provided in order to investigate the impact of hypoxia and exo-
somal communication on cellular biochemistry.
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Chapter 1
Introduction
Raman spectroscopy is an optical technique based on the inelastic scattering of light, whereby
the scattered light is a different colour to the incident light. This phenomenon was discovered
by Sir C.V. Raman in 1921. (1) Raman spectroscopy has come a long way since the 1920’s,
achieving a surge of enthusiasm over the last decade, with many research groups worldwide
applying this technique for the identification of the minute biomolecular changes associated
with cancer progression. This thesis aims to apply Raman micro-spectroscopy and multivariate
statistical algorithms in order to identify, and therefore diagnose, cancer cells that are present
within a cytology sample.
From a clinical perspective, the primary focus of this thesis is on the diagnosis of bladder
cancer. Bladder cancer is the seventh most common cancer in the UK and Ireland, with around
10,000 people diagnosed every year; the majority of which are diagnosed in males. Bladder
cancer has the highest recurrence rate of any cancer, and it has been reported as the most ex-
pensive malignancy from diagnosis to death for health care systems worldwide, costing the
National Health Service (NHS) in the UK approximately £55 million a year. (2) The American
Urological Association recommends cystoscopic surveillance every 3–6 months for 3 years,
and at least once a year thereafter, particularly for high risk patients; however, cystoscopy is
invasive, involving passing an endoscopic probe through the urethra into the urinary bladder,
which is not without significant risk to the patient. It is also expensive, time consuming, and
can result in patient anxiety and morbidity. Urine cytology is often used as an adjunct to cys-
toscopy; this is where a urine sample is obtained from the patient, and bladder cells that have
naturally shed into the urine are analysed under a microscope by a cytopathologist. However,
the process of isolating and identifying bladder cancer cells from a voided urine sample can
be challenging, particularly for early stage bladder cancers, with diagnostic accuracies as low
as 28% being reported. (3) Furthermore, long waiting lists, which are prominent within public
health care systems, often lead to diagnostic delays, and therefore delays in the management of
the cancer, with resultant poorer outcomes for the patient.
Within this thesis, Raman micro-spectroscopy is applied to cell lines that simulate urine
cytology samples in order to develop an approach for detecting bladder cancer in a completely
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non-invasive manner. If successful, this technique has the potential to revolutionize urological
diagnostics, particularly for patients who are undergoing lifelong cystoscopic surveillance for
bladder cancer. When developing a diagnostic device, it is important to design one that can
be integrated into a busy clinic as efficiently as possible. In order to achieve this, the research
within this thesis focuses on translating Raman micro-spectroscopy into a urology clinic, and is
involved in understanding the needs and demands of such an environment. By systematically
examining a range of consumables, protocols, lasers, and other instrumentation, this project
aims to design and build a Raman system that can analyse the cells obtained from a urine sam-
ple using standard clinical protocols, such as the use of glass slides and common cell preserving
agents, as well as being able to remove any blood cells present within urine. The removal of
blood cells is particularly important as over 90% of patients presenting with bladder cancer
have blood in their urine, and unfortunately blood has a large Raman signal that often hinders
the ability to detect the biomolecular changes associated with cancer in bladder cells. By in-
corporating standard consumables and protocols into a Raman micro-spectroscopy system, the
resultant cost to health care systems could be reduced, as well as allowing for further clinical
tests to be applied to the same patient sample post-Raman acquisition, resulting in an overall
better diagnosis and better patient outcome.
Additional experimentation on the comparison of Raman micro-spectroscopy with Fourier
transform infrared (FTIR) spectroscopy for the classification of bladder and prostate cells ob-
tained from urine cytology is also provided. And finally, Raman micro-spectroscopy is applied
to investigate the impact of hypoxia on cellular biochemistry, and the role of exosomes in cancer
communication.
1.1 Thesis outline
This thesis is intended to be legible to both the biomedical physicist and the clinician, and in
order to achieve that, Chapters 2–5 provide a detailed background on the physics, engineering,
numerical methods, and biology involved in each of the experiments presented throughout this
thesis. A further break-down of the thesis is as follows:
Chapter 2: Raman spectroscopy
Chapter 2 provides information on the physics involved in the Raman scattering process; this
includes classical and quantum physics descriptions of rotational, vibrational, and rotational-
vibrational Raman spectroscopy. The basic components involved in a Raman spectrometer are
discussed, along with an overview of the biomedical applications of Raman spectroscopy. Addi-
tionally, a brief introduction to the physics of FTIR, another vibrational spectroscopy technique,
is provided.
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Chapter 3: Design and building a confocal Raman micro-spectrometer
Chapter 3 presents information on the design considerations required when building a confo-
cal Raman micro-spectrometer; these include the source laser, microscope body, spectrometer,
CCD detector, and confocal aperture. A detailed description of our in-house custom Raman
micro-spectrometer is provided, which was built as part of this PhD project. Additional infor-
mation is also provided for three alternative Raman system designs.
Chapter 4: Numerical methods
The application of Raman micro-spectroscopy for cell classification involves the use of numer-
ical processing techniques that are designed to reduce the impact of noise, eliminate unwanted
background artifacts, and standardise Raman spectra in terms of calibration and normalisation,
as well as the application of multivariate statistical algorithms for classification. Chapter 4
provides information on each of the pre-processing techniques that are applied throughout this
thesis, along with overview of the two multivariate statistical algorithms that are applied for
classification throughout.
Chapter 5: The biology of cells, cancer, and exosomes
Chapter 5 provides the reader with an overview of cell biology, and the formation of epithelial
tissues. This is followed by an introduction to cancer biology, the current modalities applied
for the diagnosis of many human cancers, and the impact of hypoxia (low oxygen conditions)
within a cancerous tumour. The role of exosomes (microvesicles released by cells) within cell
biology is discussed, along with information of how exosomes can be isolated from biological
fluids. And finally, cytology sample preparation methods are discussed, with a key emphasis on
cell deposition methods and fixation agents.
Chapter 6: Bladder cancer diagnostics using Raman spectroscopy: a literature review
A literature review of the previous applications of Raman spectroscopy for bladder cancer di-
agnostics is provided in Chapter 6. This chapter begins with an introduction to the current
clinical approaches for diagnosing bladder cancer. A review of Raman spectroscopy applica-
tions to biopsy and tissue samples is provided, along with applications of Raman cystoscopic
procedures. Previous approaches for Raman based urine cytology are reviewed, allowing for
the identification of protocols and consumables that require further investigation.
Chapter 7: Sample substrates and source wavelengths for Raman based cytology
Due to the high degree of variability across experimental protocols applied for Raman cytology
to date, this chapter compares a range of sample substrates and source wavelengths in order to
determine their impact on Raman cytology spectra. A comparison is made between five source
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wavelengths ranging from 473 nm to 830 nm, with spectra recorded from cells on ten different
sample substrates. Results are presented both graphically and numerically, using three different
metrics.
Chapter 8: Algorithm for the removal of the glass signal from Raman cytology spectra
Traditional preparation methods for cytology samples involve depositing cells on glass slides;
however, the glass signal can sometimes obscure the Raman cell spectrum. Chapter 8 inves-
tigates three background algorithms for the removal of this glass signal along with the slowly
varying baseline signal that is inherent across Raman cytology spectra. The resultant spectra
are compared based on subsequent multivariate analyses. One algorithm in particular is found
to effectively remove the glass signal, and it is hoped that this study will help translate Raman
micro-spectroscopy into the clinic, where the use of glass slides is commonplace.
Chapter 9: Protocols for Raman based urine cytology
Chapter 9 attempts to move Raman micro-spectroscopy a step closer to the clinic by system-
atically examining a range of consumables, protocols, and instrumentation that are used in the
standard cytopathology laboratory. The use of glass slides, traditional fixing agents, lengthy
exposure to urine, red blood cell lysing agents, as well as common cell deposition methods, are
investigated in order to gauge their impact on the diagnostic potential of Raman based urine
cytology.
Chapter 10: Detection of prostate cancer cells using FTIR and Raman micro-spectroscopy
Chapter 10 investigates the application of FTIR and Raman micro-spectroscopy in order to
identify prostate cancer cells that may be present within a urine cytology sample. Synthetic
urine samples are prepared that contain prostate and bladder cell lines, and are deposited onto
slides using traditional clinical protocols. Both vibrational spectroscopy methods are compared
in terms of classification results, as well as in terms of practical implementation and cost.
Chapter 11: Monitoring of changes in cellular biochemistry associated with hypoxia and
exosomal communication
Exosomes are nano-sized microvesicles released by cells, and it is believed that they play a
significant role in cell signalling and communication. This chapter investigates the biomolecular
differences between normoxic and hypoxic (growing under low oxygen conditions) cancer cells
using Raman micro-spectroscopy. Further investigations are provided to monitor the ability of
exosomes isolated from normoxic and hypoxic cells to induce changes in the biochemistry of
neighbouring cancer cells. This study aims to identify the potential application of Raman micro-
spectroscopy as a reliable platform for the diagnosis of patients in need of a more intensive
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treatment plan.
Chapter 12: Conclusion
Chapter 12 concludes with a summary of the results and ideas presented throughout this thesis.
This is followed by a discussion of the potential for future commercialisation, and the clinical
translation, of Raman based urine cytology for bladder cancer surveillance. And finally, an
overview is provided of the future work that could be achieved within the areas of Raman
based urine cytology, exosome communication, as well as future applications of vibrational
spectroscopy technologies for cancer diagnostics.
Chapter 2
Raman spectroscopy
2.1 Introduction
In 1921, upon a voyage from England to India, Sir Chandrasekhara Venkata Raman began to
question the origin of the blue radiance of the Mediterranean sea and surrounding glaciers,
and believed that it could not be explained by Lord Rayleigh’s light scattering explanation. (4)
When he returned to India, Raman performed many experiments to observe light scattering
from water and transparent blocks of ice, and published his own scientific explanation in the
journal Nature. (1) In 1927, following news of Professor Compton receiving the Nobel Prize
for his explanation on the scattering of x-rays (5; 6), Raman employed a spectrograph to record
monochromatic light penetrating transparent materials, resulting in the detection of new spectral
lines, which would later become known as “Raman lines”. Raman presented his discovery in
1928, leading to his achievement of the Nobel Prize in Physics in 1930. (7)
Raman scattering has come a long way from the first time Sir C.V. Raman asked “why is
sea water blue?”, to today, where this technology is being applied for cancer diagnostics. The
invention of the laser, the double monochromator, and electronic methods of signal detection
in the 1960s led to an expansion of the range of applications for which Raman scattering is
useful; such as quality control in the pharmaceutical industry, analysis of sample purity in the
semi-conductor industry, monitoring of drug/cell interactions, and disease diagnosis, which is
the key focus of this thesis.
This chapter provides an insight into the physics of Raman scattering, covering rotational (Sec-
tion 2.3), vibrational (Section 2.4), and rotational-vibrational Raman spectroscopy (Section
2.5). Section 2.6 discusses the basic components required for a Raman spectrometer, with a
more detailed approach provided in Chapter 3. Section 2.7 provides an overview of the biomed-
ical applications of Raman spectroscopy. A brief discussion of FTIR spectroscopy, another form
of vibrational spectroscopy, is provided in Section 2.8, followed by a summary in Section 2.9.
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2.2 The physics of Raman spectroscopy
Raman spectroscopy is a powerful tool for analysing the biomolecular composition of bio-
logical samples. This technique is based on the inelastic scattering of monochromatic (laser)
light; this means that when light interacts with a biological sample, the emitted photons have
a different energy to the incident photons. Only about 1 in 107 photons will undergo Raman
scattering, the rest will undergo Rayleigh scattering as normal, with a small number undergo-
ing Mie, Brillouin, Thompson, or Compton scattering. (8) Figure 2.1 shows a Jablonski energy
level diagram, which compares the energy differences between photons emitted during Rayleigh
scattering and Raman scattering, and illustrates that there is no change in energy between in-
cident photons and Rayleigh scattered photons; however, Raman scattered photons either gain
energy (Anti-Stokes) or lose energy (Stokes) during this scattering process. The magnitude of
the change in energy observed in the Raman photons is dependent on the rotational and vibra-
tional energies of the molecules in the sample (9), as will be discussed in more detail in Sections
2.3 and 2.4 respectively, and is described by the following equation:
∆ν˜(cm−1) =
[
1
λincident(nm)
− 1
λscattered(nm)
]
× 10
9(nm)
102(cm)
(2.1)
where ∆ν˜ represents the change in energy in terms of Raman shift, or wavenumbers (cm−1),
and λ is the wavelength (nm) of the incident or scattered photons.
Figure 2.1: Jablonski energy level diagram for Rayleigh and Raman scattering.
By analysing the intensity and wavelength of the Raman photons, it is possible to infer
information regarding the molecular composition of the sample being investigated. Typically
only Stokes photons are measured since these have a higher intensity than Anti-Stokes photons.
By recording and measuring the emission of inelastic photons in the form of Raman spectra, it
is possible to detect the differences between normal and diseased, or cancerous, cells within a
biological sample. Furthermore, Raman spectra can be recorded from cells or tissue samples
without photo-damaging the individual cells, making it an ideal technique for diagnostics.
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2.3 Rotational Raman spectroscopy
For a molecule to undergo rotational Raman scattering, the molecule must be anisotropically
polarizable (i.e. the polarization varies with different crystallographic orientation). (10) Linear
molecules that are anisotropically polarizable, but do not possess permanent dipole moments,
such as O2, N2, and H2, have a rotational Raman spectrum. In order to determine the polariz-
ability of a molecule, the impact of an applied static electric field on the electron charge distri-
bution of the molecules being analysed must be considered. The induced dipole moment (first
order) is proportional to the electric field, and is given by:
µinduced = αE (2.2)
where µinduced is the induced dipole moment, E is the amplitude of the external electric field,
and α is the polarizability of the molecule; a property that indicates how readily its electron
distribution can be distorted by the external electric field.
If the external electric field is due to an intense beam of light, such as a laser beam, then
the induced dipole moment is a second order process. This means that the light initially creates
a dipole, and then interacts with that dipole. Transitions created through this process are very
weak, but observable. The induced dipole moment (second order) is given by:
µ = αE(t) = αE0cos(ωit) (2.3)
where E0 is the amplitude of the electric field, ωi is the angular frequency of the electric field,
and t is time.
If an anisotropic molecule is rotating at an angular frequency of ωR, then variations in its
polarizability (∆α) will be time dependent:
α(t) = α0 + ∆αcos(2ωRt) (2.4)
with α ranging from α0−∆α to α0+∆α as the molecule rotates through 2pi, where α0 represents
the spherical average of the parallel and perpendicular components. By substituting the expres-
sion for polarizability (Equation 2.4) into the expression for induced dipole moments (Equa-
tion 2.3), then we get:
µ = [α0 + ∆αcos(2ωRt)]× [E0cos(ωit)] (2.5)
µ = α0E0cos(ωit) + E0∆αcos(ωRt)cos(ωit) (2.6)
µ = α0E0cos(ωit) +
E0∆α[cos(ωit+ 2ωRt) + cos(ωit− 2ωRt)]
2
(2.7)
where α0E0cos(ωit) corresponds to Rayleigh scattering, 12E0∆α[cos(ωit+ 2ωRt)] corresponds
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to Anti-Stokes Raman scattering, and 1
2
E0∆α[cos(ωit− 2ωRt)] represents Stokes Raman scat-
tering. If the molecule is not anisotropically polarizable (i.e ∆α = 0), then the Stokes and
Anti-Stokes components disappear. The distortion induced in a linear molecule by an external
electric field returns to its initial value after a rotation of 180o.
In order to fully understand the physics involved with Raman scattering, it is necessary to
consider the quantum effects that are taking place. A diatomic molecule has nuclear, electronic,
vibrational, and rotational degrees of freedom. (11) A molecule can simply be approximated as
a rigid motor and an anharmonic oscillator. (12) The typical energy level structure of a diatomic
molecule is shown in Figure 2.2, represented using Morse curves. Morse curves provide a
good approximation for lower vibrational levels, however this is not true for higher vibrational
levels. (13) Electronic levels are represented by S, vibrational levels as v, and rotational levels
as J . The Maxwell-Boltzmann distribution can be applied to calculate the most populated
rotational levels for a given temperature, T ; however only the ground electronic level (n = 0)
is appreciably populated at room temperature. (14; 15; 16)
Figure 2.2: General structure of the energy levels of a diatomic molecule, determined with
Morse potential curves, showing the electronic energy levels (S), vibrational levels (v), and
rotational levels (J).
Two photons are involved in the Raman spectroscopy process, and in nuclear physics terms,
each photon is a spin-1 particle. (10) This means that a maximum change in angular momen-
tum quantum number of ±2 is possible. This gives us the selection rule for rotational Raman
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Figure 2.3: An illustration of the moments of inertia about the three axes for a rotating molecule.
spectroscopy:
∆J = ±2 (2.8)
where J is the rotational angular momentum quantum number of the molecule, and can be
described as:
Jx = IxΩx (2.9)
where Ix is the moment of inertia and Ωx is the angular velocity about an axis x. A molecule
can have three different moments of inertia about orthogonal axes x, y, and z, as illustrated in
Figure 2.3. Therefore, the energy of a rotating molecule, EJ , is given by:
EJ =
1
2
IxΩ
2
x +
1
2
IyΩ
2
y +
1
2
IzΩ
2
z (2.10)
EJ =
J2x
2Ix
+
J2y
2Iy
+
J2z
2Iz
(2.11)
Or alternatively,
EJ =
h2J(J + 1)
8pi2I
(2.12)
with h representing Planck’s constant.
The energy of a rotational state is usually given by the Rotational Term F (J):
F (J) =
∆EJ
hc
= BJ(J + 1) (2.13)
with c representing the speed of light constant, and B is the rotational constant (cm−1) of the
molecule, given by:
B =
h
8pi2Ic
(2.14)
Spacing between lines in rotational spectra are often given in terms of B, with Raman lines
appearing at displacements of 6B, 10B, 14B, etc. either side of the incident source radiation,
as described further in the following paragraphs.
For Stokes scattering, the molecule gains rotational energy of ∆J = +2, and is represented
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by the following equations:
ν˜Stokes = ν˜i − ν˜0 (2.15)
where ν˜Stokes is the frequency of the Raman shift (wavenumbers) for Stokes scattering, ν˜i cor-
responds to the incident radiation (e.g. laser source), and ν˜0 corresponds to the Raman scattered
photons. Therefore,
ν˜(J + 2)− ν˜(J) = ν˜i − [F (J + 2)− F (J)] (2.16)
where ν˜ is the Raman shift (wavenumbers) for the transition of J to J + 2. By substituting
Equation 2.13 into Equation 2.16, the following equations can be used to represent rotational
Stokes scattering:
ν˜(J + 2)− ν˜(J) = ν˜i − [B(J + 2)(J + 3)−BJ(J + 1)] (2.17)
ν˜(J + 2)− ν˜(J) = ν˜i − 2B(2J + 3) (2.18)
Stokes lines appear on the low frequency side of the incident line source, and at displacements of
6B, 10B, 14B, etc. from ν˜i (Rayleigh position) for J = 0, 1, 2, etc., as illustrated in Figure 2.4.
Figure 2.4: Pure Rotational Raman energy levels and corresponding spectrum, showing Stokes
and Anti-Stokes energy transitions and spectral lines.
When the molecule makes a transition of ∆J = −2, the scattered photon emerges with
increased energy. These transitions account for the Anti-Stokes lines of the spectrum, given by
the following equations:
ν˜(J − 2)− ν˜(J) = ν˜i + [F (J − 2)− F (J)] (2.19)
ν˜(J − 2)− ν˜(J) = ν˜i + [B(J − 2)(J − 1)−BJ(J + 1)] (2.20)
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ν˜(J − 2)− ν˜(J) = ν˜i + 2B(2J − 1) (2.21)
Anti-Stokes lines occur at displacements of 6B, 10B, 14B, etc. for J = 2, 3, 4, etc., to the high
frequency side of the incident line source, as shown in Figure 2.4.
2.4 Vibrational Raman spectroscopy
For vibrational Raman spectroscopy to occur, the polarizability of the molecule must change
as the molecule vibrates. As diatomic molecules vibrate, the interaction between the electrons
and nuclei changes resulting in a change in polarizability. Therefore, all diatomic molecules
are vibrationally Raman active. (17) For polyatomic molecules, group theory must be applied
to decide if a particular vibrational mode is Raman active. (18) There are two specific selection
rules for vibrational Raman spectroscopy:
1. Harmonic approximation: ∆n = ±1
2. Anharmonic approximation: ∆n = ±1,±2,±3...
The classical description of vibrational Raman spectroscopy is similar to that presented for
rotational Raman spectroscopy in Section 2.3. However, for vibrational Raman spectroscopy,
the vibration of the molecular bond is accompanied by a periodic stretching and compression
of the electron distribution, which gives an oscillation of the polarizability along the direction
of the electric field.
Based on Equation 2.4, it can be shown that the induced dipole oscillates in phase with the
vibrational motion of the molecule:
α(t) = α0 + δαcos(2piνvibt) (2.22)
where δα is the amplitude of the change in the polarizability during one vibrational cycle, α0
is the average value over one complete cycle, νvib is the vibrational frequency, and t is time. It
should be noted that ν represents the frequency of a wave in hertz (Hz), not wavenumbers, such
that:
ν˜ =
ν
c
(2.23)
Similar to rotational Raman spectroscopy, if the external electric field is due to an intense
beam of monochromatic light, the combination of Equations 2.4 and 2.22 gives the following
expression for a time dependent induced dipole moment:
µ = α0E0cos(2piνit) +
E0δα[cos(2pi[ν0 + νvib]t) + cos(2pi[ν0 − νvib]t)]
2
(2.24)
where νi is the frequency of the incident beam, νo is the oscillating frequency, and νvib is the
vibrating frequency. As for the case of rotational Raman spectroscopy, this equation includes
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Rayleigh scattering at the same frequency as the incident light, α0E0cos(2piνit), Anti-Stokes
scattering at ν0 + νvib, and Stokes scattering at ν0 − νvib. The main difference here is that the
frequency shift is ±νvib, rather than ±2νvib. As a result, the vibrational Raman selection rule is
based on the strong preference for ∆n = ±1, which governs normal infrared spectroscopy.
As previously mentioned, almost all molecules are in the ground state (n = 0) at room tem-
perature (due to Maxwell-Boltzmann distribution), and the predominant transition is absorption
from the n = 0 to n = 1 state. This explains why the Anti-Stokes lines are very weak com-
pared to the Stokes lines. (19) Interestingly, it is possible to determine the exact temperature of
a system based on the ratio of the intensity of the Stokes lines to the intensity of the Anti-Stokes
lines. (14; 20)
It is possible to solve the Schrodinger equation, with the Morse potential, to find the allowed
energy levels for a vibrational Raman system (21), such that for every vibrational mode of a
molecule, the energy of that mode is given by:
G(n) =
En
hc
=
(
n+
1
2
)
ν˜0 −
(
n+
1
2
)2
χeν˜0 (2.25)
G(n) =
En
hc
= ν˜0
[
1− χe
(
1
2
)](
n+
1
2
)
(2.26)
where G(n) represents the vibrational terms of a molecule (cm−1), En is the energy level, and
χe is the anharmonicity constant given by:
χe =
ν˜0
4Deq
(2.27)
with Deq representing the depth of the Morse potential. (22)
Diatomic molecules have only one vibrational frequency mode; therefore, the Raman spec-
trum of a diatomic molecule should consist of only one single Stokes and one Anti-Stokes line
(ignoring overtones, hot bands, and rotational fine structure). However, Raman vibrational ac-
tivity in polyatomics is more complicated, and it is usually necessary to apply group theory
to determine if a molecule is Raman active or not. Some general rules can be applied to poly-
atomics; (i) if the molecule has no symmetry (e.g. HCl), then usually all of its vibrational modes
are Raman active; (ii) if the molecule is symmetric (e.g. CO2, H2O), then it’s symmetric vi-
brations will produce intense Raman lines, but non-symmetric vibrations are weak and often
unobservable.
Fundamental: (∆n = ±1)
For Raman active modes, fundamental transitions can be observed. For Stokes scattering, ∆n =
+1, a molecule starts in the n = 0 state, is excited by the incident radiation, and de-excites to
the n = 1 state. Thus the molecule has gained energy, and the scattered photon has lower
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energy than the incident photon. ∆n = −1 corresponds to the Anti-Stokes line; this occurs
when the molecule starts in the n = 1 vibrational state, is excited by the incident radiation, and
de-excites to the n = 0 vibrational state; the molecule has lost energy, and the scattered photon
has a higher energy than the incident photon. A pure vibrational Raman spectrum consists of a
series of intense lines to the low wavenumber side of the excitation line (laser), and a weaker
mirror image series of lines on the high wavenumber side, as shown in Figure 2.5.
Figure 2.5: Fundamental vibrational Raman lines, with corresponding energy equations.
Overtones and hot bands: (∆n = 2, 3, ...)
It is also possible to observe overtone and hot bands in Raman spectra. Overtones are produced
when ∆n = 2, 3, .., the first overtone is produced as n = 0 → n = 2, the second for n =
0 → n = 3, and so on. Hot bands are produced when n = 1 → n = 2, 3, 4, ... However, since
the Raman scattering process is already a weak technique, we typically can ignore all processes
such as overtones and hot bands since these are very weak, even in infrared spectra.
2.5 Rotational-vibrational Raman spectroscopy
Also known as rovibrational, or roto-vibrational, Raman spectroscopy, this topic covers the
combination of rotational and vibrational Raman scattering. Since angular momentum must
be conserved when a photon is emitted or absorbed, vibrational transitions are often accom-
panied by a change in the rotational quantum number J , resulting in a rotational-vibrational
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transition. This level of detail is rarely resolved in Raman spectra, with the exception of di-
atomic molecules. Using the Born-Oppenheimer approximation (23), the rotational-vibrational
spectrum can be represented in terms of S(n, J) (combined rotational-vibrational term):
S(n, J) = F (J) +G(n) (2.28)
S(n, J) = BJ(J + 1) +
(
n+
1
2
)
ν˜ −
(
n+
1
2
)2
χeν˜ (2.29)
Figure 2.6: Energy level diagram and corresponding spectrum for rotational-vibrational Raman
scattering.
For diatomic molecules, the following selection rules exist: ∆J = 0,±2, and n = 0 →
n = 1. This gives us three branches of rotational-vibrational Raman: Q-Branch, S-Branch, and
O-Branch, (16) as illustrated in Figure 2.6, which are mathematically defined as follows:
• Q-Branch (rotational energy does not change):
∆J = 0 : ν˜Q = ν˜i − ν˜(1− 2χe) (2.30)
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• S-Branch (gain rotational energy):
∆J = +2 : ν˜S = ν˜i − ν˜(1− 2χe) + 2B(2J + 3) (2.31)
• O-Branch (lose rotational energy):
∆J = −2 : ν˜O = ν˜i − ν˜(1− 2χe)− 2B(2J + 3) (2.32)
where ν˜i is the frequency of the incident radiation (e.g. laser frequency).
2.6 Basic experimental set-up for Raman spectroscopy
A basic Raman spectroscopic set-up must consist of four main components: (i) an excitation
source (i.e. laser), (ii) an optical system to deliver the light to the sample with minimum power
loss, (iii) a collection system with highly efficient optics that can collect an optimum amount
of Raman scattered light whilst being able to remove all Rayleigh signals, and (iv) a detection
system (i.e. spectrograph and detector). A basic design of this optical method is shown in
Figure 2.7, where additional optical elements can be inserted to optimise the system.
Since the scattered Raman signal is very weak relative to the laser source beam, it is impor-
tant to have efficient optical systems for both delivering the laser beam directly to the sample
with sufficient power, and for collecting the scattered Raman photons. To achieve this, a series
of mirrors and lenses are used to guide the optical path directly to where it is needed, and filters
are used to remove unwanted signals. It is also possible to include a confocal aperture to iso-
late the spectrum from a particular location in the sample. The detection system consists of a
spectrograph and a CCD (charge coupled device) detector. Thermal energy can often generate
noise and dark current on the CCD device, which can block out the distinct Raman peaks. To
avoid this, and to maintain a good signal-to-noise ratio (SNR), the CCD must be cooled. Further
information on the design of Raman optical systems is given in Chapter 3.
2.7 Biomedical applications of Raman spectroscopy
The different wavelengths that are emitted from a Raman scattering incident are unique to a
particular molecule, which enables fingerprint-like recognition of complex molecular combina-
tions. It has been shown that recording spectra from tissue and cells with a known pathological
status allows for the training of statistical classification algorithms that enables the diagnosis
of disease from unknown samples. (24; 25; 26) Various supervised and unsupervised statistical
techniques have been employed to analyse Raman spectral datasets, and have been so far im-
pressively successful in differentiating normal versus diseased samples; these will be discussed
later in Section 4.6.
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Figure 2.7: Basic set-up used for Raman spectroscopy.
Raman spectroscopy has many advantages over other diagnostic techniques; it is fast, giving
diagnostic results in real-time, and accurate for diagnosis, but there are also limitations to this
technique that need to be considered. Strong background effects are often detected that overlap
with the Raman spectral irradiance, making it difficult to distinguish the signals associated with
the biological sample. A variety of pre-processing statistical techniques have been developed
in order to remove this noise (see Section 4.3), and a range of substrates and laser wavelengths
have also been used to minimise background signals. Additionally, background signals vary
significantly across source wavelength and sample substrate. (27) Good substrates for Raman
spectroscopy should be transparent in the visible/NIR region, produce a low background signal,
and should be biocompatible and non-toxic for the cells or tissues placed on them. For example,
glass in particular is known to produce a large background signal when used in conjunction with
a near-infrared (NIR) laser source, so the use of other optically transparent substrates such as
calcium fluoride (CaF2) or quartz are preferred for Raman spectroscopy in the NIR. A more
detailed discussion on pre-processing methods is given in Chapter 4, the choice of lasers in
Section 3.2, and sample substrates in Chapter 7.
2.8 Fourier transform infrared (FTIR) spectroscopy
FTIR spectroscopy is another form of vibrational spectroscopy that can be applied to cells and
tissues for diagnostics. In Chapter 10, FTIR spectroscopy is applied to bladder and prostate
cells for cancer diagnostics, and a comparison is made between the two modalities. In terms of
the physics involved, FTIR relies on the absorbance, transmittance, reflection, or transflection of
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infrared (IR) light. Vibrating molecules in a sample absorb distinct wavelengths of IR light that
correspond directly with the vibrational frequencies of the molecular bonds within the sample.
There are fundamental physical differences between FTIR and Raman spectroscopy; Raman is
dependent upon a change in polarisation of a molecule, and is based upon the inelastic scattering
of radiation, whereas IR spectroscopy is dependent upon a change in the dipole moment of
a molecule, and is based upon monitoring of wavelengths of light that are absorbed by the
molecule; whereby the absorbance can be modelled using the Beer-Lambert Law. (28)
Similar to Raman spectroscopy, there are specific selection rules that govern the allowed
energy transitions that occur within IR spectroscopy. These selection rules are approximated
with an anharmonic oscillator:
1. The dipole moment must change, in magnitude or direction, as the molecule oscillates
2. ∆n = ±1,±2,±3... All transitions are allowed, but ±n = ±1 transitions are the most
common
3. Angular momentum must be conserved when photons are absorbed; therefore, all transi-
tions are rotational-vibrational with ∆J = ±1 (although ∆J = 0 is sometimes possible).
The allowed energy levels can be found with these selection rules using Equation 2.29.
An FTIR system measures the intensity of the IR signal as a function of time, and applies
a Fourier transform to this signal to produce a spectrum as a function of frequency (or wave-
length/wavenumbers). To achieve this, a Michelson interferometer is used (28; 29), as shown
in Figure 2.8. The Michelson interferometer introduces a variable path length in the interfer-
ence measurement; the interference signal is collected at many different path lengths, which is
achieved by changing the position of the “movable” mirror. The recorded spectrum is recon-
structed using a Fourier transform to produce a frequency domain spectrum.
There are many biomedical applications for FTIR, such as chemical imaging of tissue sam-
ples (30; 31) and cells (32; 33), as well as disease diagnostics (34; 35; 36). Applications of
FTIR for the diagnosis of prostate and bladder cancer cells is investigated further in Chapter 10.
Raman spectroscopy and FTIR have many differences, these include:
• Ability to analyse aqueous solutions with Raman spectroscopy; water is a strong absorber
in the IR, but it is a relatively weak Raman scatterer
• Raman spectroscopy has a higher spatial resolution which allows for subcellular analysis
• FTIR is significantly faster than Raman spectroscopy, allowing for tissue mapping to be
achieved with relatively short acquisition times
• Fluorescence, or photoluminescence, can often swamp the weak Raman signal
• Raman lasers can damage tissue and cell samples during acquisition, whereas IR light
sources emit within the biological window
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Figure 2.8: Basic set-up used for an FTIR system, consisting of a Michelson interferometer, a
source, and detector.
• With FTIR, the whole spectrum is obtained across the entire frequency range at once; no
need to change gratings to obtain different frequency ranges
• FTIR instrumentation is relatively inexpensive compared to Raman micro-spectroscopy
systems
• It is possible to use glass slides with Raman spectroscopy (see Chapter 7), but the fluo-
rescent glass signal is problematic for FTIR analysis, particularly within the fingerprint
region (37).
There are advantages and disadvantages associated with each method, but typically Raman
spectroscopy is applied for cellular and sub-cellular analysis, and FTIR is applied for the anal-
ysis of tissue sections.
2.9 Summary
The physics behind rotational, vibrational, and rotational-vibrational Raman spectroscopy is
discussed in this chapter, in terms of both classical and quantum physics. Section 2.8 provides
an overview of FTIR, and a short comparison is made between Raman and FTIR spectroscopy.
The basic elements of a Raman micro-spectrometer are discussed, with a more detailed de-
scription on the design and building of Raman micro-spectrometers given in Chapter 3. The
biomedical applications of Raman spectroscopy are introduced here, and are investigated in
further detail throughout this thesis.
Chapter 3
Design and building a confocal Raman
micro-spectrometer
3.1 Introduction
The basic Raman spectroscopy set-up discussed in Section 2.6 can be integrated into a conven-
tional microscope, such that Raman spectra may be obtained from sub-micron locations within
a biological sample, e.g. a cell or tissue sample. The name often used for such an instrument is
a Raman micro-spectrometer. This can be further amended with a confocal aperture in the col-
lection path in order to introduce a three dimensional spatial resolution, resulting in a confocal
Raman micro-spectrometer; this chapter discusses the important considerations required for the
design of one of these systems, particularly for the application of classifying different cell types.
The overarching objective of designing this system is for the identification of cancer cells, with
an emphasis on the area of urine cytology. As well as discussing the key design questions, and
describing in detail the confocal Raman micro-spectrometer that was built during this research
project, this chapter also briefly discusses the optical designs of Raman tweezers and Raman
fiberoptic systems, which are not directly applied in this thesis, but are referenced throughout.
There are many considerations when designing a Raman micro-spectrometer for applica-
tions in cell classification: (i) the first key component is the source laser, for which all optical
elements must be optimised, (ii) secondly, the integration of a microscope body and the choice
of microscope objective (MO) must be considered, (iii) thirdly, collection of the Raman spec-
trum is achieved using a spectrograph and CCD, and (iv) fourthly, an appropriate confocal
aperture can be included to tailor the spatial resolution of the system. Each of these four con-
siderations are discussed in Section 3.2–3.5, respectively, and in Section 3.6, the design of four
different Raman systems is discussed, including the custom built Raman micro-spectrometer
used for much of the work presented throughout this thesis.
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3.2 Source laser
When choosing a laser for a Raman system, one must consider the Raman scattering efficiency,
in terms of both penetration depth and the power of the Raman spectrum, background signals
generated from surrounding materials, including fluorescence from the sample itself and the
substrate (see Chapter 7 for more information), photodamage, and resonance Raman effects
that may be generated. Sections 3.2.1 and 3.2.2 deal with these issues in more detail in terms of
the source wavelength.
3.2.1 Source wavelength
There are various advantages and disadvantages associated with a given excitation laser wave-
length that must be considered in order to obtain an optimum Raman spectrum. Many materials,
including the biological sample, the substrate, and the MO, produce a background signal in par-
ticular wavelength bands, which may swamp any weak Raman signals present. Some materials,
e.g. glass, emit a large fluorescent background signal as the excitation laser moves from the blue
region up to the red or NIR region, making a laser in the lower wavelength region of the visible
spectrum preferable. On the other hand, it has been shown that Mie scattering from biological
samples can also contribute to an underlying baseline signal. (38) This scattering is minimised
at longer wavelengths, as is photodegradation of tissue samples. (39)
The amount of photons scattered is also indirectly related to the excitation wavelength, with
the intensity of Raman lines being proportional to the fourth power of the laser frequency:
I ∝ ν4. (40) Therefore, when a comparison is made between a 473 nm laser and an 830 nm
laser: (
ν473
ν830
)4
=
(
c
λ473
× λ830
c
)4
= 9.481 (3.1)
it can be seen that the 473 nm laser produces Raman lines that are approximately 9.5 times
more intense than those produced by an 830 nm laser for the same laser powers, assuming
non-resonant conditions. Therefore, it can be seen that the scattering efficiency is higher at
lower wavelengths, resulting in the use of shorter integration times and lower powered lasers in
the blue/green regions, although the quantum efficiency of the grating and CCD detector being
used must also be taken into consideration. Another important factor is that the optical window
for biological tissues exists within the NIR region, where the absorption of light within the
tissue sample is minimal. (41) Within this optical window (700–900 nm), biological samples are
considered relatively transparent, and measurements in this region result in less tissue damage
from the laser. (39) Furthermore, for the same reason, an NIR source can penetrate deeper
into tissue and cell samples, resulting in an increase in the number of Raman scattered photons.
However, this improvement is not usually significant enough to offset the reduction in scattering
efficiency described by Equation 3.1.
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Figure 3.1: Transverse electromagnetic (TEM) laser mode patterns
In terms of transverse electromagnetic modes (TEM), a laser with a Gaussian beam pro-
file (TEM00) is preferable for a Raman micro-spectrometer, as illustrated in Figure 3.1. A
TEM00 laser allows for easier alignment, and optimum deposition of laser power into a specific
targeted region, such as a cell nucleus; it also allows for a diffraction limited spatial resolution
on the order of half a wavelength, provided that the optics of the delivery path are used to expand
the laser beam such that 1/e2 width of the Gaussian profile matches the diameter of the back
of the MO. (42) The effect of the source optical mode for Raman spectroscopic measurement
of human tissues has previously been analysed by Li et al. (2014) (43), whereby the influence
of single-mode (SM) and multi-mode (MM) excitation lasers at 785 nm and 830 nm were com-
pared in terms of the background signal intensity generated by tissue autofluorescence and the
Raman signal intensity measured. The authors reported a reduction in background, an increase
in SNR, and a reduction in Mie scattering for the 785 nm SM source when compared to the
785 nm MM source. In terms of source wavelength, 785 nm spectra had a lower background
intensity than that at 830 nm, and a SNR between 1.2–1.6 times higher was reported for the
785 nm MM source than that recorded from the 830 nm MM source. (43)
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3.2.2 Laser – tissue interactions
The two main reactions of concern when tissues and cells are exposed to laser radiation are
either thermal or optical. One form of irreversible thermal damage is coagulation due to the de-
naturization of cells and proteins, similar to the process in which the albumin of an egg becomes
white upon cooking. For all tissue and cell types, coagulation is visibly apparent. (44) When
the temperature at the laser-tissue interface exceeds that required for coagulation, vaporization
occurs. Typically this happens at temperatures above 100oC since the major component of cells
and tissues is water. (45) While these effects are desirable in laser surgical procedures, such as
an angioplasty, they should be avoided in Raman spectral analysis.
To consider the optical response of cells to laser radiation, Beers Law and the laser fluence
rate must be investigated. Beers Law states that the fluence rate decreases exponentially as it
passes through cells or tissue. (46) This attenuation of the laser beam is due to absorption and
scattering, given by the following equation for a continuous laser beam:
Ez = (1− rs)E0exp(−µtz) (3.2)
where Ez is the attenuated beam, E0 is the irradiance, µt is the attenuation coefficient, z is the
thickness of the sample, and rs is the Fresnel specular reflection for non-polarized light, which
is approximately 2% for light that is incident along the normal to the air-tissue interface. (46)
Since it is possible to have a significant amount of scattering and absorption, particularly at
the air-cell interface due to the difference in refractive indices, a water or oil-immersion MO is
sometimes used to reduce this effect. (38)
The laser power should be selected to optimise the Raman signal whilst minimising the
photodamage within the biological sample. A suitable laser power should be applied, and the
response of tissues and cells should be monitored upon laser irradiation for any form of pho-
todamage. For valuable samples, the laser power should initially be turned down low, and
increased carefully until an acceptable point is achieved, resulting in a maximum Raman signal
without any sample damage. (47)
3.3 Microscope body
Raman measurements of biological samples sometimes require long acquisition times, in the
order of 10-60 s. The stability of the laser focus position at the sample therefore needs special
care. When building a Raman micro-spectrometer, one can make use of a commercially avail-
able microscope body, such as the inverted Nikon phase contrast microscope (Nikon, Toyko,
Japan; Diaphot 300), which we have incorporated into our system (Section 3.6.1, Figure 3.4).
In this case, the laser is directed into the microscope using the fluorescence cube cavity di-
rectly below the MO. In order to maintain full imaging functionality of the microscope after the
addition of Raman optical filters into the system, it is important to choose a microscope that
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employs infinity MOs. The reason for this is that the addition of filters into the imaging path of
the microscope changes the optical path length, and if this occurs in any domain other than in
an infinity domain, the focal plane of the microscope will be slightly altered, and the image will
appear out of focus.
The Nikon Diaphot 300 was one of the first research grade microscopes that adapted the
concept of infinity optics, such that fluorescence cubes could be readily inserted into the cavity
immediately below the MO turret. However, the microscope did not actually employ infinity
MOs that are commonplace today. Instead, it was the last of its kind to employ fixed focal length
MOs with a focal length of 160 mm. A convex lens was glued into the MO turret immediately
below the MO in order to transform the light into an infinity domain before entering the cavity.
In order to employ modern infinity MOs, the entire turret of the microscope is replaced with a
turret that does not contain a convex lens.
With a Raman micro-spectrometer, the biological sample should be placed on a stable trans-
lation stage; this translation stage should be movable in the horizontal xy plane, as well as in
the z direction. To achieve movement in the z plane, it is possible to move either the translation
stage or the MO. For our custom-built system, we have incorporated the former approach; more
details about the specific translation stage used are provided in Section 3.6.1.
Alternatively, one could build a stable Raman system using cage optics, whereby the op-
tical elements (lenses, mirrors, filters, etc.), cameras, and light sources are the same as those
employed in a standard custom built Raman system, with the distinct difference of having them
connected with cage optics. (48) There are many advantages of using cage optics such as ease
of laser alignment, stability, ease of construction, and convenience. However, the associated
disadvantages include lack of freedom and flexibility (cannot send beams at arbitrary angles).
A cage optics Raman micro-spectrometer was also built during the course of this PhD, but the
details of that system are not provided here.
It should be noted that when using an excitation wavelength in the NIR, it may be preferable
to use a fluorite MO in order to reduce the fluorescent background signal emanating from the
objective. These MOs, which are produced by the large optics companies, often have various
names, e.g. fluor, fluorite, fluortar, neofluar, and are manufactured using a mineral form of CaF2.
These MOs have the desirable property of optimal correction for chromatic aberration (allowing
different wavelengths to come into focus at the same plane), which is important in the context
of focusing the Raman scattered light onto the spectrograph slit. The background signal from
the MO can also be reduced by using a suitable confocal aperture (27), as discussed further in
Section 3.4.
3.4 Spectrometer and CCD detector
The performance of a Raman micro-spectrometer depends, among other things, on its sensitiv-
ity and spectral resolution. The sensitivity is defined as the probability of detecting a scattered
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photon, and determines how long it will take to record a spectrum with a given SNR. The sen-
sitivity is determined by numerous factors, including (i) the grating reflectivity, also known as
the diffraction efficiency, (ii) the optical transmission of the various optical elements in the col-
lection system such as lenses, filters, beamsplitters, etc., and (iii) the quantum efficiency of the
CCD detector. The spectral resolution determines the accuracy of extracting subtle information
from a Raman spectrum, as discussed further in Section 3.3.1. The spectral resolution is deter-
mined by the focal length of the spectrometer and the line density of the grating used to disperse
the light. (49)
Figure 3.2: Schematic of a Czerny-Turner spectrograph.
A spectrograph is designed to accept light with a broad spectrum of wavelengths, to sep-
arate the wavelengths spatially, and to detect each wavelength on a multichannel detector,
which today is synonymous with a CCD. The spectrograph used for our custom Raman micro-
spectroscopy system is the Andor Shamrock 500 (Andor Technology Ltd., Belfast, UK), in
association with an Andor iDus cooled CCD camera (DU420A-BR-DD, Andor Technology
Ltd., UK) operating at -80oC. This spectrograph is based on a Czerny-Turner system, as shown
in Figure 3.2. Raman signals are focused onto the entrance slit of the spectrograph, where it
diverges until it reaches a concave (or collimating) mirror whose focal length corresponds to the
distance between the mirror and slit; after being reflected by the mirror, the light is collimated.
This collimated beam then hits the diffraction grating, which is an array of finely spaced lines
on a reflective surface, where constructive and destructive interference occurs, a phenomenon
which is both wavelength and angle dependent. Consequently, each wavelength is reflected at a
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slightly different angle onto the focusing mirror. This results in each wavelength reaching a dif-
ferent pixel on the array detector (CCD). The CCD consists of an array of photodiodes (i.e. light
sensitive pixels) that can convert photons into electrons, allowing for accurate measurement of
the number of photons incident onto the CCD for a particular wavelength.
Additionally, it is important to align, and expand the laser beam, such that it matches the f
number of the spectrograph. To achieve this, the f number can be calculated as follows:
f =
F
D
(3.3)
where F is the focal length of the lens, andD is the diameter of the laser beam that is illuminated
onto the lens, as shown in Figure 3.3.
Figure 3.3: An illustration for the calculation of the f number for a given spectrometer.
3.4.1 Spectral resolution
As mentioned in the previous section, the spectral resolution of the system is determined by
the diffraction grating, the detector, and the focal length of the spectrometer. The wavelength
bandwidth that can be observed at the output of a spectrometer is a function of the angular
dispersion and the focal length of the spectrometer. Since the angular dispersion is itself a
function of wavelength, the observable bandwidth differs depending on the centre wavelength
that is chosen. The Andor Shamrock 500 spectrograph enables rotation of the grating, which
allows for the selection of different regions of interest. Precise calculation of this bandwidth for
a particular centre wavelength can be achieved using the grating equation, and requires knowl-
edge of the various spectrograph parameters such as grating angle, focal length, output aperture
size, and grating period. (50) For gratings with relatively low dispersion, e.g. 300 grooves per
mm (gr/mm), the observable wavelength bandwidth (and therefore resolution in nm) is approx-
imately constant for different centre wavelengths ranging from 500 nm to 900 nm, though this
approximation fails for highly dispersive gratings. However, in Raman spectroscopy, where
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units such as Raman shift or wavenumbers are more often used, the spectral resolution (in
wavenumbers) of the system increases with the source wavelength. When the wavelength is
shifted through Raman spectroscopy from the incident wavelength λi to the scattered wave-
length λs, the shift in wavelength ∆λ is given by:
∆λ = λi − λs (3.4)
but the corresponding wavenumber shift (∆ν˜) is given by Equation 2.1, therefore,
∆ν˜ =
[
∆λ
λi(λi −∆λ)
]
(3.5)
Assuming that the wavelength bandwidth, ∆λ, remains constant regardless of the centre wave-
length chosen, it follows that the ratio of spectral bandwidths for two different incident wave-
lengths, λi1 and λi2, will be given by:
∆ν˜1
∆ν˜2
=
λi2(λi2 −∆λ)
λe1(λe1 −∆λ) (3.6)
Thus, for a sample case of ∆λ = 150 nm, it can be concluded that 473 nm excitation wavelength
results in approximately 3.7 times more spectral bandwidth than 830 nm. Conversely, the res-
olution at 830 nm is ∼3.7 times smaller than that at 473 nm. The overall diffraction efficiency
of a grating also depends on the blaze angle of the grating, and the polarization of the incident
light, both of which are not considered here. Typically, gratings are selected in order to provide
the best resolution within a specific acquisition time frame over the desired spectral range for
the chosen laser wavelength.
3.5 Confocal aperture
Another important consideration is the use of a confocal aperture within a Raman micro-
spectrometer. The confocal aperture controls how much of the Raman spectral irradiance passes
through into the spectrograph slit and onto the detector. Its primary function is to achieve spatial
resolution for a given spectrum, as well as to remove any background signals emanating from
the MO or other optical elements that are common to both the delivery and collection paths.
Confocal apertures range in size, typically from small (10–20 µm) up to large (150–300 µm).
The larger the aperture, the greater the Raman signal reaching the CCD, however larger aper-
tures also degrade the spatial resolution of the system. In a well designed system, the size of the
confocal aperture is matched to the magnification of the MO, but some experimentation can be
done to determine the optimum aperture for specific purposes.
The size of the confocal aperture should in turn be approximately matched to the size of
one pixel area in the CCD camera. This is achieved with an appropriate design of the imaging
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system from the confocal aperture to the spectrograph slit. For example, for a confocal aperture
of 100 µm and a pixel size of 25 µm, the magnification factor of the imaging system should be
0.25. The f number of the spectrograph must also be considered when designing this imaging
system, such that the angle of light entering the slit of the spectrograph does not exceed the
largest acceptance angle for that spectrograph.
3.6 Raman system designs
There are many types of Raman systems, both commercial and custom built, which have many
advantages and disadvantages. Careful consideration should be made in order to design a Ra-
man system suitable for specific experimental needs. Here, four different Raman systems are
compared, including a custom built system from the Biophotonics Lab in Maynooth University,
the commercial Horiba LabRam HR (Horiba Jobin Yvon Inc., US) at the Focas Institute (Dublin
Institute of Technology, Ireland) which is used to perform various experiments for this thesis, a
standard Raman tweezers system, and a fiberoptic Raman system. The latter two types of Ra-
man system were not employed in any experiments associated with this thesis. However, they
are directly relevant to a number of discussions in the thesis, and are often used in the analysis
of tissue and cell samples for disease diagnostics. For these reasons, a brief discussion on these
system designs is included.
3.6.1 In-house custom Raman micro-spectrometer
A custom Raman micro-spectroscopy system is designed and built as part of this thesis. This
system consists of a 532 nm laser (150 mW; TEM00; 1 mm beam diameter, 0.4 mrad beam
divergence; Torus, Laser Quantum, UK), a spectrograph operating with a 600 lines.mm−1 grat-
ing, and a cooled CCD camera (outlined in Section 3.4), as illustrated in Figure 3.4. This basic
design can be found in many commercial Raman micro-spectrometers from long established
companies such as Horiba (Horiba Jobin Yvon Inc., US). A state of the art Raman microscope
will cost in the order to $100k, but an equivalent one can be built from basic elements for less
than half this amount.
The design of our system is as follows: the laser, with a narrow bandwidth, is first passed
through an optical isolator (OI) which prevents back reflections in the set-up from returning into
the laser cavity and damaging the laser head. This is followed by a line pass filter (LP) which
removes any spurious lines from the laser that may result from additional modes being present,
allowing only the 532 nm line to pass through. A neutral density filter can be inserted after
the LP, which can be rotated to vary the power of the laser beam. Two lenses (L1, L2; Thor
Labs, US) are used to expand the laser beam such that the diameter of the collimated beam is
approximately equal to the back aperture of the MO (Olympus 50x, 0.8 NA, UMPlanFl). The
collimated beam is directed onto a dichroic beam splitter (DB; Semrock, US; LPD01–532RS),
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which reflects light at 532 nm, but transmits longer wavelengths, i.e. Raman Stokes scattered
photons.
The DB reflects the beam towards a dichroic short pass filter (DS; Edmund Optics, US; 69-
202) reflecting all wavelengths above 500 nm, and transmitting shorter wavelengths. The DS
is located within the fluorescence cube cavity of an inverted Nikon phase contrast microscope
(Nikon Diaphot 300), and is carefully aligned such that it reflects the beam directly into the
back of the MO. The MO is chosen such that it has a high numerical aperture (NA), which
is essential to recover as many Raman back scattered photons as possible. It is also essential
that the MO efficiently transmits visible light as this will also impact on the system’s ability
to recover a strong Raman signal. The sample is placed on an xyz translation stage (TS, ASI,
LS–2000 and LS–50) that enables sample positioning relative to the laser spot. In the case of
Raman diagnostics, it is desirable to position the cell such that the spot is located within the cell
nucleus, or nucleolus, as this results in optimum diagnostic sensitivity. (51)
The back scattered Raman photons (532 nm – 650 nm) propagate back through the MO,
are reflected by the DS, and then pass through the DB. Lens L3 focuses the light to a 100 µm
confocal aperture (Thor Labs). Lens L4 collimates the beam, with lens L5 focusing the light
onto the entrance slit of the spectrograph. A long pass filter (LgP; Semrock, UK; LP03–532RU–
25) is placed near the entrance slit in order to further reduce any Rayleigh scattered/laser light
that has reached the spectrograph. Via a Czerny-Turner spectrometer, the image of the slit is
projected onto the cooled CCD camera, and the Raman spectrum is recorded using the Andor
Solis software system. It is essential to use a high quantum efficiency, low noise, cooled CCD
in order to recover the weak Raman signal with minimal noise.
The various lenses in this system are chosen such that (i) a laser spot size of ∼3 µm is
located at the object plane of the microscope, (ii) the 100 µm confocal aperture is imaged to the
spectrograph slit with a demagnification factor of 4, such that the confocal aperture is matched
to a single camera pixel (26 µm), and the angle of the light entering the slit falls within that
allowed by the f number of the spectrograph (for the Andor Shamrock, f = 6.5).
Independently, light from the 100 W halogen lamp (HL; Nikon, Japan) is focused onto the
sample and into the MO. Since some of this light has a shorter wavelength than 500 nm, it
passes through the DS. This light passes into the body of the microscope where it reflects from
a mirror through an internal imaging system, and images onto a digital camera (DC; Basler AG,
Germany; acA2000–340km) fixed to the front exit port of the microscope.
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Figure 3.4: Schematic of the custom built Raman spectroscopy set-up in the Biophotonics Lab in
Maynooth University, along with images of individual components. LP, line pass filter; L, lens;
M, mirror; DB, dichroic beamsplitter; DS, dichroic short pass filter; MO, microscope objective;
S, sample stage; HL, halogen lamp; CA, confocal aperture; LgP, longpass filter; DC, digital
camera.
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3.6.2 Commercial Horiba LabRam HR
Commercial Raman micro-spectroscopy systems are widely available from companies such as
Renishaw (Renishaw plc, UK), Horiba (Horiba Jobin Yvon Inc., US), and Ondax (Ondax Inc.,
US). The Horiba LabRam HR 800 system, which is employed across studies within this thesis,
is an integrated, robust, and high performance Raman micro-spectroscopy system, as shown
in Figure 3.5. There are many advantages to this commercial device, such as high spectral
resolution, multiple laser and detector options, along with a flexible choice of gratings and
aperture sizes.
Figure 3.5: Image of Horiba LabRam HR 800 dual microscope system at the Focas Institute,
Dublin Institute of Technology, Ireland.
The LabRam HR is operable for Raman micro-spectroscopy with five different source wave-
lengths, as outlined in Table 3.1. These source wavelengths range from 473 nm (blue) through
to 830 nm (NIR), allowing for a direct comparison between Raman spectra across different
wavelengths, as investigated further in Chapter 7.
Wavelength Power Details
473 nm 50 mW Solid state diode laser
532 nm 50 mW Solid state diode laser
660 nm 100 mW Solid state diode laser
785 nm 300 mW CLDS point mode diode laser
830 nm 200 mW CLDS point mode diode laser
Table 3.1: Details of the lasers employed within the Horiba LabRam HR 800 commercial sys-
tem.
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3.6.3 Raman optical tweezers
Although a Raman tweezers system is not employed in the course of this work, these systems
are often used in similar studies, and for this reason, a brief description is included here. Ra-
man tweezers are based on combining the principle of Raman micro-spectroscopy with optical
trapping (52; 53), as illustrated in Figure 3.6. Optical trapping, or optical tweezing, is a tech-
nique that utilises a high NA MO, usually configured in an inverted microscope, together with
a suitable laser, to trap a cell in the waist of focused laser beam. The tightly focused light cre-
ates a sharp gradient of intensity which leads to gradient forces trapping the cell. The trapped
cell can be suspended in a liquid (or air) environment, and moved in three dimensions by ma-
nipulating a component in the optical set-up. By combining Raman micro-spectroscopy with
optical trapping, individual cells can be biochemically probed under physiological conditions,
or in microfluidic chips.
Figure 3.6: (a) Schematic of a standard Raman optical tweezers set-up, (b) schematic of a dual
beam Raman tweezers set-up. HL, halogen lamp; C, condenser; MO, microscope objective; L,
lens; M, mirror; DC, digital camera; DB, dichroic beam splitter; CA, confocal aperture, LP,
long-pass filter.
Raman tweezers offer exciting new avenues of research, particularly in the areas of microflu-
idics and urine cytology. This technique can be used for investigating the biochemistry of living
cells in their natural environment with 3D spatial resolution. (54) It can also be used for diag-
nostic classification of bladder and prostate cancer cells, as shown elsewhere (55; 56; 57; 58).
3.6.4 Raman spectroscopy with a fiberoptic probe
Similar to Raman tweezers, a fiberoptic Raman spectroscopy system is not applied within this
thesis, but it is discussed as an alternative diagnostic approach. A fiberoptic Raman set-up con-
sists of a specialised fiber probe, an excitation source (laser), fiber couplers to deliver the light
in and out of the fiber, filters to remove unwanted signals, and a detection system (spectrograph
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and cooled CCD camera), as can be seen in Figure 3.7. This fiberoptic probe can be inserted
during a cystoscopic diagnostic procedure, and be used to give real-time analysis and classi-
fications of the bladder wall. Similar to conventional Raman micro-spectroscopy, the Raman
fiberoptic probe can be used to monitor in vitro and ex vivo specimen also. The main advan-
tages of this system include the potential to replace the need for multiple biopsies, reductions in
the turn-around time for diagnosis, reductions in histological/pathological costs, and improved
surgical procedures by using the probe to identify border regions of diseased or damaged tissue.
Figure 3.7: Schematic of a basic Raman fiberoptic probe set-up, which can be applied to bio-
logical samples both in vivo and in vitro, with a front view of the design of a fiberoptic probe
inset, showing the central delivery fiber which is surrounded by several collection fibers. It is of
note that it is often more conventional to integrate the filters into the tip of the fiberoptic probe
instead, but for ease of illustration, they have been shown in the positions above.
A Raman probe for cystoscopic or endoscopic diagnostics must be able to fit into the in-
strument channel of a standard cystoscope (or endoscope or catheter), be biocompatible, and
robust enough to withstand decontamination/disinfection processes. NIR lasers (785–830 nm)
are generally used for Raman fiberoptic probes since they minimise thermal damage to the
tissue sample being analysed. It is also essential that there are low fluorescence, or photolumi-
nescence, signals generated within the probe. The general design of a Raman fiberoptic probe
is shown in Figure 3.7; consisting of a central delivery fiber that is surrounded by several col-
lection fibers, where the diameter of each fiber is between 100 and 400 µm depending on the
system design. Typically a bandpass filter is placed at the tip of the excitation fiber to remove
unwanted background signals, and a longpass filter is placed at the tip of the collection fibers
to prevent Rayleigh scattered light from entering these fibers. Lenses (such as a ball lens, made
from sapphire) at the probe tip or tapered fiber tips can also be used to improve the efficiency
of delivering both the excitation light to the tissue and Raman scattered light into the collection
fibers (further information is available in Ref. (59)).
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3.7 Summary
Each of the key components of a Raman micro-spectrometer have been discussed here. Impor-
tant considerations for the design of a Raman system include the source laser, the microscope
body, choice of spectrometer and CCD, and the utilisation of a confocal aperture. As has been
highlighted in this chapter, it is particularly important to choose a laser that is suitable for the
application involved, such as a laser with a TEM00 Gaussian profile. Other considerations in-
volve choosing an NIR laser in order to minimise the possibility of tissue damage, or choosing a
laser in the visible wavelength region (e.g. 532 nm) if shorter acquisition times are desired. It is
also important to choose a spectrograph and CCD camera that have good quantum efficiencies
within the desired acquisition range.
The custom Raman micro-spectrometer that was designed and built in our laboratory has
been described in Section 3.6.1, with information given on each of the optical components
within the system, such that the design could be replicated in another laboratory. Further details
on commercial Raman systems, along with a Raman tweezers set-up and a fiberoptic Raman
system have also been provided.
Raman spectroscopy is an opto-electronic technique, resulting in complex spectra that re-
quire the development of pre-processing and multivariate statistical algorithms in order to achieve
reliable and reproducible spectra, which are necessary for the development of an accurate di-
agnostic classifier. Such algorithms involve accurate system calibration (post-acquisition), re-
moval of unwanted background signals, and noise reduction, as discussed discussed in further
detail in Chapter 4.
Chapter 4
Numerical methods
4.1 Introduction
In the previous two chapters, the physics of Raman spectroscopy was discussed, followed by
a detailed discussion on the design and construction of a confocal Raman micro-spectrometer.
However, Raman spectroscopy is not a purely optical technique, it also incorporates a suite of
numerical processing techniques designed to reduce the impact of noise, eliminate unwanted
background artifacts, and standardise the output spectra, in terms of calibration and normalisa-
tion, such that the spectra can be reliably compared. As high quality spectroscopic equipment
has become available for the analysis of chemical, pharmaceutical, and biological samples,
there has been a parallel development of multivariate statistical tools for the analysis of the
corresponding spectra. These statistical tools are focused on identifying subtle variations in
spectral datasets and exploiting these patterns for the purpose of classification.
Raman spectra consist of three main components: Raman signals, a baseline, and noise. The
presence of these unwanted baseline and noise signals is often reduced using pre-processing
techniques before the classification process as they can lead to a larger diagnostic error other-
wise. Section 4.2 discusses the calibration of Raman datasets, and in Section 4.3 the reduction
of noise is discussed. Baseline correction methods are reviewed in Section 4.4, followed by
a discussion of normalisation methods in Section 4.5. Finally multivariate classification algo-
rithms are reviewed in Section 4.6, with a summary provided in Section 4.7.
4.2 Calibration
Small changes in the optical set-up (e.g. rotation of a grating), and/or a change in temperature
can result in a shift in the Raman spectrum along the wavenumber axis. Furthermore, the op-
tical components, such as the grating and camera, as well as the optical lenses and filters, can
have a significant impact on the intensity values of the spectrum recorded by a given Raman
micro-spectrometer. Accurate calibration is therefore required to allow for a fair and mean-
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ingful comparison of Raman data obtained from different Raman micro-spectroscopic set-ups.
This is particularly important when creating standard medical diagnostic databases for disease
identification. It is possible to perform calibration on the system itself, or retrospectively, to
the spectral datasets after acquisition. To perform calibration on a dataset, the wavelength axis
should first be calibrated, followed by intensity calibration, and finally, wavenumber calibration.
Wavelength calibration is performed in order to assign exact wavelength positions to each
column of pixels along the CCD camera. There are two causes for nonlinearity in the wave-
length dispersion across the CCD caused by the spectrograph grating. The first is inherent in
the sine function that describes wavelength dispersion (using the grating equation), while the
second is the result of distortions that are present in all spectrograph optical designs. Theo-
retically, a one- or two-point calibration could be sufficient to compensate for the first cause
of nonlinearity, however multi-point calibration is required to correct adequately for distortion
and permit spectrograph-to-spectrograph comparisons. (60) To achieve this, the spectrum from
a known sample, such as a Neon lamp, is measured. The spectrum of Neon contains many
spectral peaks, and the position of each peak is calibrated against a reference spectrum, which
contains the precise wavelength position for each spectral line. (61)
Intensity calibration is then performed to correct for the wavelength-dependent transmission
efficiency of the optical elements within the system, as well as correcting for the sensitivity of
the detector itself. This can be achieved using a National Institute of Standards and Technol-
ogy (NIST) calibrated white light source (61; 62), or using the fluorescent signal from green
glass. (63)
Finally, wavenumber calibration is performed. This step is particularly important if the
source wavelength is not accurately known. The purpose of wavenumber calibration is to assign
a particular wavenumber shift to each column of pixels in the CCD camera. (64) To perform
wavenumber calibration, a known sample such as silicon is recorded, and the position of the
peak(s) obtained using Raman spectroscopy are calibrated with the precisely known Raman
peak positions for the calibration sample used. Further information on Raman system calibra-
tion can be found elsewhere. (61; 65; 66; 67)
It should be noted that whilst such a rigorous approach is necessary for the sharing of data
across different systems, the datasets analysed within this thesis have only been wavenumber
calibrated based on the position of the silicon peak. In order to minimise intensity artifacts,
spectra were recorded within relatively short time periods for each study, i.e. within one or two
weeks, without any system adjustments, and with the room temperature maintained as constant
insofar as possible.
4.3 Noise
There are four main sources of noise to consider with Raman spectral acquisition when us-
ing a CCD detector. These are (i) shot noise, which arises from statistical fluctuations in the
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number of photons collected by the CCD pixels; (ii) dark current, caused by thermally gener-
ated electrons within the CCD pixels; (iii) readout noise, generated by the electronic circuitry
in the CCD; and (iv) cosmic ray artifacts, originating from high energy particles from outer
space. (68; 69; 70) In order to achieve a suitable SNR for a given dataset, these sources of noise
should be minimised insofar as possible.
Smoothing is often applied to Raman spectra to remove high frequency noise signals. A
Savitzky Golay filter is often used, which consists of a moving window based polynomial fitting
procedure. (71) A Savitzky Golay filter requires specific parameters such as the size of the
moving window and the polynomial order. As the window size increases, some of the Raman
bands may disappear, so it is important to choose appropriate parameters for the data being
smoothed. Alternatively, a Gaussian or median filter can be used for noise removal instead. (60)
During Raman acquisition, particularly with long duration measurements, it is common to
find cosmic ray artifacts in spectra. Due to their nature, cosmic ray artifacts occur randomly in
time and space, and can be identified as intense narrow spikes present on Raman spectra. Cos-
mic rays are often removed from raw spectra by collecting two spectra for each experiment and
comparing them on a pixel by pixel basis. If the difference exceeds a predetermined threshold,
then the presence of a cosmic ray is assumed, and the lesser value is used for that pixel. (72)
Otherwise the average value is taken, thereby taking full advantage of the SNR offered by the
full acquisition time of both recordings.
4.4 Baseline correction
The baseline of a spectrum is described as the slowly varying curve seen in the lower range
of the spectrum without the distinct Raman peaks. This baseline can be varying or sloped,
and is most often ascribed to an auto-fluorescence from the sample itself. (73; 74) However,
the source of this signal is debatable, with some authors suggesting that it may originate from
sample morphology and Mie scattering of the source laser wavelength. (75) Regardless of its
origins, it is possible to characterise the signal as a slowly varying polynomial. It is necessary
to remove this baseline signal insofar as possible in order to facilitate an accurate comparison
of related spectra, in particular for the application of chemometrics for the classification of a
given sample spectrum. The three baseline correction algorithms that have been applied to the
data within this thesis are discussed in Sections 4.4.1–4.4.3.
4.4.1 Modified polynomial
The modified polynomial baseline correction method, as proposed by Lieber et al. (73), is based
on the subtraction of a polynomial using an ordinary least squares (OLS) fitting approach. (76)
In an automated approach, the Raman spectrum is first fitted with an N order polynomial using
OLS. The values of the spectrum that lie above the polynomial are set equal to the value of the
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polynomial; the resultant signal is again fitted with an N order polynomial, and the process is
iteratively repeated, until a point is reached such that the polynomial lies directly underneath the
Raman spectral peaks. This method requires two input variables, the order of the polynomial
N and the number of iterations for the algorithm to run; both of which are typically dataset
dependent.
4.4.2 Modified polynomial plus known background signal
An algorithm is used in Chapter 7 of this thesis which is based on some minor changes to the
method proposed by Beier et al. (2009). This algorithm is based on the subtraction of a known
background signal and an N order modified polynomial fit (77), which can be used to remove
both the baseline and any unwanted background signals present within Raman spectra, such as
the background glass signal present in spectra recorded from cells on glass slides. (78; 27)
Firstly, two or three spectra are recorded from the substrate (or another known contaminant),
and an average background spectrum B0(λ) calculated. Since this is a discrete numerical algo-
rithm, it is more appropriate to describe the signals in terms of their discrete representations;
where λ → nδλ and n takes integer values from 0 → N − 1, where δλ denotes the sampling
interval of the recorded spectrum and Nδλ is equal to the bandwidth. A Gaussian smoothing
function is applied to the background spectrum to reduce the presence of noise. Equation 4.1
represents the process of discrete convolution with a Gaussian filter that is sampled at the same
rate as the spectrum. The width of the Gaussian function is taken to beMδλ, which corresponds
to the region where the function has appreciable values, for example if Mδλ = 6σ, then the
region will contain over 99% of the Gaussian signal’s energy.
B0(nδλ) =
N−1∑
m=0
B0(mδλ) exp
[
δλ2(m− n)2
2σ2
]
(4.1)
where σ is the standard deviation, and n takes the same range of values as previously mentioned.
This equation can be calculated by applying zero padding followed by multiplication of the
Discrete Fourier Transform (DFT) of the signal and that of the Gaussian filter followed by an
inverse DFT.
A range of different weights, or concentrations C, of this background signal B0(nδλ) are
subtracted from the recorded cell spectrum X0(nδλ), followed by the subtraction of an N order
polynomial P (nδλ), which is generated using Matlab’s polyfit function, resulting in a spec-
trum, R(nδλ), consisting of residual values:
R(nδλ) = [X0(nδλ)− (C ×B0(nδλ))]− P (nδλ) (4.2)
The sum of the square of these residual values was obtained for each C value, until a minimum
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R1(nδλ) value was obtained, resulting in a new estimate of the background spectrum B1(nδλ):
B1(nδλ) = X0(nδλ)−R1(nδλ) (4.3)
B1(nδλ) = [C1 ×B0(nδλ)] + P1(nδλ) (4.4)
A new spectrum X1(nδλ) is now defined that is made up of the values of both X0(nδλ) and
B1(nδλ), where for each individual spectral component, the minimum value is taken from the
two corresponding components of X0(nδλ) and B1(nδλ):
X1(nδλ) = min[X0(nδλ), B1(nδλ)] (4.5)
This entire process is then repeated by replacing B1(nδλ) with Bi(nδλ) until the optimal fit of
Bi(nδλ) to Xi(nδλ) is found such that the peaks of the original cell spectrum, X0(nδλ), all lie
above the modelled background Bi(nδλ):
Ri(nδλ) = [Xi−1(nδλ)− (B0(nδλ)× Ci)]− Pi(nδλ) (4.6)
Bi(nδλ) = [Ci ×B0(nδλ)]− Pi(nδλ) (4.7)
Xi(nδλ) = min[Xi−1(nδλ), Bi(nδλ)] (4.8)
The Raman peaks can then be isolated from the original cell spectrum by:
Raman peaks = X0(nδλ)−Xfinal(nδλ) (4.9)
Figure 4.1 demonstrates the application of this algorithm to one of the spectra recorded in this
thesis, whereby different values of C are applied to B0(nδλ), resulting in a new Bi(nδλ) for
each proceeding iteration, in order to obtain a residual spectrum containing only Raman peaks
without any background contributions.
The background subtraction algorithm described here is based on the method developed
by Beier et al., which can be consulted for further information. Some notable changes to this
algorithm have been made; firstly, a smoothing filter has been applied to the initially recorded
background signal to reduce noise; secondly for the estimate of C, a uniformly sampled range
of C is searched in each iteration as opposed to the use of an empirically chosen factor and the
fminsearch function in Matlab; and finally, the background is modelled on a combination of
C times the recorded background, B0(nδλ), instead of C times the recorded cell data, X0(nδλ)
as suggested by Beier and colleagues. (77) It should be noted that the algorithm applied in
Chapter 8 is based on the exact method proposed by Beier et al., not on our modified version.
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Figure 4.1: An example of the modified polynomial plus glass signal algorithm being applied
for background subtraction - whereby the recorded background signal is combined with a fifth
order polynomial until a value of C is found such that the modelled background fits directly
under the Raman peaks of the original cell spectrum.
4.4.3 Extended multiplicative signal correction
An extended multiplicative signal correction (EMSC) algorithm can also be applied to Raman
spectra to remove known background contaminants along with the slowly varying baseline sig-
nal. (79) This algorithm computes an optimum baseline made up of an N order polynomial and
a weighted contaminant signal that is recorded at the beginning of each experiment (e.g. signal
from a glass substrate), as described in further detail in Chapter 8. The EMSC algorithm applies
a least squares fit to (i) a reference Raman spectrum, (ii) the contaminant signal, and (iii) an N
order polynomial. The weight of (i) and (ii), as well as the coefficients of the polynomial are
returned by the EMSC algorithm. The reference spectrum provides a basis for all other spec-
tra to be fitted, and for the purposes of this thesis, it is represented by an epithelial cell type
recorded on a CaF2 substrate. Following an OLS determination of the “best fit” for a given
Raman spectrum, components (ii) and (iii) are subtracted from the raw spectrum. The value of
N is dataset dependent, with higher order polynomials required for accurate modeling of the
baseline signal across some datasets. It has been shown elsewhere that the use of high values of
N (up to N = 7) does not result in over-fitting with EMSC (80), although for many of the cases
presented here, only a straight line (N = 1) is required (see Chapter 8).
EMSC can also be applied for the removal of Mie scattering artifacts from FTIR datasets,
as applied in Chapter 10. This algorithm is based on a reference spectrum either generated from
Matrigel or from the mean spectrum for a given dataset. Further information on the application
of EMSC for resonant Mie scatter correction is available elsewhere. (81; 82; 83)
Based on the same notation as Section 4.4.2, EMSC can be defined as follows: a raw spec-
trum, X0(nδλ), which can be described as a linear superposition of the Raman spectrum of
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interest, R(nδλ), the baseline signal, P (nδλ), and the contaminant signal, B(nδλ):
X0(nδλ) = R(nδλ) +B(nδλ) + P (nδλ) (4.10)
The goal is to estimate the values ofB(nδλ) and P (nδλ) such that they may be subtracted from
the recorded spectrum. Although noise will always be present in the raw spectrum (84), it is
assumed that the SNR is sufficiently high such that the noise signal may be ignored.
A reference spectrum, r(nδλ), is first obtained such that it may be assumed thatR(nδλ) can
be approximated by the product of this reference spectrum and a certain weight:
R(nδλ) ≈ cr × r(nδλ) (4.11)
where cr is a scalar for a given spectrum.
Similarly, by recording a spectrum directly from a pure contaminant (e.g. a glass slide),
b(nδλ), it is possible to represent the spectral contribution of glass in the recorded cell spectrum,
B(nδλ), as the product of the pure glass spectrum and a certain weight:
B(nδλ) = cb × b(nδλ) (4.12)
It should be noted that both cr and cb are scalar values that are unique to each cell spectrum, and
are dependent on experimental parameters such as the Raman acquisition time.
The slowly varying baseline P (nδλ) can be represented using an appropriate N order poly-
nomial:
PN(nδλ) = c0 + c1(nδλ) + c2(nδλ)
2 + ...+ cN(nδλ)
N (4.13)
where N is the order of the polynomial, and cm for m = 0 → N represents the various
coefficients in the polynomial. (76)
The raw spectrum, X0(nδλ), the reference spectrum, r(nδλ), the contaminant spectrum,
b(nδλ), and the order of the polynomial, N , are all input to the EMSC algorithm, which returns
estimates for cr, cb, and cm for m = 0→ N . These estimates are based on an optimal fit of the
various vectors in Equation 4.14 in an OLS sense. (80; 79)
X0(nδλ) ≈ [cr × r(nδλ)] + [cb × b(nδλ)] +
[
N∑
m=0
cmnδλ
m
]
(4.14)
The background corrected cell spectrum, Xfinal(nδλ), is given by:
Xfinal =
X0(nδλ)− [cb × b(nδλ)]−
[
N∑
m=0
cmnδλ
m
]
cr
(4.15)
For consistency, the same notation has been used throughout Sections 4.4.2 and 4.4.3, however,
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if the reader prefers vector notation to describe this algorithm, this is available in Ref. (85).
4.4.4 Other background correction methods
Various other background algorithms and techniques exist that are not applied within this thesis.
The modified polynomial method can sometimes lead to unstable behavior at the end points of
the baseline of a spectrum, which led to the development of the “rubberband” method. This
method fixes the endpoints of the dataset in order to avoid any such alterations from occur-
ring. (74)
The presence of contaminant signals is highly undesirable in Raman spectra. These signals
can arise from unwanted chemical artifacts or from the sample substrate (see Chapter 7). These
signals can be removed using the methods highlighted in Sections 4.4.2 and 4.4.3, or using an
independent component analysis (ICA) approach. Tfalyi et al. applied ICA along with non-
negative least squares to remove residual wax contributions from Raman spectra of biological
samples that had previously been stored in embedded paraffin. (86) A similar method was ap-
plied for the removal of pharmaceutical drug components (87), and the signal from polystyrene
nanoparticles (88), present in Raman cell spectra.
Alternatively, it is possible to record Raman spectra using different Raman system designs
in order to reduce the background signals. Such systems include the ultrafast optical Kerr
effect (89; 90), or the use of a modulated laser source (9; 91). However, both of these methods
are expensive, and experimentally complicated.
4.5 Normalisation
Normalisation in the intensity axis is performed to adjust peak intensity values from each spec-
trum in order to provide a common scale for comparing Raman peaks across a range of spectra.
Normalisation is achieved by dividing each variable in a spectrum by some constant. There are
a few normalisation methods that can be utilised for Raman spectra; peak normalisation and
vector normalisation are most commonly applied, but area normalisation or min-max normal-
isation could also be applied. For peak normalisation, the constant is measured as the height
difference between the baseline and the maximum point of a chosen peak; vector normalisa-
tion obtains the constant value by calculating the sum of the intensity values for each variable
in the spectrum, and finding the square root of this value; for area normalisation, the constant
corresponds to the sum of the intensity values for each variable in the spectrum; and min-max
normalisation involves setting the maximum intensity value to 1, and the lowest intensity value
to 0. (92; 93)
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4.6 Multivariate statistical algorithms
In the last ten years, there has been growing interest into the diagnostic potential of Raman
spectroscopy for classifying healthy and cancerous tissues and cells, as well as identifying the
grade (or stage) of cancer present. This approach generally involves the training of a statistical
algorithm based on known pathological samples, and as such, some degree of human error is
introduced into the method from the beginning. Nonetheless, Raman based diagnostics have
shown increasingly impressive results in recent years. This section provides information on
the different multivariate techniques that have been used to develop diagnostic algorithms for
classification of data obtained from Raman spectroscopy. Techniques such as principal compo-
nent analysis (PCA) and linear discriminant analysis (LDA) are most commonly employed for
classification of biological samples, but other techniques have also been demonstrated.
4.6.1 Principal component analysis
PCA is an unsupervised statistical tool used to reduce the number of variables within a data
set. To do this, PCA transforms the spectral data into a set of variables called principal compo-
nents (PC), whereby all PCs are orthogonal to each other and they are generated in such a way
as to represent as much variance within the dataset as possible. This is achieved by finding the
direction through the data set that explains the maximum variance, which is known as the first
PC coefficient, and is equivalent to finding the line of best fit through plotted data points. (94)
Additional PC’s must be orthogonal to the previous ones, whilst describing the maximum vari-
ance remaining in the data, as shown in Figure 4.2.
Figure 4.2: A representation of PCA, whereby component axes are used to maximise the vari-
ance within a dataset
Computationally, PCs are found by determining the covariance matrix of the data set, and
calculating the eigenvectors and eigenvalues of this covariance matrix. The eigenvector, or
“loading”, with the largest eigenvalue represents the first PC, and the eigenvector with the sec-
ond largest eigenvalue is the second PC, and so on. When the values of each PC are calculated,
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it is then possible to use basic geometry to express each sample data set in terms of linear sum-
mations multiplied by a scalar value, known as a “score”. (95) With this technique it is possible
to significantly reduce the number of variables in a dataset whilst still maintaining almost all of
the spectral information; for example, in an average Raman spectral measurement, data is col-
lected between 400–1800 cm−1, with measurements taken approximately every 3 cm−1, thus
resulting in ∼500 variables in the original data set, which can be reduced to ∼20 using PCA.
Further analysis can then be applied to these PCs to organise them into groups, or clusters, rep-
resenting different pathologies; to achieve this, techniques such as LDA are often utilised. The
main advantage of this tool is that it provides a simpler representation of the data and allows for
faster classification algorithms to be designed.
4.6.2 Linear discriminant analysis
LDA, also known as Fisher’s discriminant analysis, is a supervised multivariate technique used
to optimise class separability by finding the direction that provides the best separation for two
or more groups of data. LDA is often applied to PC scores to further reduce the dimensionality
of the data set. Similar to PCA, this is achieved by finding a linear combination of vectors that
maximise the variance of the dataset, but with the addition of finding the component vectors that
maximise the separation between multiple classes, as shown in Figure 4.3. (64) By maximising
the variance in this manner, LDA is able to provide the optimum separation for each group, thus
improving classification results.
Figure 4.3: Representation of LDA, which maximises the component axes to provide class-
separation
So, in short, PCA is an “unsupervised” algorithm, which means it “ignores” class labels, and
its goal is to find the directions (PCs) that maximise the variance in a dataset. In contrast, LDA
is “supervised” and computes the directions (LDs) that represent the vectors that maximise the
separation between multiple classes. In general, dimensionality reduction does not only help
with reducing computational costs for a given classification task, but it can also be helpful to
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avoid overfitting by minimising the error in parameter estimation.
4.6.3 Cross validation
Cross validation is often used to estimate how accurately a diagnostic classification model will
perform. This is achieved by assessing the results of the statistical algorithm when applied to
a validation set of data. The most common method used for assessing Raman spectra models
is leave-one-out cross validation. Leave-one-out is based on using a single spectrum as the
validation set, and the remaining spectra are used as the training set for the algorithm. This
is repeated to test each spectrum in the dataset iteratively, and can be used to determine how
accurate the model is at predicting the pathological status of the sample. Alternative variations
include k-fold cross validation, blind testing, or double blind testing. K-fold cross validation
involves partitioning the datasets, such that k spectra are used for validation with the remaining
spectra used for training, blind and double blind testing are based on concealing pathological
information from the data in order to remove possible observer bias.
Classified as:
Cancerous Healthy
Cancerous samples TP FN
Healthy samples FP TN
Table 4.1: Basic demonstration how samples may be classified following PC-LDA with a cross
validation approach. TP, true positive; FN, false negative; FP, false positive; TN, true negative.
Diagnostic classification results are often presented in terms of sensitivity and specificity,
which provides a good representation of the performance of the algorithm. Based on the values
shown in Table 4.1 for a basic classifier, the sensitivity and specificity values can be calculated
as follows:
• Sensitivity:
Refers to the proportion of things that are being looking for that are found, basically how
good the model is at getting things right:
sensitivity =
TP
TP + FN
(4.16)
whereby TP is the true positive, and FN is false negative.
• Specificity:
The proportion of things that are not being looked for that are not found, basically how
good the model is at making sure the wrong things aren’t found:
specificity =
TN
TN + FP
(4.17)
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whereby TN is the true negative, and FP is false positive.
4.7 Summary
Raman micro-spectroscopy is a complex modality that can be applied for disease classification.
The physics of Raman spectroscopy, and the design of Raman micro-spectrometers, have been
discussed in Chapters 2 and 3, respectively. However, due to the presence of noise, unwanted
background signals, as well as calibration errors, it is necessary to apply a range of numerical
methods to produce Raman spectra that are reliable and reproducible. This chapter presents
various pre-processing tools that are available for calibration, noise reduction, and normalisa-
tion. Additionally, baseline correction methods and algorithms for the removal of unwanted
contamination signals are discussed in Section 4.4. These techniques are essential to produce
spectra that can be used for the accurate diagnosis of disease pathologies.
Following pre-processing, Raman data collected from different biological samples can be
classified using multivariate statistical algorithms. The most common algorithms applied for
classification of Raman spectra involve PCA and LDA, as discussed in Section 4.6, with sensi-
tivity and specificity results often calculated based on a leave-one-out cross validation approach.
Furthermore, in order to produce reliable classification algorithms, it is important to record Ra-
man spectra from biological samples that have been prepared using suitable sample preparation
methods, as discussed in further detail in Chapter 5.
Chapter 5
The biology of cells, cancer, and exosomes
5.1 Introduction
In order to appreciate the application of Raman micro-spectroscopy to biological specimen
for disease diagnostics, it is essential to understand the fundamental biology involved in cells
and tissues, the origin and progression of cancer, and the role of exosomes within the body.
Section 5.2 provides an overview of cell biology, Section 5.3 discusses how cancer occurs, and
Section 5.4 investigates the origin of exosomes and their potential role in disease progression.
The methods involved in the preparation of cytology samples during the course of this thesis
are discussed in Section 5.5. The main focus of this chapter is on the biology of the urinary
bladder, as the development of Raman based urine cytology protocols are the primary focus of
this thesis. This chapter is followed by a more detailed discussion of bladder cancer, and recent
work in the area of bladder cancer diagnostics using Raman spectroscopy.
5.2 Cell biology
Cells are single units that work together to carry out all of the necessary functions of an or-
ganism. (96) Whilst cells all have similar components, individual subgroups exist that can do
specialised jobs. There are two main types of cells: prokaryotic (bacteria) and eukaryotic (an-
imals and plants); however, this thesis is only focused on eukaryotic cells. Cells share the
following common organelles: nucleus, nucleolus, endoplasmic reticulum (smooth and rough),
golgi apparatus, lysosomes, peroxisomes, and mitochondria, which are shown in Figure 5.1.
Cell nuclei vary in size depending on the cell type, but typically have a diameter of ∼5 µm.
The nucleus is the ‘control centre’ of a cell, where genetic information is stored in the form
of chromatin. The nucleus is surrounded by a nuclear membrane consisting of a phospholipid
bilayer (similar to that found in the cell’s plasma membrane), with the outer membrane attached
to the rough endoplasmic reticulum, and the inner membrane carrying unique proteins that are
specific to the nucleus. Nuclear pores can be found along the nuclear membrane to allow for
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Figure 5.1: Schematic of a typical eukaryotic cell
the transport of RNA from the nucleus into the cytoplasm for protein synthesis, and for the
transport of specific proteins into the nucleus. The nucleolus is found within the nucleus, and is
the location of DNA, and many types of RNA and proteins. Further information on the roles of
other cellular organelle can be found elsewhere. (97)
Four levels of organisation can be found within vertebrate organisms: (i) cells, (ii) tissues,
(iii) organs, and (iv) organ systems. Groups of cells which have a similar structure and function
form tissues (e.g. epithelial tissue); organs are composed of tissues that form a structural and
functional unit (e.g. bladder); and an organ system consists of a group of organs that work
together to perform the major activities of a body (e.g. urinary system).
5.2.1 Epithelial tissue
Epithelial tissue, otherwise known as an epithelium, is a continuous layer of tightly packed
cells that covers the surface of the body and inner cavities. External epithelial surfaces protect
the body from invasion, injury, and dehydration. The internal surface mainly offers protection,
with some cell types secreting mucus (e.g. digestive tract), removing impurities (e.g. respiratory
tract), or absorbing molecules (e.g. kidney tubules). (98)
There are three types of epithelial tissue: (i) squamous: composed of flattened cells, and
provides protection, diffusion, and filtration; these cells are mainly found in the lining of the
lungs and blood vessels; (ii) cuboidal: these are cube shaped cells which provide protection,
secretion, and adsorption, and are found in the lining of kidney tubules; and (iii) columnar:
composed of rectangular or column-shaped cells, which provide protection, secretion, and ad-
sorption, and are mainly found along the digestive tract. Additionally, the epithelium can be
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simple (i.e. single layer of cells), stratified (i.e. layers of cells on top of each other), or pseudos-
tratified (i.e. appears to be layered, but all cells touch the base line). (98) Figure 5.2 illustrates
the differences between each type of epithelial tissue.
The urinary bladder is lined with transitional epithelium, otherwise known as the urothe-
lium or bladder mucosa, which consists of multiple layers of epithelial cells that can contract
and expand to accommodate large volumes of urine. The urothelium provides protection to
surrounding tissues from acidic or alkaline urine.
5.3 Cancer biology
Cancer is defined as a disease that involves a group of cells growing uncontrollably by disregard-
ing the normal rules of cell division (i.e. mitosis). (99) Cells are constantly subject to signals
that dictate whether the cell should divide, differentiate, or die. Cancer cells do not respond cor-
rectly to these signals, resulting in uncontrolled growth and proliferation, which can eventually
become fatal. Cancer is a disease that involves changes or mutations in the cell genome, and
these changes disrupt the delicate cellular division process, resulting in cells that keep dividing
and form cancerous tumours. Malignant tumours must not be confused with benign tumours,
which are slow growing and remain confined to their original location, and typically are not
life-threatening. (100)
Approximately one in three people will suffer from cancer during their lifetime, with inci-
dence rates varying dramatically across countries and populations. (100) Cancer is a multi-gene,
multi-step disease originating from a single abnormal cell with a DNA mutation. Subsequent
rounds of mutations and expansion of these cells results in the formation of a tumour. (101)
Death as a result of cancer is due to the invasion, erosion, and spreading of tumours into sur-
rounding tissues (i.e. metastasis). Many factors are involved in the initiation and progression of
cancer, including the environment (tobacco, chemicals, radiation) and factors within the cell it-
self (inherited mutations, hormones, immunity). It is important to note that it takes a significant
amount of time for these DNA mutations to accumulate and result in a detectable cancer. (102)
There are four distinct types of cancer: (i) carcinoma: this is a malignancy found within
epithelial cells and tissues; (ii) sarcoma: this is a solid tumour found within connective tissues;
(iii) leukemia: a cancer that arises from blood-forming cells; and (iv) lymphoma: a cancer
formed within immune-system cells. Further subgroup classifications are also made to define
the tissue and cell types involved in the cancer. (102)
Although cancerous tumour cells share common characteristics, every type of cancer has
its own particular sequence of mutations and uncontrolled growth. These common character-
istics include a lack of differentiation, abnormal enlarged nuclei with an abnormal number of
chromosomes, and the ability to induce angiogenesis and metastasis. Additionally, cancer cells
can form tumours, this is particularly evident when growing cells in a petri dish; normal cells
grow to cover the bottom of the dish in a single layer, and require a growth factor to induce
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Figure 5.2: A comparison of each of the different epithelial tissue subgroups.
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Figure 5.3: Typical differences found between normal and cancerous cells.
division, whereas cancer cells continue growing on top of each other within the dish. Figure 5.3
illustrates the typical differences seen between normal and cancerous cells, with large, variable
nuclei, small cytoplasm to nuclei ratios, variations in cell size and shape, and a disorganised
arrangement of cells being the most obvious differences. (100)
5.3.1 Cancer diagnostics
A myriad of diagnostic tests are available for the detection and evaluation of human can-
cers, ranging from whole body PET-CT (positron emission tomography-computed tomography)
scans, invasive endoscopic procedures, cytological smears, to blood tumour marker tests. Many
non-invasive and highly accurate diagnostic modalities have been identified, however despite
these significant research efforts, many organ-specific cancers remain without an accurate diag-
nostic tool. One cancer in particular is urothelial carcinoma (i.e. bladder cancer), which does not
carry any specific symptoms, and can only be accurately identified with an invasive cystoscopic
procedure. (103) New optical techniques are currently being developed for cancer diagnostics,
such as optical coherence tomography (OCT) (104), diffuse reflectance spectroscopy (105), and
spatial light interference microscopy (SLIM). (106) This thesis is interested in the application
of vibrational spectroscopic techniques for highly accurate, non-invasive cancer diagnostics.
5.3.2 Hypoxic cancer tumours
Hypoxia is a key feature of solid tumours and occurs when the tumour has outgrown its vas-
culature supply. (107) Tumour hypoxia is associated with several aspects of aggressive tumour
behaviour including increased invasiveness and proliferation, the formation of metastasis and
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poor patient survival rate. Importantly, hypoxic tumours are known to be highly resistant to ra-
diation and chemotherapy treatments. (108; 109) It has been shown by Watson et al. (110) that
hypoxia can cause cells to become senescent (i.e. they are still viable, but now cease to divide),
which is problematic for treatment since many chemotherapies target actively dividing cells, and
therefore senescent cells may remain unaffected when chemotherapeutically challenged. Para-
doxically, chemotherapeutics themselves can also cause senescence, termed therapeutic induced
senescence (TIS). (111) Tumour hypoxia results in a poor patient survival rate, so knowing the
cause and extent of hypoxia is invaluable for treatment planning.
5.4 Exosome biology
Exosomes are microvesicles (40–100 nm in diameter) of endocytic origin released into the ex-
tracellular environment by most cell types and play a significant role in cell signalling and
communication by virtue of their capacity to traffic miRNAs, mRNAs, and proteins to re-
cipient target cells. (112) Exosomal content originates in the cytoplasm of the parent cell, as
illustrated in Figure 5.4, whereby compartments are formed within cells known as multivesic-
ular endosomes (MVE). These compartments contain membrane-bound proteins, cytoplasmic
proteins, mRNAs, and miRNAs, and are released when the MVE fuses with the cell’s mem-
brane. (113; 114)
Figure 5.4: Illustration of the process of exosome formation, whereby compartments are formed
within the cell containing proteins and RNA, which are then released from the cell when fused
with the cell’s membrane.
Exosomes can be found in biological fluids, and it is believed they can play an important role
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in the pathogenesis of disease, which will be discussed further in Chapter 12. Recent evidence
has shown the role of tumour derived exosomes in cancer progression, whereby exosomes have
the ability to suppress the immune system and thus hinder the development of anti-tumour
responses. (114; 115) On the other hand, it has also been shown that exosomes can act as
an acellular source of antigenic determinants that could be exploited in the design of cancer
vaccines. (116; 117) While all cells have the ability to produce exosomes, either constitutively
or upon activation/stress, it has been reported that the levels of exosomes in patients with cancer
are significantly higher than those in normal plasma. (118) It has also been shown that cancer
cells growing in hypoxia produce more exosomes in comparison to cancer cells growing in
normal oxygen conditions. (119) Exosomes have received increasing attention in recent years
because of their potential use as non-invasive biomarkers for the detection of diseases such as
cancer.
5.4.1 Exosome isolation
Exosomes can be found in biological fluids such as blood, urine, and cell culture medium,
however, due to the complex nature of biological fluids, it is extremely difficult to isolate pure
samples of exosomes. The most common procedure for the isolation of exosomes from fluid
involves a series of centrifugations, which removes cells and large debris, followed by a high
speed ultracentrifugation step to pellet the exosomes. However, this does not isolate exosomes
from other microvesicles or large proteins, so further testing is often needed to identify the
presence of exosomes. Instruments such as the NanoSight (Malvern Instruments, UK) can be
used to visualise and measure the size of exosomes, as well as counting the number of exo-
somes present in the solution. When analysed with a transmission electron microscope (TEM),
exosomes have a characteristic ‘saucer-like’ morphology, as shown in Figure 5.5. (120) The
molecular composition of exosomes can be determined using techniques such as western blot-
ting, fluorescence-activated cell sorting (FACS), or Raman spectroscopy. (120; 121; 122)
5.5 Cytology sample preparation methods
There are three main considerations involved with the preparation of cytology samples for Ra-
man micro-spectroscopy, (i) the method of depositing cells onto the microscope slide, (ii) cell
fixation, and (iii) the potential re-use of expensive spectroscopic substrates, which are discussed
in Sections 5.5.1 – 5.5.3, respectively.
5.5.1 Cell deposition
Clinical cytology samples are often prepared within the cytopathology laboratory using liquid
based processing techniques, such as SurePath (Becton Dickson and Company, USA) or Thin-
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Figure 5.5: TEM image of exosomes, showing their characteristic ‘saucer-like’ morphology.
Image obtained by our collaborator Luke Gubbins at the Conway Institute, University College
Dublin, Ireland.
Prep (Hologic, USA). These systems are designed to prepare uniform monolayer cells onto
glass slides with minimal cell debris or blood residue in the background. SurePath is a density
gradient based cell enrichment process that fixes cells with an ethanol based solution, whereas
ThinPrep is a filter based cell concentration technique that uses the methanol based solutions
PreservCyt and CytoLyt. (123; 124; 125) The ThinPrep method is applied in the preparation of
many of the cell samples throughout this thesis.
Figure 5.6 shows the ThinPrep 2000 (T2), which can be used to prepare both gynaecology
and non-gynaecology cytology samples. As this thesis is focused only on non-gynaecology
samples, the following description applies to the preparation of these samples only. For urine
cytology, a vial of urine is collected from the patient, and mixed in a 2:1 ratio of urine to
PreservCyt, this prevents the cells from degrading within the urine solution. The cell pellet
can be obtained at a later time following centrifugation. The cell pellet should be exposed to
CytoLyt, a red blood cell lysing agent, to remove any residual blood present within the sample.
A few drops of the cell pellet is then suspended in a ThinPrep vial of PreservCyt, such that
a slightly cloudy solution is formed. The cells remain in the PreservCyt solution for at least
15 min to allow for adequate fixation. The vial is placed into the T2, as shown in Figure 5.6,
along with a ThinPrep glass slide, and a filter tube.
In order to transfer the cells from the PreservCyt vial onto the glass slide, the filter tube
is inserted into the vial, where it rotates, creating currents within the fluid, allowing for the
separation of debris and mucus, without damaging cell integrity, as illustrated in Figure 5.7(a).
A gentle vacuum is then applied within the filter tube, allowing for the collection of cells onto
the exterior surface of the filter membrane, as shown in Figure 5.7(b), whilst allowing residual
PreservCyt solution to flow up through the filter tube, where it is passed along to an exterior
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Figure 5.6: Image of the ThinPrep 2000 (T2) system, with the key internal components identified,
which is located in the School of Biological Sciences, Dublin Institute of Technology, Ireland.
waste collection vial. The rate of flow through the filter tube is controlled by the T2 software,
and varies across cytology samples. When an adequate number of cells have collected onto the
filter membrane, the filter tube is removed from the PreservCyt vial, and rotated 180o, such that
it can come into contact with the microscope slide, as shown in Figure 5.7(c). Natural attractive
forces, and slight positive air pressure, causes the cells to detach from the filter membrane and
adhere to the glass microscope slide. This method of depositing cells onto a slide allows for an
even distribution of cells within a specific region of the slide.
Alternative methods for cell deposition include (i) a basic drop-dry method, where the
cell pellet is simply dropped onto a microscope slide and left to dry at room temperature;
(ii) cytospin, whereby the cell suspensions are spun onto a microscope slide via centrifuga-
tion forces (126); or (iii) growing of cells directly onto microscope slides, however this is only
possible for sterile, biocompatible substrates. (127)
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Figure 5.7: ThinPrep sample preparation process; (a) rotation of the ThinPrep filter to separate
debris and mucus; (b) collection of cells on the filter membrane; and (c) transfer of cells from
the filter membrane onto the ThinPrep microscope slide.
5.5.2 Fixation methods
It is important to fix, or preserve, cytology samples in order to prevent morphological or spec-
troscopic changes occurring during Raman spectral acquisition. Additionally, it is essential to
fix samples that have been obtained from the clinic, where the presence of infectious pathogens
is unknown. With the ThinPrep method, as discussed in Section 5.5.1, the cells are fixed with a
methanol solution prior to deposition onto the slide. Alternative fixation methods include (i) dry
fixation, where the cells are allowed to dry onto the slide; or (ii) formalin fixation, whereby the
cells are placed into a solution of 10% buffered formaldehyde for approximately 10 min to allow
for cross-linking of the collagen amine groups. (128)
After fixation, it is often necessary to wash the slide to remove any residual fixation so-
lution, although it should be noted that washing is not necessary following ThinPrep sample
preparation due to its filter-based properties. Washing of cells should be performed with sterile,
filtered PBS (phosphate buffered saline) or deionized (DI) water. PBS is the preferred option
since DI water can cause cell lysis, however, the salt crystals within PBS can result in additional
contamination peaks within the cell spectra, therefore it is recommended that the PBS is filtered
prior to any washing steps.
5.5.3 Cleaning of sample substrates
Spectroscopic substrates such as CaF2, quartz, or MgF2 are often very expensive, and therefore,
it is necessary to have a protocol in place to allow for adequate cleaning and re-use of such
slides. Within this thesis, this is achieved by (i) autoclaving, whereby pressurised steam is
applied to the substrates to sterilise them, (ii) gently cleaning with 2-Propanol (isopropanol) to
remove any residual dirt, (iii) dipping the substrates into acetone, followed by DI water, and
(iv) placing the substrates into a bath of ethanol for 30 min. Step (iv) is repeated three times,
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using fresh ethanol each time. The substrates should be quickly dried, and stored in a sterile,
sealed container until needed.
5.6 Summary
The cellular and subcellular components involved in cancer progression are discussed within
this chapter. Information on cell biology is given in Section 5.2, along with further information
on how cells form tissues and organs, as well as identifying the different subtypes of epithelial
tissues that exist within the human body.
Section 5.3 defines cancer as an uncontrolled growth process that results in cells forming
malignant tumours. It has been noted that although cancer cells share many common charac-
teristics, every cancer subtype is the result of a unique sequence of mutations. It is important to
be able to identify if a cancerous tumour has outgrown its vasculature supply, resulting in a hy-
poxic tumour. Hypoxic tumours have poor patient survival rates and require specific treatment
plans, which will be discussed further in Chapter 12.
The role of exosomes in cancerous tumours is briefly discussed in Section 5.4. These mi-
crovesicles are the topic of many recent research investigations, with increasing evidence show-
ing that exosomes have the ability to communicate with neighbouring cells. Chapter 12 applies
Raman micro-spectroscopy to monitor changes in cells that have been exposed to exosomes.
An important consideration when preparing cytology samples for Raman micro-spectroscopy
is the choice of cell deposition method. Section 5.5.1 focuses on the liquid based processing
technique known as ThinPrep, which is applied for the preparation of many cytology samples
throughout this thesis. The ThinPrep method provides monolayer cell distributions onto glass
slides, and is routinely applied in the cytopathology laboratory. Fixation agents and the poten-
tial re-use of expensive spectroscopic substrates are other important considerations that need
to be factored into the design of Raman micro-spectroscopic experiments involving cytology
samples.
Chapter 6
Bladder cancer diagnostics using Raman
spectroscopy: a literature review
This chapter has been published as part of the following paper:
• L.T. Kerr, K. Domijan, I. Cullen, B.M. Hennelly. Applications of Raman spectroscopy to
the urinary bladder for cancer diagnostics. Photon. Lasers Med., 3(3), 193-224, 2014.
6.1 Introduction
The main focus of this thesis is on the diagnosis of bladder cancer cells that have been shed into
urine using Raman micro-spectroscopy; therefore, this chapter provides a literature review of
this topic, and provides an analysis of previous studies that have been carried out in this area.
Additional investigations into the presence of prostate cells in urine, and the ability to classify
between bladder and prostate cells, are discussed in Chapters 10 and 11. Information on the
role of exosomes in cancerous tumours can be found in Chapter 12, and although this chapter
focuses on exosomes found in breast cancer tumours, similar exosomes could be isolated and
analysed from urine samples instead.
Bladder cancer is the fourth most common cancer in men, with approximately 200 new
cases diagnosed in men and women every day in the USA. (129) As with most solid organ ma-
lignancies, early diagnosis, detection, and treatment are imperative for good clinical outcomes.
Cystoscopy is the cornerstone of bladder diagnostics for real-time visualisation of the bladder
mucosa. However, by its nature, it is an uncomfortable invasive procedure, and is not without
significant risk or potential complications. Urine cytology often serves as a useful non-invasive
diagnostic adjunct in the diagnosis of bladder cancer. Examination of voided urine or bladder
washing specimens for exfoliated cancer cells has high sensitivity in high grade tumours, but
low sensitivity in low grade tumours. (130) It has been shown that delays in the process of diag-
nosis leads to unsatisfactory outcomes and adverse effects for the patient involved. (131; 132)
Therefore, there is a real clinical need to develop and integrate a non-invasive, sensitive, and
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specific technique to assist in bladder cancer diagnosis.
Optical diagnostic tools in medicine are becoming more popular in recent times because
they can provide fast, highly accurate results, without damaging the biological samples with
toxic chemical markers. Raman spectroscopy, which was introduced in Chapters 1 and 2, is
one of the most promising optical diagnostic tools that can be applied to cells from the urinary
bladder as it is able to detect changes in the molecular composition of tissue samples. This
is not only useful for discriminating between different grades and stages of disease, but may
also provide epigenetic clues as to the etiology of the malignancy. This chapter reviews the
contributions over the past decade on the application of Raman spectroscopic techniques for
improving the accuracy of detecting bladder cancer.
The breakdown of this chapter is as follows; firstly, we build upon the basic discussion
of biology that was introduced in the preceding chapter to provide an introduction to bladder
pathology and current diagnostic approaches, which are given in Section 6.2. Section 6.3 sum-
marises all previous applications of Raman spectroscopy to diagnose bladder biopsy and tissue
samples in vitro and ex vivo. Section 6.4 focuses on the use of Raman fiberoptic probes inte-
grated into cystoscopic procedures for real-time cancer diagnostics in vivo. And Section 6.5
describes the completely non-invasive technique of combining Raman spectroscopy with urine
cytology.
6.2 Bladder cancer
6.2.1 Diagnosis of bladder cancer
Bladder cancer is generally diagnosed using cystoscopy, aided by urine cytology. Cystoscopy is
an invasive endoscopic procedure of the urinary bladder carried out via the urethra, as shown in
Figure 6.1; however it is sometimes indeterminate, and there are variables that can result in false
negative results. Bladder mucosa inflammation (cystitis) is commonly encountered in individ-
uals with a urinary tract infection and individuals with indwelling catheters, and carcinoma in
situ (CIS), a particularly aggressive form of non-invasive bladder cancer with a high propensity
to progress to muscle invasive disease, also appears as as inflamed bladder lining.
Cytology is useful when a high grade cancer or CIS is present, but its use in the diagnosis
of low grade cancers is very limited owing to its low level of sensitivity. (133) As a standard
procedure, cystoscopy is performed using white light. However, the use of white light can lead
to missing lesions that are present but not visible, which is why new technologies are being
developed to aid the clinician. Photodynamic diagnosis (fluorescence cystoscopy) is performed
using violet light after intravesical (intra-bladder) instillation of 5-aminolevulinic acid (5-ALA)
or hexaminolevulinic acid (HAL). It has been confirmed that fluorescence guided biopsy and re-
section are more sensitive than conventional procedures for the detection of malignant tumours,
particularly for CIS of the bladder. (134)
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Figure 6.1: Illustration of a typical cystoscopy procedure, whereby a cystoscope is passed
through the urethra into the bladder for the visualisation of bladder disease.
6.2.2 Classification of bladder carcinoma
Approximately 90% of all bladder cancers are diagnosed as urothelial carcinoma (UC), other-
wise known as transitional cell carcinoma (TCC). (135) UC develops in the urothelium of the
bladder wall, and is the second most common malignancy of the genitourinary tract. (136) The
remaining∼10% of bladder cancers consist of squamous cell carcinoma, adenocarcinoma, lym-
phoma, and metastatic tumour cells from different neoplastic primaries. Almost 80% of patients
with UC present with non-muscle-invasive, or superficial UC, the remainder being infiltrative,
invading the detrousor muscle and potentially spreading to loco-regional lymph nodes and vis-
cera. (137) There are two main diagnostic classification systems for UC based on histological
grading and pathological staging. Histological grading represents the degree of differentiation
present between the carcinoma cells and normal urothelial cells, which can be used to predict
the rate at which the carcinoma cells are multiplying. Pathological staging is used to assess the
extent of cancer invasion into the bladder wall in order to determine if the disease has spread.
Histological grading
The histological grade of a UC tumour is determined under a microscope using a specific set of
criteria to establish how much the tumour resembles normal (healthy) tissue. Within histolog-
ical grading, there are two systems in use; the WHO 1973 grading system and the WHO 2004
grading system. Most histopathologists still use the WHO 1973 system, which is based on a
three-tiered grading system as summarised in Table 6.1. Grade 1 represents well differenti-
ated cells that are slow growing and look similar to healthy bladder cells, Grade 2 cells are
moderately differentiated, and Grade 3 are poorly differentiated, fast growing cells that look
very different to healthy cells (138), as illustrated in Figure 6.2. Histological grading is often
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criticised given the subjective nature of this test.
Figure 6.2: Basic representation of (a) normal (healthy) cells, and (b) poorly differentiated
cancer cells.
Histological grading is very subjective since it is based on the pathologist’s perception of
cell differentiation. Generally, diagnosis is made by two or more pathologists per sample in
order to avoid misclassification; however there is still often inter-observer variation (between
pathologists) and intra-observer variation (from one pathologist at different times). (139) Thus,
this method of classification is time-consuming with a high degree of variability. The future
trend is leaning towards the use of the newer system (WHO 2004), which is based on simply
grading cancers as low or high grade, thus reducing inter-observer variation.
Pathological staging
Pathological staging is based on the TNM (tumour, node, metastases) system, whereby the
pathologist assesses the location of the tumour (T), if the cancer has spread to nearby lymph
nodes (N), and the extent of metastases (M). A number is assigned to each value ranging from
1 to 4, where higher numbers indicate a more aggressive, invasive carcinoma. (103) The tu-
mour (T) value, which is the most important value here, represents the location of the tumour
with respect to the inner lining of the bladder wall. Stages Ta, T1, and CIS are non-muscle-
invasive UC, with Ta and CIS both confined to the urothelium. Most Ta and T1 tumours are low
grade and are less likely to become muscle-invasive. CIS is a flat, high grade, non-invasive UC.
Macroscopically, CIS can be missed at cystoscopy or be considered as an inflammatory lesion
if not biopsied. A summary of each pathological stage can be seen in Table 6.1, and Figure 6.3
illustrates the extent of the growth of the tumour with respect to the inner bladder wall lining.
6.3 Biopsy and tissue sample diagnostics
In this section, the specific studies relating to the application of Raman spectroscopy to biopsy
and tissue samples for the purpose of bladder disease diagnosis are reviewed. This section
begins by discussing the sources of tissue and the manner in which they can be stored and
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Figure 6.3: Staging of bladder tumours representing the location of each tumour with respect
to the urothelium.
prepared for Raman spectroscopic analysis. This is followed by a review of each of the major
studies in the area, the techniques used, and the resulting sensitivities and specificities that were
achieved.
To diagnose bladder tissue using conventional Raman spectroscopy, tissue samples can
be removed from tumourous regions during transurethral resection surgical procedures, such
TURBT (transurethral resection of bladder tumour) or TURP (transurethral resection of the
prostate). Both of these are minimally invasive surgical procedures, carried out via the urethra
by passing surgical tools through a cystoscope into the bladder. Large tumours or CIS are more
difficult to remove or analyse during TURBT or TURP, so biopsy samples can be taken during
cystoscopy procedures instead. A more invasive surgical procedure for the removal of all or
part of the bladder is known as a cystectomy, and these tissue samples can also be diagnosed
using Raman spectroscopy.
Raman spectroscopy can be effectively applied to both fresh and preserved bladder tissue
samples. There are numerous methods of preserving bladder tissues so that they can be stored
for long periods of time without largely affecting their natural biochemistry. Tissue samples
can be snap-frozen with upon removal from the patient, and then stored at −80oC. The main
advantage with freezing is that the biochemistry of the samples are not altered, and they can
be analysed simply by returning the samples to room temperature. Bladder tissue could also be
stored in paraffin wax blocks; however it is more difficult to analyse tissue samples that have
been stored in paraffin with Raman spectroscopy since paraffin has large distinct peaks that ap-
pear in the Raman spectra. Additionally, the dewaxing agents applied for the removal of paraffin
wax are known to alter the biochemical integrity of the biological sample, and therefore, alter
the corresponding Raman spectra. (140) Despite this, with the use of particular deparaffinization
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Histological grade Description of cancer cells
GX Unable to determine the extent of differentiation
G1 / Low grade Well differentiated
G2 Moderately differentiated
G3 / High grade Poorly differentiated
Pathological stage Description of tumour
T0 No primary tumour
Ta Non-invasive papillary tumour, confined to urothelium
CIS High-grade, flat tumour, confined to urothelium
T1 Invasive tumour; invades lamina propria (connective tissue re-
gion)
T2 Muscle invasive tumour
T3 Tumour invades perivesical fat layer beyond the muscle region
T4 Tumour invades nearby tissues such as the prostate, vagina,
uterus, pelvic wall, or abdominal wall.
Table 6.1: Description of bladder cancer corresponding to histological grade and pathological
staging. (103)
methods or complex data processing techniques, it is sometimes possible to obtain diagnostic
results from these samples. (141)
In 2002, in what is thought to be the first Raman based bladder cancer diagnostic study,
Stone et al. investigated the application of conventional Raman spectroscopy to classify, or dis-
tinguish between, different pathological grades of bladder tissue. (142) Bladder tissue samples
were collected during cystoscopy procedures from 12 patients, and classified as being normal,
CIS, low grade, medium grade, and high grade carcinoma by histopathologists. Following PC-
LDA classification, the spectra separated into five distinct groups with sensitivities between
78% and 98%, and specificities between 96% and 99%. These results show excellent group
separation; however, some overlap was found between CIS and low grade cancer, and between
medium grade and high grade cancer, which the authors note is either due to the biochemical
continuum of disease, or due to difficulty in distinguishing between pathological groups during
histopathological classification.
Members of the previous study, further developed this diagnostic model using Raman spec-
troscopy to distinguish between a larger range of bladder tissue pathologies in vitro. (143) Con-
ventional Raman spectroscopy was applied to a range of bladder tissue pathologies – normal,
cystitis, CIS, G1, G2, G3, G3 squamous dysplasia, and adenocarcinoma. These tissues were ob-
tained from 72 patients during TURBT, TURP, and cystectomy procedures, and samples were
classified by a consultant uropathologist and a consultant pathologist. All tissues were snap-
frozen and stored at -80 oC, and then brought back to room temperature for measurement. This
study resulted in sensitivities and specificities greater than 82% and 95% respectively.
De Jong and colleagues (2006) used Raman spectroscopic mapping (mapping refers to bio-
chemical images obtained using Raman micro-spectroscopy to create a spectral model that
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could differentiate between tumour and non-tumour bladder tissue in vitro. (144) Fifteen snap-
frozen bladder tissue samples were obtained consisting of normal, cystitis, T2-T3, and CIS, as
confirmed by a pathologist. Spectra were obtained from each tissue sample in order to create
a 2-D Raman map of the area. PCA was applied to cluster the spectra into 90 separate clus-
ters, whereby the spectra within each cluster showed a similar biochemical composition. Each
cluster was assigned a colour code, and in this way, images were created highlighting areas of
similar biochemical composition. Following LDA based classification, 100% sensitivity and
95% specificity results were achieved.
And finally, Grimbergen et al. (2009) investigated the potential of a combined diagnostic
modality using fluorescence with conventional Raman spectroscopy. (145) This was achieved
by applying Raman spectroscopy to bladder biopsy samples, with and without the presence of
5-ALA, in vitro. 5-ALA is a photosensitive dye that leads to an accumulation of photopor-
phyrin IX (PpIX) in malignant cells, and is often used in fluorescence cystoscopy to improve
the detection of bladder cancers. 92 biopsies were obtained from 73 patients without 5-ALA
during TURBT, and 38 biopsies with 5-ALA were obtained from 19 patients that underwent
fluorescence-guided endoscopy, which were evaluated as normal, cystitis, CIS, G1, G2, and G3
by a histopathologist. Standard Raman spectra were measured from all biopsy samples, and
classification of non-5-ALA samples, based on an algorithm trained from non-5-ALA samples,
resulted in 88% sensitivity and 80% specificity. However, when applied to the 5-ALA samples,
a sensivitiy of 42% and a specificity of 71.1% were found, indicating a change in the biochem-
istry of bladder tissue in the presence of 5-ALA. Further algorithms were developed based on
a combination of Raman spectroscopy and fluorescence prediction measurements, resulting in
a sensitivity of 100% and specificity of 80.8% for distinguishing between cancerous and non-
cancerous biopsy samples containing 5-ALA. This combined modality of Raman spectroscopy
with fluorescence would allow for in vivo analysis of bladder tissue.
6.4 Raman cystoscopy
Raman fiberoptic probes can be easily inserted during a cystoscopy procedure to give real-
time analysis and classifications of the urothelium. Similar to conventional Raman micro-
spectroscopy, fiberoptic Raman probes can also be used to measure samples in vitro and ex
vivo. This section provides information on the progression of fiberoptic Raman probes applied
to the urinary bladder for diagnostics.
In 2005, Crow et al. were the first group to integrate a fiberoptic probe into Raman spec-
troscopy to differentiate between benign and malignant bladder tissue in vitro. (146) Bladder
tissue samples were obtained from 24 patients during TURBT and TURP, and classified as nor-
mal, cystitis, or UC by a uropathologist. Raman spectra were obtained by holding the probe in
contact with these tissue samples. Based on PC-LDA classification, a sensitivity of 89% and
specificity of 79% was achieved for separating benign and malignant tissues. The probe used
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in this study was designed to be compatible with the working channel of a standard rigid or
flexible cystoscope so that it could easily be integrated into in vivo studies. While it is proposed
that the probe could be used in vivo, the reported experimental work focused on bladder tissue
in vitro as a proof of concept.
Grimbergen and colleagues (2009) also investigated the potential of using Raman spec-
troscopy for bladder tissue diagnosis during cystoscopy by examining bladder tissue biopsies
ex vivo using an endoscopic probe. (147) 107 bladder tissue samples were obtained from 54
patients during TURBT, where 5-ALA was used to enhance tissue contrast. Samples were
graded as normal, cystitis, CIS, G1, G2, G3, and atypia by a pathologist. Raman spectral mea-
surements were obtained from fresh tissue samples, resulting in a sensitivity and specificity of
78.5% and 78.9%, respectively. Whilst this study was based on ex vivo experimentation, these
results show the possibility of using a Raman spectroscopic probe for discerning normal from
malignant bladder tissue in vivo in the presence of 5-ALA.
Draga et al. (2010) were the first group to investigate the use of a Raman based fiberoptic
probe for the diagnosis of bladder cancer in vivo. (148) Raman spectra were obtained during
TURBT procedures on 17 patients without any photosensitive dyes, 12 patients with 5-ALA,
and 9 patients with HAL, representing a mixture of normal, Ta, T1, and T2 bladder tissues.
Spectra were measured with a high-volume Raman probe, and diagnostic algorithms were de-
signed using PC-LDA, resulting in a sensitivity of 85% and a specificity of 79%. Draga et al.
successfully demonstrated the use of Raman spectroscopy for the diagnosis of bladder cancer
in vivo, both with and without the presence of photosensitive dyes, showing the potential of
integrating a Raman probe into fluorescence cystoscopy procedures to improve diagnosis.
In 2012, Barman et al. proposed the use of a confocal fiberoptic Raman probe to increase the
specificity (in terms of tissue depth discrimination) for bladder cancer diagnosis in this proof-of-
concept study performed ex vivo. (149) Bladder tissue samples were excised from 14 patients
during TURBT, and confirmed as being normal or cancerous by a uropathologist. Raman spec-
tra were obtained from each sample (ex vivo) using both a high-volume probe and a confocal
probe to compare the sensitivities and specificities achieved for each. The confocal probe was
designed by placing a pinhole aperture into the high-volume probe to decrease the depth of field
from 520 µm to 280 µm, thus suppressing the spectral information from surrounding regions
and from deeper tissue layers beyond the region of interest. Diagnostic algorithms were devel-
oped using PCA and logistic regression analysis (LRA), with the high-volume probe producing
a sensitivity of 85.7% and specificity of 85.7%, whereas the confocal probe had a sensitivity
of 85.7% and specificity of 100%. The significant increase in specificity values of the confocal
probe in comparison to the high-volume probe are associated with the smaller depth of field val-
ues, giving this particular device an advantage in the application of Raman probes for real-time
in vivo diagnosis of bladder disease.
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6.5 Raman based urine cytology
Within the last decade, studies have begun investigating the potential use of Raman micro-
spectroscopy for analysing and classifying disease from bladder cells rather than tissue, thus
moving to the completely non-invasive procedure of detecting bladder cancer from voided urine.
This technique has the potential of replacing standard biopsy or cytology procedures. Within
this section, we attempt to extrapolate the best practice (in advance of our own contributions as
part of this thesis, which are detailed in Chapters 7-10) in terms of the methods and tools used.
The first study to analyse bladder cells using Raman spectroscopy was investigated by Har-
vey et al. (2008), where Raman optical tweezers were used to trap and analyse both live and
chemically fixed bladder cells, and to differentiate between normal and cancerous cells. (57) In
the first part of this study, the Raman tweezers technique was applied to discriminate between a
malignant bladder cell line (MGH-U1, otherwise known as T24 (150)) and a malignant prostate
cell line (PC-3). All of the cells were fresh and stored in PBS before and during measurement.
Raman spectra were obtained using a 514.5 nm laser, and all spectra were pre-processed by
removing the baseline contribution, followed by EMSC. Spectra were then subjected to PCA
analysis to discriminate between both cell types, and the PCA plot of this shows that they can
be identified as separate cell groups. The second part of the study investigated the use of Raman
tweezers to discriminate between the following alcohol fixed cell lines: malignant bladder cells
(MGH-U1), malignant prostate cells (LNCaP, PC-3), and benign prostate cells (BPH). All cells
were fixed using SurePath, and stored at<4oC. Raman spectra were recorded and pre-processed
the same way as for live cells. Spectra were then subjected to PC-LDA to differentiate between
each cell group, resulting in sensitivities of 73–94% and specificities of 95–98%. This initial
study based on the application of Raman tweezers to differentiate between different urological
cell lines has shown the diagnostic potential of this technique for detecting both bladder and
prostate cancer.
Harvey et al. (2009) continued on from this initial study to further investigate the applica-
tion of Raman tweezers to classify cultured cell lines that were chemically fixed using either
SurePath or formalin, as well as investigating the effect of exposure to urine on these cells. (55)
Raman tweezers were first used to distinguish between the following cell lines fixed with
SurePath: malignant bladder cells (MGH-U1), malignant prostate cells (LNCaP, PC-3), nor-
mal prostate cells (PNT2-C2), and benign prostate cells (BPH). Raman spectra were recorded
from 100 MGH-U1, 104 BPH, 104 LNCaP, 115 PC-3, and 110 PNT2-C2 cells. A diagnostic
model was designed by applying PC-LDA to the spectra, resulting in sensitivities of 73–100%
and specificities of 93–98%. The authors note that the MGH-U1 and PC-3 cells were found to
be larger in SurePath than when unfixed. The second section of this study was based on the
use of Raman tweezers to distinguish between the following formalin fixed cells: malignant
bladder cells (MGH-U1), urethral cells (from patients), benign prostate cells (BPH), normal
prostate cells (PNT2-C2), and malignant prostate cells (LNCaP, PC-3). Raman spectra were
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recorded from 135 cells in each group, and following PC-LDA classification, results showed
88-100% sensitivity and 98-100% specificity. A comparison between both chemical fixing
methods showed that formalin resulted in better diagnostic performance and a greater SNR,
although this is due to the higher laser power used for these measurements. There was also
no contamination in spectra from the formalin solution, whereas a significant contribution was
found in the SurePath spectra. And finally, the last part of this study was to determine the ef-
fects of exposure to urine on the ability to classify cells. To investigate this, all cells (MGH-U1,
BPH, LNCaP, and PC-3) were unfixed and stored at room temperature before being exposed to
urine for the following time durations: 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h,
and 12 h. PC-LDA was applied to the spectra, and it was shown that in general the prediction
values do not deteriorate over 12 h. Overall, this study has shown the potential of using Raman
tweezers to distinguish between bladder cells and prostate cells, and also between cancerous
and non-cancerous cells.
In 2011, Shapiro et al. investigated the possibility of applying Raman spectroscopy to blad-
der cells from voided urine in order to determine whether or not UC was present. (151) For
this study, fresh urine samples were obtained from 340 patients (116 without UC, 92 with low
grade UC, and 132 with high grade UC). To prepare the urine samples for Raman spectroscopic
measurements, the cell pellet was obtained from the urine sample following centrifugation and
filtration. The cells were then cytospin deposited onto aluminium slides. Raman spectra were
obtained from an average of five cells per slide using a 532 nm laser. The resulting spectra
showed a positive 1584 cm−1 Raman peak for cancerous cells that was not present for non-
malignant cells. Shapiro and colleagues developed a model based only on this peak (no PCA
or LDA required) that could classify spectra as normal, low grade, or high grade UC by evalu-
ating the height of the 1584 cm−1 peak above the baseline at 1500 cm−1, resulting in an overall
sensitivity of 92% and a specificity of 91%. A second part of this study involved comparing
the Raman spectra from these bladder cells with spectra obtained from bladder tissue samples.
These bladder tissue samples were obtained from surgical touch preps and were frozen prior to
Raman measurements. This study showed that the spectra from bladder cells and tissue were
virtually identical, and that it is possible to determine the histological grade of both cells and
tissue based on the height of the distinct Raman peak at 1584 cm−1.
Canetta et al. (2011) developed the first application of modulated Raman spectroscopy (MRS)
for the identification of human bladder cell lines in urine, whilst monitoring cell viability after
exposure to urine, and the differences between standard Raman spectroscopy (SRS) and MRS
for cell classification were also examined. (91) Healthy human urothelial cells (SV-HUC-1) and
malignant bladder cells (MGH-U1) were cultured, and then exposed to a solution containing 2
parts fresh urine and 1 part PreservCyt for the following time durations: 0 h (control), 30 min,
3 h, and 6 h. This solution was then centrifugated, and the cells were resuspended in Preserv-
Cyt for storage. Prior to Raman spectral measurements, the cells were washed with PBS before
being resuspended in PBS, and placed in a sample chamber between a quartz slide and a quartz
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coverslip. Cells were allowed ∼30 min to sediment onto the quartz before Raman measure-
ments were obtained. Spectra were recorded from 40 urothelial cells and 40 bladder cancer
cells for each of the urine exposure times using a 785 nm modulated laser (modulated with a
ramp wave of 50% symmetry, 40 mHz modulation frequency, 60 GHz modulation amplitude
- corresponding to 0.2 nm). For each cell, 40 stacked spectra were recorded with a total inte-
gration time of 200 s. PCA was then applied to classify these spectra, resulting in sensitivities
of 80–95% and specificities of 87–95%. These results show that it is possible to distinguish
between both cell groups using MRS, even after exposure to urine for 6 h. The second part of
this study involved monitoring cell viability in urine using 1% Fast Green dye (Sigma Chemi-
cal Co. Ltd., USA), and it was found that after 1 h, the viability of the cancer cells decreased
to ∼60% and ∼64% for healthy cells, and the reproductive capacity of both cells decreased
rapidly after exposure to urine. This mirrors the Raman data obtained from different exposure
times where changes in the biochemistry can be seen with progressing exposure times. The ro-
bustness of MRS in comparison to SRS was then investigated by comparing the Raman spectra
obtained from each method for fixed urothelial cells and fixed bladder cancer cells that were
not exposed to urine (control group). The SRS spectra showed a strong autofluorescence signal
from the quartz substrate, and Raman peaks from the cells are not well defined. On the other
hand, the MRS spectra allow for Raman peaks to be clearly observed. PCA was applied to both
the SRS and MRS spectra to discriminate between both cell groups, and a Fourier transform
was also applied to the SRS spectra to estimate between the slow varying background and the
Raman peaks, resulting in a sensitivity of 97% and specificity of 72%. In Fourier space, the
background signals were present at low frequencies, whereas the Raman signals were present
at high frequencies, therefore the Fourier transform was able to separate the most important
Raman signals from the background. Higher sensitivities and specificities were achieved with
MRS, which may be due to the better SNR obtained by filtering out the Raman peaks associ-
ated with the biological cells from the fluorescence background signals. It has also been noted
that the healthy urothelial cells show relatively strong protein and carbohydrate Raman peaks
(1100–1300 cm−1 region) in comparison to the cancerous cells, and there was an increase in
ring breathing modes for the cancerous cell spectra (669, 727, 785, 828, 1095, 1578 cm−1)
indicating a higher concentration of DNA in malignant cells.
6.6 Summary
It is clear from the results reviewed in this chapter that there is growing potential for the ap-
plication of Raman spectroscopy to the study of urinary bladder disease in order to improve
patient treatment and patient outcome. This technique can be applied in a number of different
forms, including conventional Raman micro-spectroscopy, as well as using Raman tweezers
or fiberoptic probes. Raman micro-spectroscopy has been shown to be a strong candidate for
improving the diagnostic sensitivity and specificity of urine cytology, with particular interest
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for the case of low grade UC cells, for which a recent (and the first) patient study showed a
sensitivity and specificity of 92% and 91% respectively. However, this study applied Raman
micro-spectroscopy to unfixed cells which is not an ideal method to introduce into a clinic due
to the possible presence of highly infectious disease. Furthermore, spectra were classified based
on the 1584 cm−1 peak (151), an assignment that has not been acknowledged for the identifica-
tion of bladder cancer elsewhere in the literature.
Raman fibers have been shown to return similar results for both in vitro/ex vivo and in vivo
samples, allowing for their potential integration into cystoscopic procedures. The improvement
in sensitivity obtained for Raman cystoscopy over existing diagnostic procedures is not only due
to the additional biochemical information provided by the Raman spectrum, and the ability to
classify this using multivariate diagnostic algorithms, but it is also partially due to the reduction
in inter- and intra-observer variation, which can vary by up to 45–50% using current clinical
methods. (139; 152)
This chapter highlights the potential for Raman micro-spectroscopy in the diagnosis of blad-
der cancer, both in vivo via a cystoscopic procedure, and in vitro to urine cytology samples.
However, this chapter also highlights the shortcomings that have been observed to date, in
terms of the variability of experimental parameters and consumables that have been utilised
across different research groups. The lack of standardisation, and in particular the lack of ad-
vancement towards the translation of Raman technology towards the clinic, is something that
needs to be addressed. In order to identify the optimum methodologies for Raman based urine
cytology, Chapter 7 of this thesis investigates a range of source wavelengths and sample sub-
strates, and Chapter 9 systematically compares different cell deposition techniques, fixation
agents, and the impact of applying red blood cell lysing agents to urine samples prior to Ra-
man micro-spectroscopic analysis, with the aim of integrating Raman micro-spectroscopy into
current clinical protocols insofar as possible.
Chapter 7
Sample substrates and source wavelengths
for Raman based cytology
This chapter has been published as part of the following paper:
• L.T. Kerr, H.J. Byrne, B.M. Hennelly. Optimal choice of sample substrate and laser
wavelength for Raman spectroscopic analysis of biological specimen. Anal. Methods,
7(12), 5041-5052, 2016.
7.1 Introduction
In the preceding chapters, Raman micro-spectroscopy has been introduced as an experimental
technique, and it’s application to understanding the etiology and diagnosis of bladder cancer was
reviewed. In particular, improving the diagnostic potential of urine cytology was identified as a
key area of research. However, our review of progress in this area, and indeed in other related
applications of Raman micro-spectroscopy, has highlighted a high degree of variability across
experimental protocols, some of which result in large background signals that can often over-
power the weak Raman signals being emitted. These protocols need to be standardised before
the technique can provide reliable and reproducible experimental results in an everyday clinical
environment. The objective of this chapter is to investigate the impact of different experimental
parameters involved in the analysis of biological specimen. This study investigates the Raman
signals generated from healthy human cheek cells using different source laser wavelengths;
473 nm, 532 nm, 660 nm, 785 nm, and 830 nm, and different sample substrates; Raman-grade
calcium fluoride, IR polished calcium fluoride, magnesium fluoride, aluminium (100 nm and
1500 nm thin films on glass), glass, fused silica, potassium bromide, sodium chloride, and zinc
selenide, whilst maintaining all other experimental parameters constant throughout the study
insofar as possible. The results obtained throughout this study are presented both graphically
and numerically. Numerical results are based on the analysis of the spectral data using three
different statistical metrics: discrete correlation, normalised covariance, and mean square er-
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ror (MSE).
The breakdown of this chapter is as follows; firstly the importance of standardising the
experimental parameters associated with Raman micro-spectroscopy is discussed. Section 7.3
provides information about the experimental materials and methods used in our study. Results
from all experiments are shown in Section 7.4, followed by a discussion of these results in
Section 7.5, and a summary in Section 7.6.
7.1.1 Standardisation of Raman micro-spectroscopy
While Raman micro-spectroscopy has been demonstrated to produce accurate diagnostic re-
sults, further development is necessary to ensure that Raman spectroscopic systems are suffi-
ciently robust for everyday clinical usage. (153) The lack of standardisation, in terms of equip-
ment, consumables, and measurement protocols has resulted in the recording of significantly
differing spectra across studies to date, and it is believed that this has hindered further ad-
vancement of this technique. Even within the application of Raman micro-spectroscopy to the
diagnosis of one particular pathological disease (e.g. bladder cancer), a wide range of sample
substrates, source laser wavelengths, and integration times have been applied to date, as dis-
cussed in Chapter 6; all resulting in moderately varying spectra for the same disease. (154) If
Raman micro-spectroscopy is ever to become a commonly used clinical tool, then it is important
for standardised procedures to be established in order to overcome these inconsistencies. (155)
This chapter aims to identify the optimum source wavelength and sample substrate for Raman
micro-spectroscopic measurements of biological samples, and also to identify the similarities,
or lack thereof, between spectra recorded using these different experimental parameters.
7.2 Raman sample substrates
Sample substrates for Raman micro-spectroscopy should produce low background signals, be
biocompatible, and non-toxic for the cells and tissues placed on them, and be as cost effective as
possible. Previous studies have reported the use of a wide range of substrates including calcium
fluoride (145; 156; 144; 141), aluminium (151; 147; 157), quartz (91; 89; 158), glass (159; 78),
and 3D collagen gels (160). However, substrates that produce low background signals for NIR
sources are often expensive, and are available in different levels of purity/film thicknesses,
which can produce variable results with Raman micro-spectroscopy. Therefore, this study anal-
yses a wide range of sample substrates and source wavelengths in order to identify which sub-
strates produce the lowest background signals at each wavelength, while monitoring the cost
effectiveness associated with each substrate.
An important consideration that is not included in this study is the biocompatibility asso-
ciated with each of the various substrates. This is particularly important for experimentations
involving living cells, which often involve the incubation or growth of cells directly onto the
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substrate. However, this has been previously explored by Meade et al. (2006), whereby sub-
strates were coated with fibronectin, laminin, and gelatin, resulting in improved cell prolifera-
tion and similar Raman spectra to those achieved without the use of any coatings. (161)
7.3 Materials & methods
7.3.1 Sample preparation
Fresh cheek cells are swabbed from a single healthy human volunteer, placed directly onto each
of the substrates before each set of experiments, and are allowed to air dry for 5 minutes before
measurement. No additional preserving/fixing agents, or washing steps, are applied to the sam-
ples, and therefore some spectral signals relating to dried saliva, or other oral contaminants, may
be present across all spectra. It is noted that no debris or contaminants are visible in the images
of the cells that are used in this experiment, and there is no obvious contamination observed
in any of the spectra recorded. While the presence of saliva and other possible contaminates is
acknowledged, the associated Raman signals are not expected to significantly affect the results
presented in Section 7.4. It is noted that all experiments were performed in compliance with our
institute’s Ethics Committee (BSREC-2015-008), and informed written consent was obtained
from the donor prior to experimentation.
7.3.2 Raman spectral acquisition
Raman micro-spectroscopy measurements are performed across two similar commercial Raman
systems (both Horiba Jobin Yvon LabRam HR 800) with Synapse cooled CCD detectors, as dis-
cussed in Section 3.6.2. These systems operate with a 50x MO (Olympus MPlanN, 50x/0.75,
∞/0/FN22), 50 µm confocal aperture, and a 300 gr/mm grating. Spectra are recorded with
an acquisition time of 30 s averaged over 2 iterations, allowing for the subsequent removal of
cosmic rays. (162) It should be noted that the confocal aperture is opened to 100 µm for mea-
surements with the 830 nm source due to the low photon count and lower quantum efficiency of
the CCD in this region. Both systems are calibrated using a silicon wafer prior to measurements.
Background spectra are recorded from each substrate at every wavelength, and are used to
isolate the Raman signals from the recorded biological spectra using the background subtrac-
tion method that was previously explained in Section 4.4.2.
The following substrates are used for this study:
• calcium fluoride – Raman-grade (Crystran Ltd., UK),
• calcium fluoride – IR grade polished (Crystran Ltd., UK),
• magnesium fluoride (Crystran Ltd., UK),
• 100 nm aluminium thin film on glass (Deposition Research Laboratory Inc., USA),
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• 1500 nm aluminium thin film on glass (Deposition Research Laboratory Inc., USA),
• glass,
• fused silica – IR grade polished (Crystran Ltd., UK),
• potassium bromide (Edmund Optics, UK),
• sodium chloride (Edmund Optics, UK),
• zinc selenide (Crystran Ltd., UK).
Measurements made using the 473 nm, 660 nm, and 830 nm lasers are performed on one
Raman system, and measurements at 532 nm and 785 nm on the other system, with all other
parameters maintained as constant insofar as possible; variances however are present in the out-
put power of each source laser (see Section 3.6.2). The lasers, and their corresponding powers,
used for this study are similar to those regularly employed in commercial Raman systems for
biological measurements.
7.4 Results
Background signals present in Raman spectra are the result of intrinsic Raman signals and/or
fluorescence from the sample substrate and other optical elements within the Raman system,
as previously discussed in Chapters 3 and 4. The MO, in particular, is known to produce a not
insignificant background signal. In order to gauge the contribution of the optical system alone,
this section begins by presenting the spectra obtained from the system without the presence of
any samples or substrates. The results are shown in Figure 7.1 for each source wavelength. The
majority of this signal contribution is associated with the MO used, with the signal being most
significant for the 785 nm source.
Figure 7.1: Background signals generated by the optical elements within the Raman system for
each of the above wavelengths - a Gaussian smoothing function was applied to all spectra.
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Figure 7.2: A single Raman spectrum obtained from fresh human cheek cells on Raman-grade
calcium fluoride with a 532 nm source laser, with key biomolecular regions highlighted.
Figure 7.2 represents a single baseline-corrected spectrum recorded from fresh human cheek
cells on Raman-grade calcium fluoride using a 532 nm source laser, recorded using the pa-
rameters outlined in Section 7.3; this spectrum proved to be the optimum spectrum recorded.
Figure 7.2 highlights the key Raman peaks associated with cheek cells, and the important
biomolecular regions that are often used in the analysis of cells in Raman based cytology stud-
ies have been identified. A more detailed analysis of cellular Raman spectra can be found
elsewhere. (163; 164)
The spectra shown in Figure 7.3 to Figure 7.12 represent the background signals and Raman
cell peaks associated with each substrate for every wavelength, using the parameters outlined
in Section 7.3 (i.e. all spectra are recorded with an acquisition time of 30 s, averaged over
2 iterations). The (a) component of these figures represents the background signals obtained
from each substrate at each wavelength, and are shown at their recorded intensity values, after
convolution with a Gaussian smoothing function is applied to remove any additional noise con-
tributions. This noise reduction is necessitated by the low photon count, and therefore high shot
noise, brought about by the presence of a 50 µm confocal aperture. The corresponding spectra
in (b) are recorded from fresh cheek cells on each substrate for each wavelength; these spectra
have been baseline corrected using the background subtraction algorithm discussed in Section
4.4.2. Following this, the spectra were area normalised by dividing each spectrum by the sum
of its intensity.
Background spectra are recorded between 200–1800 cm−1 for all substrates. Cell spectra
are generally shown between 400–1800 cm−1. The reason for this is two fold; firstly this is
the fingerprint region for biological specimen, and is the most commonly observed spectral
region for Raman related biochemical investigations, and secondly, this removes any issues
with baseline correction of large background contributions in the lower wavenumber region;
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problems can occur when applying the background subtraction algorithm in regions where the
background has relatively strong intensities, e.g. the CaF2 peak at approximately 321 cm−1,
which results in a breakdown of the algorithm. This is easily avoided by discarding the lower
part of the spectrum for both the cell signal and the background. Additionally, some substrates
produce large background signals between 400–600 cm−1, which are not entirely removed by
the background subtraction algorithm, such as zinc selenide (for all source wavelengths) and
fused silica at 532 nm. For this reason, these spectra (and their corresponding metric values in
Tables 7.1–7.3) relate only to the 600–1800 cm−1 region.
(a)
(b)
Figure 7.3: (a) Background signal of Raman-grade calcium fluoride recorded for each of the
above wavelengths, (b) normalised Raman signals from cells recorded on Raman-grade calcium
fluoride for each of the above wavelengths, with an acquisition time of 30 s (x2).
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(a)
(b)
Figure 7.4: (a) Background signal of IR polished calcium fluoride recorded for each of the
above wavelengths, (b) normalised Raman signals from cells recorded on IR polished calcium
fluoride for each of the above wavelengths, with an acquisition time of 30 s (x2).
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(a)
(b)
Figure 7.5: (a) Background signal of fused silica recorded for each of the above wavelengths,
(b) normalised Raman signals from cells recorded on fused silica for each of the above wave-
lengths, with an acquisition time of 30 s (x2). Note, the cell spectrum at 532 nm is only shown
between 600-1800 cm−1 due to the large background contribution in the lower wavenumber
region.
7.4. RESULTS 78
(a)
(b)
Figure 7.6: (a) Background signal of 100 nm aluminium thin film on glass recorded for each of
the above wavelengths, (b) normalised Raman signals from cells recorded on 100 nm aluminium
thin film for each of the above wavelengths, with an acquisition time of 30 s (x2).
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(a)
(b)
Figure 7.7: (a) Background signal of 1500 nm aluminium thin film on glass recorded for
each of the above wavelengths, (b) normalised Raman signals from cells recorded on 1500 nm
aluminium thin film for each of the above wavelengths, with an acquisition time of 30 s (x2).
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(a)
(b)
Figure 7.8: (a) Background signal of glass recorded for each of the above wavelengths, (b)
normalised Raman signals from cells recorded on glass for each of the above wavelengths, with
an acquisition time of 30 s (x2). Note, the recorded background signal at 785 nm saturated in
the 1400 cm−1 region.
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(a)
(b)
Figure 7.9: (a) Background signal of magnesium fluoride recorded for each of the above wave-
lengths, (b) normalised Raman signals from cells recorded on magnesium fluoride for each of
the above wavelengths, with an acquisition time of 30 s (x2).
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(a)
(b)
Figure 7.10: (a) Background signal of potassium bromide recorded for each of the above wave-
lengths, (b) normalised Raman signals from cells recorded on potassium bromide for each of
the above wavelengths, with an acquisition time of 30 s (x2).
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(a)
(b)
Figure 7.11: (a) Background signal of sodium chloride recorded for each of the above wave-
lengths, (b) normalised Raman signals from cells recorded on sodium chloride for each of the
above wavelengths, with an acquisition time of 30 s (x2).
7.4. RESULTS 84
(a)
(b)
Figure 7.12: (a) Background signal of zinc selenide recorded for each of the above wavelengths,
(b) normalised Raman signals from cells recorded on zinc selenide for each of the above wave-
lengths, with an acquisition time of 30 s (x2). Note, the cell spectra are only shown between
600–1800 cm−1 due to the large background contribution in the lower wavenumber region.
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In order to perform a quantitative evaluation of the quality of each of the recorded spec-
tra, the background subtracted spectra are all directly compared to that recorded from cells on
Raman-grade calcium fluoride using a 532 nm laser, as seen in Figure 7.2. For the sake of
completeness, three separate metrics are employed in this comparison; (i) discrete correlation,
(ii) normalised covariance, and (iii) MSE. These three metrics compare overlapping regions of
spectra, and thus, produce a value representing how similar the spectra are to that recorded from
Raman-grade calcium fluoride at 532 nm. In this way, it is possible to get a good estimate of
how similar the Raman peaks, and the associated SNR, are when recorded across a range of
substrates and source wavelengths.
Discrete correlation is defined by the following equation:
(X ? Y )(nδλ) =
2N−1∑
m=0
X∗[nδλ]Y [(n+m)δλ] (7.1)
where δλ is the sampling interval of the two signals X and Y , which both have length N ,
? represents correlation, and X∗ is the complex conjugate of X . Previously, in Section 3.4.1,
the relationship between spectral resolution and laser wavelength for an identical spectrograph
grating was discussed. In order to employ the discrete correlation of spectra recorded using
different source wavelengths, it is necessary to ensure that they have identical sampling inter-
vals. This is achieved by applying an interpolation function in Matlab. Correlation was then
implemented using Matlab’s xcorr function. and the corresponding coefficient values that are
recorded can be seen in Table 7.1, where 1.000 is the optimum result defining a perfect match
between spectra, values above 0.900 are a good match, and lower values represent less correla-
tion between spectra.
The second metric, normalised covariance, has a similar range of values between 0 and 1.
Normalised covariance is defined as follows:
Covariance =
(X · Y )2
(X ·X)(Y · Y ) (7.2)
where (X ·Y ) represents the dot product ofX and Y . This metric has previously been applied to
compare the similarity between Raman spectra for cosmic ray removal. (165) The correspond-
ing values obtained using this method are available in Table 7.2, where 1.000 is the optimum
result, and lower values represent less covariance between spectra.
The third metric, MSE, does not have ranges between 0 and 1, but rather between 0, indicat-
ing an identical likeness, and some arbitrary maximum value that is dependent on the differences
in the values of the two signals. MSE is commonly used in signal processing to compare the
likeness of two signals and is defined as follows:
MSE = mean((X − Y )2) (7.3)
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Substrate 473 nm 532 nm 660 nm 785 nm 830 nm
Raman-grade CaF2 0.8741 1.000 0.9189 0.8286 0.6939
IR polished CaF2 0.8726 0.9817 0.8671 0.7882 0.5420
Fused silica 0.8391 0.9422 0.9168 0.7128 0.6218
Aluminium (100 nm) 0.8488 0.9766 0.9211 0.8532 0.7674
Aluminium (1500 nm) 0.8435 0.9854 0.9233 0.8302 0.7837
Glass 0.8473 0.9822 0.9221 0.7469 0.4754
Magnesium fluoride 0.8648 0.5968 0.9403 0.7561 0.7120
Potassium bromide 0.6067 0.9819 0.9112 0.7860 0.6668
Sodium chloride 0.6393 0.9839 0.9354 0.7324 0.7210
Zinc selenide 0.7044 0.3035 0.7643 0.8305 0.4284
Table 7.1: Comparison of cross correlation (xcorr) results for each substrate at each wave-
length when compared to a cell spectrum recorded on a Raman-grade calcium fluoride substrate
using a 532 nm laser, where all spectra are recorded with an acquisition time of 30 s (x2).
Substrate 473 nm 532 nm 660 nm 785 nm 830 nm
Raman-grade CaF2 0.9429 1.000 0.8814 0.6767 0.1641
IR polished CaF2 0.9191 0.9059 0.7117 0.3558 0.0066
Fused silica 0.9004 0.7682 0.9119 0.2423 0.0318
Aluminium (100 nm) 0.8668 0.8868 0.8457 0.6694 0.4999
Aluminium (1500 nm) 0.7390 0.9245 0.9179 0.5582 0.5167
Glass 0.8817 0.9125 0.8856 0.1905 0.0020
Magnesium fluoride 0.9317 0.5953 0.9343 0.3487 0.2117
Potassium bromide 0.5901 0.9235 0.8927 0.4848 0.1249
Sodium chloride 0.5216 0.9148 0.9512 0.2973 0.2646
Zinc selenide 0.2005 0.5840 0.7944 0.6929 0.2173
Table 7.2: Comparison of normalised covariance coefficient results for each substrate at each
wavelength when compared to a cell spectrum recorded on a Raman-grade calcium fluoride
substrate using a 532 nm laser, where all spectra are recorded with an acquisition time of
30 s (x2).
where mean() denotes the process of taking the average value. For comparative purposes, the
MSE values obtained have been presented relative to the maximum value (i.e. all values are
compared to the worst spectrum):
1−
(
MSE
MSEmax
)
(7.4)
This results in values ranging between 0 and 1, which are presented in Table 7.3, where similar
to the other metrics, 1.000 represents the optimum result, and lower values represent a greater
MSE between both spectra.
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Substrate 473 nm 532 nm 660 nm 785 nm 830 nm
Raman-grade CaF2 0.9634 1.0000 0.9817 0.7973 0.4800
IR polished CaF2 0.9417 0.9434 0.7986 0.6139 0.1820
Fused silica 0.9360 0.8517 0.9437 0.5428 0.3187
Aluminium (100 nm) 0.9185 0.9273 0.9073 0.6726 0.7001
Aluminium (1500 nm) 0.8399 0.9530 0.9443 0.6151 0.7089
Glass 0.9269 0.9473 0.9293 0.5079 0.0000
Magnesium fluoride 0.9584 0.6758 0.9605 0.6083 0.5197
Potassium bromide 0.6067 0.9536 0.9221 0.6756 0.4489
Sodium chloride 0.7313 0.9540 0.9703 0.5790 0.5595
Zinc selenide 0.3527 0.6398 0.8457 0.7849 0.4377
Table 7.3: Comparison of mean square error results for each substrate at each wavelength
when compared to a cell spectrum recorded on a Raman-grade calcium fluoride substrate using
a 532 nm laser, and then compared to the value from glass at 830 nm (i.e. the cell spectrum least
similar to that recorded on CaF2 at 532 nm); where all spectra are recorded with an acquisition
time of 30 s (x2).
7.5 Discussion of results
From a sample substrate perspective, the most consistent Raman spectra, regardless of source
wavelength, are obtained from Raman-grade calcium fluoride and both aluminium coated sub-
strates. This has been verified both visually from the recorded spectra (in the ability to identify
key biomolecular peaks, and from the SNR seen in the spectra, see Figure 7.3, Figure 7.6, and
Figure 7.7), and from all three of the metrics employed in this study, as shown in Tables 7.1–7.3.
Good results are also obtained from magnesium fluoride (Figure 7.9), potassium bromide (Fig-
ure 7.10), and sodium chloride (Figure 7.11).
Focusing on the NIR source wavelengths used here (785 nm and 830 nm); while it has
been shown that a number of substrates provided good results, the qualitatively best spectra
(under similar conditions of exposure time and CCD quantum efficiency) are obtained using
the aluminium coated substrates. It is believed that the reason for this is twofold. Firstly, the
aluminium coating effectively blocks the underlying glass, resulting in the lowest background
signal of all the substrates measured. Secondly, it is believed that the reflective substrates pro-
vide approximately four times more Raman scattered photons than transparent substrates; this
results in the source laser passing through the sample twice, effectively doubling the source
power, as well as reflecting all forward scattered photons back towards the MO, which would
otherwise be lost for a transparent substrate. This effect is true for a transparent sample, such as
an epithelial cell, but may not be valid for a thicker tissue sample that appears to be opaque. For
specific source wavelengths, other substrates perform as well as Raman-grade calcium fluoride
and aluminium. In the lower wavelength regions (473 nm, 532 nm, and 660 nm), IR polished
calcium fluoride, fused silica, and glass produce good biological Raman spectra, as shown in
Figure 7.4, Figure 7.5, and Figure 7.8. However, the background signals produced by these
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substrates in the higher wavelength regions swamp the Raman peaks generated from the cells.
On the other hand, zinc selenide performed poorly in the low wavelength region, but generally
improved with increasing wavelength, and even proved to be the best substrate for measure-
ments with a 785 nm laser, as seen in Figure 7.12 and Tables 7.1–7.3, thus making it a good
choice of substrate for the red and NIR region.
In terms of source wavelength, there is a greater SNR in the lower wavelength regions, with
spectra in the NIR being noisy for the integration time of 30 s used in this study, as shown in
Figure 7.3 to Figure 7.12. However, this noise can be reduced by using a longer integration
time, or using a CCD detector with a higher quantum efficiency in this region. Spectra in the
NIR region have a higher resolution than those from lower wavelength lasers, but resolution for
the lower laser wavelengths can easily be increased using a grating with higher line numbers
than that used here. NIR lasers are also better suited for biological analysis due to the optical
window in biological samples, but larger background signals, from the sample substrate and the
optical elements in the system, are present in this region. Therefore, there must be a compromise
when deciding upon a laser for Raman spectroscopic analysis of biological specimen; one must
choose between a laser that results in lower background signals, but is more likely to cause
biomolecular damage to the sample, or a laser that is biologically-friendly but which is more
likely to produce large background signals.
Other factors must also be considered when choosing a sample substrate such as cost,
reusability, and biocompatibility. Calcium fluoride, and in particular Raman-grade calcium
fluoride, is the most expensive of all of the substrates in this study at approximately 150-200
Euro per slide, but it is biocompatible and produces good biological Raman spectra throughout
the full range of laser wavelengths applied in this study. Potassium bromide and sodium chlo-
ride are a much more cost effective solution to calcium fluoride (with associated spectra shown
in Figure 7.10 and Figure 7.11), however both of these substrates are soluble in water, making
it more difficult to clean and re-use these substrates. Magnesium fluoride (Figure 7.9) is more
expensive than potassium bromide and sodium chloride, yet it is cheaper than calcium fluoride,
it has the ability to produce good Raman spectra throughout the range of source wavelengths,
and it is biocompatible and reusable. Glass is the most widely available and cheapest substrate,
but unfortunately it is not ideal for the recording of spectra in the higher wavelength region
where the biological window exists. However, for studies in the lower source wavelength re-
gion, glass has the ability to produce results comparable to that from calcium fluoride, as shown
in Tables 1–3. Similarly, IR grade calcium fluoride and fused silica work better in the lower
wavelength region, as shown in Figure 7.4 and Figure 7.5, but they are more expensive than
glass. Finally, zinc selenide is a significantly cheaper alternative to the other substrates for Ra-
man micro-spectroscopy in the NIR region. However, it is not biocompatible, although there
may be potential to functionalise this substrate with a ‘Raman-friendly’ biofunctional layer that
would improve biocompatibility without compromising the spectral quality. (160; 161)
It should be noted that some of the substrates presented in this chapter can provide better cell
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spectra for 785 nm and 830 nm despite the relatively poor results shown here in Figure 7.3 to
Figure 7.12, particularly for Raman-grade calcium fluoride (Figure 7.3). For example, previous
studies published by Stone et al. (142), Grimbergen et al. (145), and de Jong et al. (144) have
shown good spectra for samples recorded at 830 nm/845 nm using calcium fluoride substrates,
which could be achieved here by simply increasing the laser power, enlarging the confocal
aperture, or increasing the exposure time. The results presented within this chapter may also
be accounted for by considering the significantly lower number of scattered photons for higher
laser wavelengths (see Section 3.4.1 on spectral resolution) and the quantum efficiency of the
CCD detector used for recording spectra, for example, the use of a CCD detector with a higher
quantum efficiency in the NIR region would improve the spectral quality in this region. How-
ever, the purpose of this study is to compare the different substrates under identical experimental
conditions and to discover the relative performances of these parameters in a controlled exper-
iment. It is accepted that the use of two different experimental systems reduces this level of
control, but identical conditions across all experiments were applied insofar as possible.
7.6 Summary
Overall, it has been shown that there exists a high degree of variability across sample substrates
and laser wavelengths for the analysis of biological specimen using Raman micro-spectroscopy.
This high degree of variability means that there is not one single substrate and one source laser
to suit all applications of Raman micro-spectroscopy in the analysis of biological specimen.
This chapter discusses which substrates provide the optimum Raman spectra for each source
wavelength region. However, to find the true optimum combination, it is necessary to consider
the cost effectiveness and biocompatibility of the substrates, in combination with a source laser
within the biological window to prevent photodegradation of the samples, whilst having a low
background contribution.
In this study, a ‘benchmark’ spectrum is chosen, against which the quality of all other spectra
were compared, to have come from a Raman-grade calcium fluoride substrate with a source
wavelength of 532 nm. However, these substrates are very expensive and source lasers in this
region are known to result in biomolecular damage within the sample. Therefore, with these
considerations, it can be concluded that the use of aluminium coated glass substrates with an
NIR laser provides the optimum Raman spectra for everyday clinical studies, being significantly
cheaper than most substrates, biocompatible, and resulting in good quality spectra.
When integrating a new modality into a clinical environment for routine screening or di-
agnostic purposes, it is important to maintain compatibility with existing protocols if possible.
With this consideration, the application of glass slides in conjunction with a 532 nm Raman sys-
tem provides a good compromise in terms of spectral quality and cost effectiveness. Glass slides
are cheap, readily available in the clinic, and they allow for biological samples to be stained and
analysed by a cytopathology post-Raman acquisition if desired. Unfortunately, glass slides pro-
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duce a relatively large background signal, as shown in Figure 7.8(a), which would need to be
accurately removed in order to produce reliable and reproducible spectra; Chapter 8 investigates
three different background correction algorithms for this purpose.
Chapter 8
Algorithm for the removal of the glass
signal from Raman cytology spectra
This chapter has been published as part of the following paper:
• L.T. Kerr, B.M. Hennelly. A multivariate statistical investigation of background sub-
traction algorithms for Raman spectra of cytology samples recorded on glass slides.
Chemometr. Intell. Lab., 158, 61-68, 2016.
8.1 Introduction
Traditional preparation methods for cytology samples pose a significant problem for Raman
micro-spectroscopy, with long-established clinical techniques depositing cells on glass slides.
The results from the previous chapter showed the ability to combine glass slides with a 532 nm
Raman system in order to produce cell spectra that are similar to those achieved with CaF2 sub-
strates. Furthermore, glass slides are inexpensive, biocompatible, and readily available within
the cytopathology clinic. However, the signal from the glass slide can sometimes obscure the
Raman spectrum. The intensity of the glass signal varies from cell to cell depending on mor-
phology, and although smooth, the signal is more complex within the fingerprint region than
the inherent baseline, and cannot easily be removed from the Raman spectrum using polyno-
mial fitting techniques. It is difficult to accurately remove both the glass signal and the baseline
signal simultaneously. Therefore, the use of standard glass slides compromises the capability
of pre-processing methods to extract reliable and reproducible spectra from biological cells. To
avoid this signal, Raman spectra are often recorded from cells on expensive substrates, such
as CaF2, aluminium, or quartz, as discussed in Chapter 7, but this practice is impractical for
large scale applications of Raman cytology for diagnostics or screening purposes. This chap-
ter investigates the potential of a number of background subtraction algorithms to remove both
the glass signal and the baseline, and investigates the effect of these algorithms on subsequent
multivariate analysis for the purpose of cell classification.
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It is necessary to remove background signals insofar as possible from Raman spectra in order
to facilitate an accurate comparison of related cell spectra, and in particular for the application
of multivariate classification for the purpose of disease diagnostics or screening. In general,
Raman spectra of biological samples contain a broad baseline signal that often varies randomly
from one recording to the next, as discussed in Section 4.4. The signal is most often ascribed
to an auto-fluorescence from the sample itself. (74) Although it has been suggested by some
authors (75) that it may originate from sample morphology and Mie scattering of the source
laser wavelength. Regardless of its origins, various algorithms have been developed to identify
and remove this baseline signal from Raman cell spectra, with polynomial fitting techniques
being the most common technique used today. (92; 166; 167)
The preparation of cytology samples poses a significant problem for Raman analysis, with
current clinical techniques, such as the ThinPrep or SurePath methods, producing cell samples
on glass slides for pathological evaluation. Glass is often a necessary consumable in clini-
cal cytopathology due to its low cost. Unfortunately, the background signal from glass adds
to the inherent broad baseline signal to further obscure the weak Raman cell spectrum, thus
compromising the ability of Raman micro-spectroscopy to produce reliable and reproducible
spectra from biological cells. (159) This is particularly evident in the 1050–1150 cm−1 region,
where the glass signal is often strongest when recording Raman spectra with a 532 nm exci-
tation source. The spectral profile, location, and intensity of the glass signal is dependent on
the source wavelength, as previously shown in Figure 7.8, with the ability to recover Raman
spectral peaks decreasing as the source wavelength moves from the visible to the NIR region.
This study is only focused on 532 nm laser sources, which produce a relatively low, but still
problematic glass background signal. In this study, a number of different background subtrac-
tion algorithms are investigated in order to accurately remove the glass contamination present
in Raman cell spectra, as well as the baseline signal.
Algorithms have been previously developed to remove spectral contaminants from Raman
spectra, based on a variety of techniques. Beier et al. (77) proposed an algorithm that simul-
taneously removed the baseline as well as the background signal from a known contaminant
based on an iterative polynomial subtraction method. (73) This algorithm (with minor adjust-
ments) has produced good results in the removal of the glass signal from Raman spectra of
epithelial cheek cells, as previously shown in Chapter 7; however, following extensive testing,
it is reported that for certain cell lines of particular morphology, this algorithm can result in
over-fitting and alteration of key spectral information, which has a negative impact on resultant
multivariate classification algorithms.
EMSC algorithms are gaining interest in recent times for the removal of spectral interferents
from vibrational spectroscopic data. (80) EMSC can be applied to vibrational spectra to sepa-
rate between different physical effects based on an OLS fitting approach (168), as discussed
in Section 4.4.3. This technique has been applied extensively to FTIR spectroscopic data to
correct for Mie scattering effects. (82; 83; 32) Liland et al. (79) recently applied EMSC to fit
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whole datasets to reference spectra, resulting in the removal of an interfering signal from Raman
spectra of adipose tissue. This interferent was due to an optical effect resulting from the Ra-
man system design, presenting in various intensities from spectrum to spectrum, and could not
be completely removed using traditional background correction algorithms, such as a modified
polynomial in combination with the standard normal variate. A similar approach is applied here
for the removal of the glass signal from Raman cytology spectra. It is believed that this algo-
rithm could help with the advancement of Raman cytology into a clinical setting, allowing for
the use of current clinical pathology techniques, such as glass slides. Additionally, the results
of the EMSC algorithm, and subsequent PCA results, are compared with two other background
algorithms.
8.2 The EMSC algorithm for removal of glass signal
The EMSC algorithm, as mathematically described in Section 4.4.3, can be applied for the
removal of the glass signal from Raman cytology spectra. This algorithm can be implemented
via an adapted version of Matlab’s polyfit function, as shown below. This code uses the same
notation as in Section 4.4.3. It is assumed that the inputs r and b have been smoothed using a
Savitzky Golay filter (or another similar smoothing technique), and that X0, r, and b are all 1D
vectors (i.e. spectral irradiance values only, no wavenumber axis, in [m× 1] format).
function [X_final, background, c_r, c_b, B_N] = EMSC(X_0, r, b, N)
% Create dummy axis
axis = 1:length(X_0);
mu = [mean(axis); std(axis)];
axis = (axis - mu(1)) / mu(2);
axis = axis’;
% Construct Vandermonde matrix
V(:,N+1) = ones(length(axis),1,class(axis));
for j = N:-1:1
V(:,j) = axis.*V(:,j+1);
end
V(:,N+2) = b;
V(:,N+3) = r;
% Solve least squares problem
[Q,R] = qr(V,0);
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p = R\(Q’*S);
% Calculate outputs
P_N = polyval(p(1:N+1), x);
c_b = p(N+2);
c_r = p(N+3);
background = P_N + (c_b*b);
X_final = (X_0 - background) / c_r;
The choice of the reference spectrum, r, is a subject of particular interest. It is common
to set r to be equal to the mean spectrum for a given dataset of interest. (79; 80) In this study,
however, in order to omit the glass signal from the reference spectrum, spectra are recorded
from similar cells on CaF2 slides, and r is taken to be equal to that mean spectrum. This
substrate produces a relatively weak background signal, as discussed in Chapter 7, and it can
therefore be assumed that r≈ rcell + Pref , where rcell denotes the true Raman spectral irradiance
of the cell on the CaF2 substrate, and Pref represents a baseline signal that is inherent in the
reference spectrum. All corrected spectra therefore will be fit to a reference that includes this
baseline signal. The presence of this constant baseline is only a matter of aesthetics since the
qualitative and quantitative data within a dataset will be unaffected so long as all of the spectra
in the dataset are processed using the same reference spectrum (80); it has been shown that this
constant baseline, therefore, has no effect on multivariate statistical analysis such as PCA that
follows after processing using EMSC.
The purpose of this study is to investigate the application of the EMSC algorithm to pre-
process Raman datasets recorded from cells on glass slides, in advance of PCA based classifi-
cation, with a view to understanding the potential of the method for improving the sensitivity
and specificity of cytology. For such an application, it is important to fully evaluate the effect
of different reference spectra on the multivariate classification of pre-processed data, in order to
assess any possible biasing of the results.
8.3 Methods
8.3.1 Raman spectral acquisition
Spectra are recorded with the custom built confocal Raman micro-spectrometer, as described in
Section 3.6.1. Spectra are recorded from each cell nucleus with an acquisition time of 5 s each;
two spectra are recorded from the same location within the nucleus, and are averaged together
using an algorithm that simultaneously removes cosmic rays. (72) Four datasets of Raman spec-
tra are recorded using this system, with 50 cell spectra present in each dataset; (i) T24 high grade
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bladder cancer cells recorded on CaF2 substrates (Raman grade CaF2, Crystran, UK); (ii) MDA-
MB-231 triple negative breast cancer cells recorded on CaF2 substrates; (iii) T24 bladder cancer
cells recorded on glass slides; and (iv) RT112 low grade bladder cancer cells recorded on glass
slides. The latter two datasets contain the spectra selected for pre-processing using the EMSC
algorithm, while the other datasets are used to generate the reference spectra used in the algo-
rithm. Further details on the growth and preparation of these cells are available in Section 9.2.1
and Section 11.2.1 later in this thesis.
8.3.2 Background subtraction algorithms
For the sake of comparison, two other well known background subtraction algorithms are first
applied to the T24 and RT112 datasets recorded on glass slides.
The first algorithm is the modified polynomial baseline correction method, as proposed by
Lieber et al. (73), and discussed in Section 4.4.1. This is an automated approach in which the
spectrum is first fitted with an N order polynomial using OLS. Those values of the spectrum
that lie above the polynomial are set equal to the value of the polynomial; the resultant signal is
again fitted with an N order polynomial, and the process is iteratively repeated, until a point is
reached such that the polynomial lies directly underneath the Raman spectral peaks. Here, this
method is applied based on a fifth order polynomial and 200 iterations. This algorithm makes
no attempt to remove the glass signal, but it is one of the most common approaches used for
baseline correction in the literature.
The second algorithm applied is the exact method proposed by Beier et al. (77), similar to
that discussed in Section 4.4.2. This method involves the subtraction of a weighted glass signal
and anN order polynomial in an iterative manner, until a point is reached such that the modelled
baseline lies directly below the Raman peaks. The fminsearch function in Matlab (Matlab,
Mathworks Inc., USA) can be applied to determine which glass weight/polynomial combination
results in the smallest residual spectrum, as described in (77). In the results presented here, N
is chosen to be 5, and the number of iterations is 200.
A glass signal is recorded by focusing the laser onto the surface of a glass slide over a 5 s
integration time. The glass signal was then smoothed using a Savitzky Golay filter (w = 3,
k = 41). In this study, only a first order polynomial is chosen for all cases (i.e. a straight line);
however, in general, the order of the polynomial is dependent upon the dataset being analysed
and the associated baseline intensity present.
The choice of reference spectrum is an important consideration as discussed in Section 8.2.
EMSC has previously been shown to work well for Raman spectroscopy; in previous examples
the mean spectrum of a dataset has been shown to be a good choice for the reference spectrum.
However, in the present study, two datasets are analysed for the purpose of cell classification,
therefore, it is essential to use the same reference for both bladder cell datasets on glass slides.
The reason for this lies in the constant baseline that is inherent in the reference. Therefore, all
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spectra must be fit to the same reference for the sake of fair comparison. In order to understand if
the choice of a particular reference spectrum can introduce any bias into subsequent multivariate
analysis, two different reference spectra are applied, and PCA analysis of the resultant dataset
pairs are compared. In order to generate a reference spectrum, 50 cell spectra are recorded
from cells on CaF2, and averaged together to form a single spectrum. No pre-processing or
baseline correction algorithms are applied to the reference spectrum, unless desired for aesthetic
purposes. Here, the first reference spectrum is generated from T24 cells that are recorded on
a CaF2 substrate, and the second reference spectrum is taken from MDA-MB-231 cells that
are also recorded on a CaF2 substrate. These two references have been chosen because they
are both from epithelial cells, but have different spectral shapes and intensities to each other.
Furthermore, one of the reference spectra is related to one of the two bladder cell lines under
investigation, while the other is unrelated to the two cell lines under investigation. In both
cases, a Savitzky Golay smoothing filter (w = 3, k = 7) is applied to the mean CaF2 spectra, to
generate the final reference spectra for use in the EMSC algorithm.
PCA is applied to both datasets following each background subtraction method, and the first
three PC coefficients are analysed for residual glass signals. Additionally, the standard deviation
across an entire dataset is monitored and compared for each background algorithm.
8.4 Results
This section begins with the results of the two well known background subtraction algorithms
discussed previously; the modified polynomial (73), and the Beier method consisting of a mod-
ified polynomial with the glass signal (77). Figure 8.1(a) shows the mean spectra for T24 and
RT112 cells recorded on glass, averaged over 50 cell spectra in each group respectively, follow-
ing the application of the modified polynomial baseline correction method and normalisation.
The shaded region highlights the presence of varying levels of glass signal across both datasets.
This varying signal is due to the different cell morphology of the two cell lines; the RT112
cells appear to contain relatively smaller nuclei sizes, and therefore their Raman spectra con-
tain a larger proportion of the glass substrate signal. It is expected that the glass contribution
will remain in the processed spectra since the modified polynomial method is designed only to
subtract the baseline signal.
Figure 8.1(b) shows the PC score plot, and the first three PC coefficients/loadings obtained
when the data in Figure 8.1(a) are subject to PCA. Here, it can be seen that the first PC has
a significant glass contribution (see Figure 8.1(c)). It is interesting to note that the spectra
are separating mainly along the first PC; the physical interpretation of this is that the cells are
effectively separation according to differing morphology across the two cell lines, which is
manifesting through the varying power of the glass signal component. Although interesting,
this is not a desirable result. It cannot be expected that a similar morphological difference will
occur in all cell classification applications. It is far more reliable in general to base classification
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on the biochemical variation across the datasets.
Figure 8.1: (a) Mean of T24 and RT112 datasets following a modified polynomial background
subtraction method; (b) PC scores, and the first three PC coefficients [(c), (d), and (e), respec-
tively] for the data shown in (a); (f) Mean of T24 and RT112 datasets following the background
subtraction method proposed by Beier et al., involving a modified polynomial and glass signal
subtraction (77); (g) PC scores, and the first three PC coefficients [(h), (i), and (j), respectively]
for the data shown in (f). The shaded areas highlight the region where the glass signal is most
present within Raman cell spectra.
The second algorithm that is investigated is the method proposed by Beier et al. (77) which,
as described in Section 4.4.2, is designed to simultaneously remove both the glass signal and
the baseline based on the combination of a modified polynomial and a weighted glass signal.
Figure 8.1(f) displays the mean spectra for T24 and RT112 cells recorded on glass, averaged
over 50 cell spectra in each group respectively, following application of this algorithm and
normalisation. This figure demonstrates a significant reduction in the amount of glass signal
present in the spectra, particularly for RT112 cells, when compared to spectra that have been
baseline corrected with a modified polynomial alone.
Figure 8.1(g) shows the PC score plot, and the first three PC coefficients obtained when the
processed data is subject to PCA. Similar to the results presented in Figure 8.1(c), the first PC
contains a signal within the 1050–1150 cm−1 region, associated with glass (see Figure 8.1(h)).
Therefore, whilst the glass signal has been reduced, it is still a significant component in both
spectral datasets, and will remain the dominant factor in any PCA based classification.
Figure 8.2 illustrates the removal of the glass signal contribution from a sample T24 cell
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spectrum recorded on a glass slide based on a reference spectrum generated from T24 cells on
CaF2 using EMSC. The red line represents the raw spectrum recorded from a T24 cell on glass,
and the black line represents the reference spectrum to which all other spectra are fitted. The
green line is the modelled background consisting of a combination of the glass signal and a
first order polynomial, determined using the EMSC algorithm, and the blue line is the corrected
spectrum, which has had the glass signal subtracted.
Figure 8.2: Raw spectrum of T24 cell (red), recorded on a glass slide, which has been fit to
a reference spectrum recorded from T24 cells on CaF2 (black) using EMSC, resulting in a
modelled background signal (green) consisting of a first order polynomial and a weighted glass
signal, and the final background corrected spectrum (blue).
Figure 8.3(a) shows the equivalent mean spectra for the same cell lines as shown in Fig-
ure 8.1, where pre-processing is implemented using the EMSC algorithm; input to this algo-
rithm is the glass signal, a reference spectrum based on T24 cells on a CaF2 substrate, as well
as the chosen polynomial order N . Here, the glass signal has been effectively removed from the
Raman cell spectra. The remaining peaks within the 1050–1150 cm−1 region are Raman cell
peaks, seen in urothelial cell spectra recorded on CaF2 and other similar substrates that produce
low background signals. (143) The standard deviation is also shown for each cell line following
EMSC processing. The amplitude of the standard deviation is amplified by a factor of 10 with
respect to the mean spectra shown in the same figure.
Figure 8.3(b) displays the PC score plot obtained when these datasets are subject to PCA,
with Figure 8.3(c), (d), and (e) illustrating the first three PC coefficients obtained. In contrast
to the PC coefficients using the previously discussed processing methods, the PC coefficients
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Figure 8.3: (a) Mean of T24 and RT112 datasets following EMSC based on a T24 reference
spectrum; (b) PC scores, and the first three PC coefficients [(c), (d), and (e), respectively] for
the data shown in (a); (f) Mean of T24 and RT112 datasets following EMSC based on a MDA-
MB-231 reference spectrum; (g) PC scores, and the first three PC coefficients [(h), (i), and (j),
respectively] for the data shown in (f). The shaded areas highlight the region where the glass
signal is strongest within Raman cell spectra.
presented in Figure 8.3 do not appear to contain a glass signal component. This is an important
result as it is essential for reliable classification algorithms to be based on biomolecular differ-
ences across cell groups, and not to be based on the presence, or absence, of a glass signal.
It is important to note that N = 1 was used for the EMSC algorithm; in this case, therefore,
the EMSC algorithm ultimately amounts to subtracting only a straight line, and a weighted glass
signal from each cell spectrum, followed by normalisation. The use of higher orders were also
investigated, but the use of N = 3, 5, or 7 appeared to offer no improvement over the results
presented here. For this reason, and since it may help to invalidate any suggestion of over-
fitting, N = 1 is chosen. For some cases, which are not presented here, where strong baseline
signals are present within a dataset, higher values of N are needed for accurate modelling of
the background signal. It has been shown elsewhere that the use of high values of N (e.g. up to
7th order) with EMSC does not result in over-fitting. (80)
Although these results are positive, and it is clear that the glass signal is removed, and will
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no longer be a factor in any subsequent classification applied to the PCA results, it could be
argued that the EMSC algorithm might inadvertently influence the results of any subsequent
multivariate analysis, particularly when the reference is based on the mean spectrum of T24
cells on CaF2 for both the T24 and RT112 glass datasets. To investigate such effects, a second
reference spectrum is used that is unrelated to the two cell lines under investigation. The refer-
ence used in this case is based on MDA-MB-231 cells on CaF2. All other parameters (i.e. glass
signal, N ) remained the same. The mean spectra of the two processed datasets are shown in
Figure 8.3(f), where it can be seen that the overall shape of these mean spectra are moderately
different from the corresponding result shown in Figure 8.3(a) for the T24 reference spectrum.
This results from the two references containing differing baselines. This difference is merely a
question of aesthetics, and has no impact on any multivariate statistical analysis that is to follow
EMSC processing. Indeed, it can be seen that the peak differences between the two spectra
is effectively the same for both references. An analysis of the standard deviations of the two
datasets also shows a very similar trend to that found for the previous T24 reference.
Figure 8.3(g) shows the PC score plot obtained when the two processed datasets are subject
to PCA. Remarkably, the PCA score plot appears to be identical to that obtained for the previous
reference. Figure 8.3(h), (i), and (j) illustrate the first three PC coefficients obtained. The PC
coefficients also appear to be identical to those presented in Figure 8.3(c), (d), and (e), thus
showing that the EMSC algorithm appears to produce results in the subsequent multivariate
analysis that are independent of the reference spectrum used, and that it has no impact on the
relative Raman peaks.
Figure 8.4: Histograms, and associated distribution fits, of the weight of the glass signal (cg)
divided by the weight of the reference signal (cr), obtained following EMSC with a T24 reference
for T24 and RT112 cells.
The ratio of cg to cr corresponds to the weight of the glass signal relative to the weight of the
reference that is present in a given spectrum. These ratios are shown in Figure 8.4 for both the
T24 and RT112 datasets following application of the EMSC algorithm with the T24 reference
spectrum. By applying a Gaussian distribution fit to these values, it is possible to estimate both
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the mean and standard deviation of the glass to reference ratio. It is clear that in general, the
RT112 cells contain a stronger glass signal and a larger standard deviation, likely resulting from
their smaller morphology. It is possible to choose a threshold ratio value, in between the two
mean values, that largely separates the two datasets. By choosing the mid-point as a simple
threshold, it is possible to achieve a sensitivity of 97% and specificity of 82% for T24 and
RT112 cells. It is believed that this classification is based purely on the morphology of the cells
being analysed, with the ratio of cg to cr being inversely proportional to the cell thickness. It is
interesting to note that in the case of the two algorithms investigated in Figure 8.1, classification
was possible using only the first PC, which was primarily composed of the glass signal, rather
than the subtle variation in the Raman spectra owing to varying biochemical concentrations. In
the case of EMSC, the glass signal can be extracted, and two approaches exist for classification:
(i) analysing the ratio of cg to cr to perform an approximate classification, or (ii) analysing the
Raman spectra after EMSC for a more accurate classification based on biomolecular variation.
In order to compare the three algorithms investigated here, the standard deviation and con-
fidence intervals, across the various processed datasets, were analysed. Figure 8.5 shows the
mean, and associated 95% confidence interval, for RT112 cells following each of the back-
ground correction algorithms. Following a modified polynomial correction, there remains a
significant deviation across the fingerprint region, with the largest differences seen in the region
where the glass signal is present. The Beier method reduces this confidence interval; however,
there remains a considerable amount of variance seen across the 1050–1150 cm−1 region. The
third method, based on EMSC, shows a reduced confidence interval across the entire spectrum,
including the 1050–1150 cm−1 region. This indicates that the glass signal has been effectively
removed from all of the spectra in the dataset.
8.5 Summary
For many years, the advancement of Raman micro-spectroscopy into the clinic has been im-
peded by its incompatibility with standard clinical protocols, particularly the use of inexpensive
glass slides, as previously discussed in Chapter 7. In this chapter, the ability to remove the glass
signal present within Raman spectra, as well as the baseline signal, has been demonstrated, re-
sulting in spectra that are free from glass contamination. The EMSC algorithm takes as input
(i) the signal generated from glass slides upon illumination with a 532 nm laser, (ii) a reference
spectrum based on a similar cell type recorded on CaF2 substrates, and (iii) a chosen baseline
polynomial order N ; based on these input parameters the algorithm estimates a background
consisting of a weighted glass signal and a slowly varying baseline curve, which can be sub-
tracted to produce spectra that are equivalent to those recorded on expensive “Raman-friendly”
substrates. The output of the EMSC algorithm is the raw spectrum with this background sub-
tracted, followed by multiplication with a normalisation factor that is related to the reference
spectrum.
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Figure 8.5: Mean, and associated 95% confidence intervals, of RT112 cells, recorded on glass
slides, following three different background algorithms: (i) modified polynomial, (ii) Beier
method based on a modified polynomial plus glass signal, and (iii) EMSC algorithm, based
on a reference spectrum of T24 cells on CaF2.
Additionally, application of PCA to the background corrected spectra indicates that EMSC
produces reliable and reproducible results that are independent of the reference spectrum used.
This is an important result since objectivity and reproducibility are crucial for providing good
diagnostic classification, and it demonstrates that the reference spectrum does not introduce
any biasing of PCA based classification. EMSC is also compared with two other well known
background subtraction algorithms, for which it can be seen that the glass signal remained a
significant component within their first PCs, thus reducing the reliability of these algorithms for
Raman based cytological diagnostics on glass slides.
At present, it is not possible to provide a universal reference spectrum that can be applied
to Raman datasets recorded on glass slides from any Raman micro-spectrometer. The rea-
soning for this is due to the lack of accurate system calibration protocols for Raman micro-
spectrometers. Such rigorous calibration tools involve wavelength calibration, using a Neon
source, intensity calibration, with a NIST calibrated white light source, followed by wavenum-
ber calibration (61; 67; 66), as discussed in Section 4.2. In order to utilise a universal Raman
reference spectrum, similar to the Matrigel spectrum applied for FTIR resonant Mie correc-
tion (83), every Raman micro-spectrometer would need to be calibrated with a similar cali-
bration tool. Furthermore, even with the application of such calibration tools, variable results
are still often recorded across different systems. (63) Therefore, it is advised for the reference
spectrum to be recorded from any epithelial cell type on CaF2 with the user’s own Raman
micro-spectrometer.
As demonstrated in Figure 8.4, the ratio of the weight of the glass signal to the weight
of the reference can be applied as a single classification metric for the case of the two cell
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lines investigated within this paper; using this approach, it is possible to separate low grade
and high grade bladder cancer cell lines with 97% sensitivity and 82% specificity. This tech-
nique could be used to quickly identify large or abnormal cells on a slide. However, as these
results are most likely based on cell thickness, it may not be possible to separate cell groups
that are more similar in size. This is an interesting application for Raman micro-spectroscopy,
but it should be noted that there are alternative modalities that can provide better informa-
tion about cell morphology, such as digital holographic imaging (169), scanning near-field mi-
croscopy (SNOM) (170), scanning electron microscopy (SEM) (171), or LiPhos (living pho-
tonics microfluidic platform) (172). Raman micro-spectroscopy identifies the biomolecular dif-
ferences between different cell groups, and by removing the glass signal from Raman spectra
with EMSC, it is possible to classify cells based on biochemistry rather than cell morphology,
which produces higher classification results and can be applied across all cell types. Therefore,
Raman micro-spectroscopy remains the prefered modality for the identification of cancerous or
diseased cells. However, it should be noted that it may be possible to include the cg/cr metric
as an additional variable, together with the processed cell spectrum, for enhanced classification;
the benefit, as well as the manner, of such an approach may be the subject of future work.
There are many further advantages of the EMSC algorithm when compared to commonly
used baseline correction methods. It is computationally less intensive, which is an important
factor when considering the high patient through-put present in cytopathological laboratories
worldwide, and produces spectral datasets with significantly smaller standard deviation, which
improves the reproducibility of results. It is hoped that this investigation will help with the
advancement of Raman based cytology into a clinical setting, allowing for the use of current
clinical techniques, such as the ThinPrep or SurePath methods, and glass slides. Further inves-
tigations into the ThinPrep method, and various other protocols employed in the cytopathology
clinic, are discussed in Chapter 9.
Chapter 9
Protocols for Raman based urine cytology
This chapter has been published as part of the following paper:
• L.T. Kerr, T.M. Lynn, I.M. Cullen, P.J. Daly, N. Shah, S. O’Dea, A. Malkin, B.M. Hen-
nelly. Methodologies for bladder cancer detection with Raman based urine cytology.
Anal. Methods, 8(25), 4991-5000, 2016.
9.1 Introduction
Urine cytology is often used as an adjunct to cystoscopy for the diagnosis of bladder cancer;
however, it has a low sensitivity in detecting low grade bladder cancers. Chapter 6 reviewed
some recent investigations into the application of Raman micro-spectroscopy for the detection
of bladder cancer via urine cytology, and it has been demonstrated to significantly improve the
diagnostic sensitivity of urine cytology for low grade bladder cancer under ideal experimental
conditions (Section 6.5). This chapter attempts to move Raman micro-spectroscopy a step
closer to the clinic by systematically examining the potential of this technology to classify
between low and high grade bladder cancer cell lines under the stringent clinical conditions that
can be expected in the standard pathology laboratory, in terms of consumables, protocols, and
instrumentation. The use of glass slides, traditional fixing agents, lengthy exposure to urine, red
blood cell lysing agents, as well as common cell deposition methods, are investigated in terms of
their impact on the diagnostic potential of Raman based urine cytology. This study investigates
urine samples that have been prepared with the ThinPrep UroCyte method, and analysed with
micro-Raman spectroscopy, in order to determine if they could provide a useful alternative to
cystoscopy for long term bladder cancer surveillance. Additionally, cytology slides are stained
post-Raman acquisition, and analysed using a photo-microscope, to determine if it is possible
to integrate Raman micro-spectroscopy into current clinical practices.
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9.1.1 Bladder cancer surveillance
Bladder cancer, or UC, has the highest recurrence rate of any cancer, and it has been reported as
the most expensive malignancy from diagnosis to death for health care systems, costing the NHS
in the UK approximately £55 million a year. (2; 173; 174) As discussed in Section 6.2, urine
cytology coupled with cystoscopic examination is the standard for bladder cancer diagnostics.
However, cystoscopy is invasive, expensive, and may miss some flat lesions. Approximately
75% of patients present with superficial disease (Ta or T1), known as non-muscle-invasive blad-
der cancer (NMIBC).
Of particular concern for public health systems internationally is the approach to surveil-
lance of patients previously diagnosed and treated for NMIBC. This particular subset of UC has
a high rate of recurrence, and therefore, these patients remain on costly invasive cystoscopic
surveillance programmes for the remainder of their lives. Previous research has been carried
out into the usefulness of urinary cytology versus cystoscopy in the follow-up of NMIBC. (175;
176) To reduce the number of cystoscopy procedures for both healthcare systems and patients,
urinary markers could be used to detect recurrent tumours before they become large and nu-
merous. However, urinary cytology is limited by its low sensitivity for low grade tumours, and
whilst urinary biomarkers are better at detecting these tumours, they are still unable to detect
half of the low grade tumours that have been identified by cystoscopy. (175; 177) According
to current knowledge, no urinary marker can replace cystoscopy during follow-up, or help to
lower cystoscopic frequency in a routine fashion. (178)
9.1.2 Standard urine cytology
Urinary cytology is usually requested for patients with unexplained hematuria, irritative void-
ing symptoms, patients suspected of bladder cancer, and patients monitored for bladder tumour
recurrence. The predominant cellular component of urine cytology is normal urothelial cells,
which can vary greatly in numbers, sizes, and shapes. These cells may appear as mononuclear,
and may be columnar, cuboidal, parabasal-like, or polyhydral. Other normal cellular compo-
nents found in urine cytology include urothelial clusters, papillary fragments, squamous and
glandular cells, renal tubular cells and casts, and prostatic and seminal vesicle cells. (179) In-
flammation, infective pathogens, and blood components are also found across many samples.
Therefore, the process of isolating and identifying urothelial tumour cells within a voided urine
sample can be challenging, particularly for low grade UC.
Cytologically, high grade UC is relatively easy to diagnose with a high degree of sensi-
tivity and specificity due to the presence of anaplastic cells. These cells have high nucleus
to cytoplasm (N/C) ratios; the nuclei are often eccentric with large irregular nucleoli. On the
other hand, low grade UC has a low diagnostic sensitivity and specificity; these tumours are
cytologically characterised by increased cellularity, and the presence of an increased number of
urothelial clusters that may or may not be papillary. The cells in these clusters have high N/C
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ratios with nuclei bulging out of the cytoplasm. CIS is a flat lesion and is the precursor to most
invasive urothelial cancers. Cytology plays an important role in the detection of urothelial CIS
since these lesions may be multifocal and not visualised on cystoscopy. These cells are large
with high N/C ratios. (179) Other types of urothelial malignancies that may be present include
squamous carcinoma, adenocarcinoma, small cell carcinoma, lymphoma, or metastatic tumour
cells from different neoplastic primaries.
The specificity of cytology is greater than 90% and the sensitivity is ∼80% for high grade
UC; however, the sensitivity is 20–50% for low grade UC. (154) The main reason for this is due
to the fact that low grade tumour cells have a similar cytomorphology to normal urothelial cells,
and the observation of increased cellularity or papillary fragments, which are associated with
UC, may instead be related to lithiasis, infection, or urinary tract instrumentation. The cohesive
nature of low grade tumours may also result in less cells being shed into the urine. (173)
9.1.3 Experimental motivation
The objective of this study is to investigate if Raman micro-spectroscopy can successfully clas-
sify low and high grade cell lines under the stringent conditions imposed by a typical patho-
logical laboratory. In order to achieve this, four experiments that systematically examine the
performance of Raman based urine cytology for cell classification across a range of parameters
are proposed.
A comparison between air dried, formalin fixed, and PreservCyt fixed UC cells is the basis
of our first experiment. The impact of formalin fixation has previously been investigated with
Raman spectroscopy (180), however, to the best of our knowledge, PreservCyt has never been
previously compared with air dried and formalin fixed cells for Raman micro-spectroscopic
analysis. This initial study allows for the identification of biomolecular differences that are
introduced to the UC cell samples by these fixation methods, and provides information on the
impact these changes have on the capacity to classify between low and high grade UC cell
lines. In order to minimise the number of variables in this initial experiment, these cells were
not exposed to urine.
An important consideration is the length of time that cells can remain within a urine solution
before Raman based classification becomes unreliable. It has previously been shown that it is
possible to distinguish between different cell types after exposure to urine using Raman micro-
spectroscopy (151; 91; 55), as previously discussed in Section 6.5. However, it should be noted
that these previous studies dealt with cells that were exposed to urine for relatively short periods
of time. In order to analyse urine samples from a clinic, it is impractical to design a Raman study
based around fresh, unfixed samples; this is due to the rapid deterioration of cells in urine, and
the fact that recording all cells on a slide using Raman micro-spectroscopy is typically a time-
consuming process. To overcome this problem, standard urine cytology involves the addition
of a preserving agent into the urine collection vial, with cells being fixed again after the urine
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solution has been decanted. (173; 158; 181; 182) However, the impact of these agents on the
recorded spectra, and the capability of multivariate statistical algorithms to classify different
cell types after fixing, must be considered. Therefore, the second experiment deals with the
impact of urine on cells over 72 h following PreservCyt fixation, with 72 h representing the
maximum expected time frame for the transfer of a urine sample from the clinic to the lab for
analysis.
Urine cytology is usually performed with a liquid based processing technique such as SurePath
or ThinPrep, as discussed in Section 5.5; the third investigation in this study involves preparing
urine/cell solutions with the ThinPrep UroCyte method for Raman micro-spectroscopy. There
are two subgroups within this experiment: (i) application of only PreservCyt, and (ii) applica-
tion of both PreservCyt and CytoLyt; this enables a make direct comparisons of both methods,
and the impact of CytoLyt on UC cells can be identified in isolation.
Hematuria is the most common symptom present in patients diagnosed with UC, occurring
in approximately 90% of cases. (183) Whilst hematuria may be intermittent for patients, it is
important to consider the impact of red blood cells in urine when analysing these samples using
Raman micro-spectroscopy. Red blood cells are known to produce a large signal that can often
swamp the weak Raman spectrum obtained from epithelial cells. Urine solutions that contain
blood can be treated with red blood cell lysing agents such as the combination of H2O2, ethanol,
and industrial methylated spirits as reported by Bonnier et al. (78), or CytoLyt, which is part of
the standard ThinPrep cytology method. In the final experiment, the impact of both scant and
frank hematuria on Raman spectra of UC cell lines is investigated. Samples are processed using
the ThinPrep UroCyte method, in conjunction with CytoLyt in order to lyse any red blood cells
that may be present.
9.2 Methods
9.2.1 Sample preparation
Cell culture
* Note: the work outlined in the following cell culture subsection was completed in collabora-
tion with Dr. Therese Lynn (Institute of Immunology, Maynooth University, Ireland).
Bladder cell lines T24 (high grade UC) and RT112 (low grade UC) are cultured in 1:1
mixture of DMEM and Hams-F12 medium supplemented with 5% fetal bovine serum and 2 mM
L-Glutamine. Flasks are maintained in a humidified atmosphere with 5% CO2 at 37oC. When
the cell lines reach between 80–100% confluency, the culture medium is removed, and the cells
are rinsed with sterile PBS. Trypsin-EDTA (0.5%) is added to the flask, which is incubated at
37oC until the cells completely detach (not exceeding 15 min). An equal volume of 5% serum-
containing medium is added to the flask to neutralise the trypsin enzyme. The contents of the
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flask are transferred into a sterilin container and centrifuged (1200 rpm, 5 min). The supernatant
is removed, and the cell pellet is resuspended in fresh medium. This solution is centrifuged, the
medium decanted, and the cells are resuspended in 1 ml PBS. This step is repeated, and the cell
pellets are processed as explained in the following subsections.
Fixing agents
In order to compare between air dried, formalin fixed, and PreservCyt fixed cells, the samples
are prepared as follows:
(A) Air dried: the cell pellet is suspended in 2 ml PBS, followed by centrifugation. The
PBS is decanted, and the cell pellet is resuspended in 1 ml PBS. 30 µl of this cell suspension is
dropped onto a glass substrate and left to air dry at room temperature for 2-3 hours.
(B) Formalin fixation: 10% neutral buffered formalin (HT501128, Sigma Aldrich, US) is
passed through a 0.2 µm filter (Minisart filters, Sigma Aldrich, US) in order to remove any
large salt crystals present in the solution. The cell pellet is suspended in 2 ml of formalin and
left for 10 min at room temperature. The solution is centrifuged, decanted, and the cells are
resuspended in 2 ml PBS. The resulting solution is again centrifuged, decanted, and the cells
are resuspended in 1 ml PBS. 30 µl of this cell suspension is dropped onto a glass substrate and
left to air dry at room temperature for 2-3 hours.
(C) PreservCyt fixation: the cell pellet is suspended in 20 ml of PreservCyt and left for
15 min at room temperature. The solution is centrifuged, decanted, and the cells are resuspended
in 2 ml PBS. This solution is centrifuged, decanted, and the cells are resuspended in 1 ml PBS.
30 µl of this cell suspension is dropped on to a glass substrate, and left to air dry at room
temperature for 2-3 hours.
Urine exposure times
In order to prepare urine samples containing UC cells, the cell pellet is suspended in 10 ml
artificial urine (AU-001, Biopanda Diagnostics, UK) and 5 ml PreservCyt. These samples are
stored in the fridge for 5 h, 24 h, and 72 h, respectively. Samples are then centrifuged, decanted,
and the cell pellet is resuspended in 20 ml PreservCyt and left at room temperature for 15 min.
The resulting solution is centrifuged, decanted, and the cell pellet is resuspended in 1 ml PBS. A
final centrifugation step is carried out, followed by decantation, and resuspension in 50 µl PBS.
This entire volume is then dropped onto a glass substrate and left to air dry at room temperature
for 2-3 hours.
ThinPrep UroCyte
In order to prepare urine samples containing UC cells with the ThinPrep UroCyte method, the
cell pellet is suspended in 10 ml artificial urine and 5 ml PreservCyt, and stored in a fridge
for 24 h. Samples are then centrifuged, and the supernatant decanted. In order to compare the
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differences between cells exposed only to PreservCyt, and those exposed to both PreservCyt
and CytoLyt, the samples are prepared as follows:
(A) Two or three drops of the cell pellet are suspended in a 20 ml PreservCyt vial and left at
room temperature for 15 min. The vial is inserted into the T2 and the cells are transferred onto
a ThinPrep glass slide.
(B) The cell pellet is vortexed and resuspended in 30 ml CytoLyt. The solution is centrifuged
and decanted, and two or three drops of the cell pellet are resuspended in a 20 ml PreservCyt
vial and left at room temperature for 15 min. The vial is inserted in the T2 system and the cells
are transferred onto a ThinPrep glass slide.
Hematuria
In order to compare the impact of scant hematuria and frank hematuria present in urine samples,
UC cells are suspended in 10 ml artificial urine, 5 ml PreservCyt, and either 0.5 ml whole
blood (creating a pink solution to represent scant hematuria), or 3 ml whole blood (producing a
deep red solution representing frank hematuria). All samples are centrifuged and decanted. The
cell pellet is vortexed and resuspended in 30 ml CytoLyt. The resulting solution is centrifuged,
decanted, and two or three drops of the cell pellet are resuspended in a 20 ml PreservCyt vial
and left at room temperature for 15 min. The vial is inserted in the T2 system, and the cells are
transferred onto a ThinPrep glass slide.
9.2.2 Raman spectral acquisition
Our custom-built Raman micro-spectroscopy system is employed for all measurements in this
study, as discussed in Section 3.6.1. Spectra are recorded within the 600–1800 cm−1 range with
an acquisition time of 5 s each. Two spectra are recorded from the same location within the nu-
cleus of 50 cells from each slide. The recording of two spectra facilitates the removal of cosmic
rays as described by James et al. (72) Following this, the EMSC algorithm is applied to remove
the glass signal and the slowly varying baseline from each Raman spectrum (as described in
Chapter 8). For this study, a 1st order polynomial is used in the EMSC subtraction algorithm
for all datasets, except for the case of T24 and RT112 formalin fixed cells on glass, which had
a particularly strong baseline signal due to experimental parameters on that given day; in this
case N was chosen to be 7. Additionally, all spectra are smoothed with a Savitzky-Golay filter
(k = 5; w = 7). In order to compare the spectra recorded across the various parameters discussed
in this study, and in order to determine the impact of these parameters on the classification of
both cell lines, a combination of PCA and LDA is applied to the two groups in each of the four
experiments. The sensitivity and specificity values are determined based on a leave-one-out
cross validation method.
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9.2.3 Haematoxylin & Eosin (H&E) staining
Following Raman spectral acquisition, all samples prepared with the ThinPrep UroCyte method
are H&E stained. (184) This is achieved by placing the slides into 95% alcohol for 10 min, and
then washing with water. Slides are placed into Harris haematoxylin (Sigma Aldrich, US) for
5 min, and then transferred into water, before being submerged into 1% acid-alcohol for 1 s,
washed with water, and placed into water for 5 min to ‘blue’ the haematoxylin. Slides are placed
into 1% eosin (Sigma Aldrich, US) for 3 min in order to counterstain the cytoplasm, following
which, the slides are submerged in water for 1 s, 95% alcohol for 1 s, and 100% alcohol for
1 s. The slides are placed into 100% alcohol for 5 min, and are then transferred into a bath
of xylene (Sigma Aldrich, US) for 3 min, and a second bath of xylene for a further 3 min.
Finally, the slides are removed and a coverslip applied with DPX mounting medium (Thermo
Fisher Scientific, Ireland), and are left to dry. Following staining, cells are examined under a
photo-microscope, with a 40x MO, for changes relating to different stages of cancer such as
abnormal cellular shape and size, abnormal nuclei, and cellular arrangement/distribution. The
amount of residual blood cells present on the slide from hematuria contaminated samples is also
monitored. Alternatively, slides could have been stained with Papanicolaou (Pap) if this method
was prefered.
9.3 Results
9.3.1 Fixing agents
The spectra shown in Figure 9.1 represent the mean Raman spectra recorded from T24 UC cells
for the cases of air dried, formalin fixed, and PreservCyt fixed, respectively. Raman spectra
of formalin fixed cells are found to be most similar to air dried cell spectra with no significant
differences observed. PreservCyt fixed cells are found to have differences in the intensity of
some peaks within the fingerprint region; an increase can be seen in the peaks at 1093 cm−1 and
1250 cm−1, which relate to PO2 stretching (DNA/RNA), and a decrease in peaks at 750 cm−1,
1310 cm−1, 1340 cm−1, and 1580 cm−1, corresponding to tryptophan, guanine, adenine, and
bending modes of phenylalanine. (185) Each individual T24 and RT112 spectrum is shown
in Figure 9.2, corresponding to all three fixation methods.
For each fixation method, a PC-LDA training model is implemented in order to classify T24
and RT112 UC cells, with associated PCA scores and coefficients shown in Figure 9.3. The
resulting sensitivities and specificities are 100% and 98.0% for air dried cells, 98.0% and 100%
for formalin fixed cells, and 100% and 100% for PreservCyt fixed cells, respectively. These
classification values indicate that the three fixing agents measured here have no significant im-
pact on the ability of PC-LDA to classify spectra across both cell types. This demonstrates that
PreservCyt fixation of cells, a common preservation method used across clinics today, can be
integrated into Raman micro-spectroscopy. Interestingly, as shown in Figure 9.3, the PC
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Figure 9.1: Mean spectrum of air dried T24 cells (black), formalin fixed T24 cells (red), and
PreservCyt fixed T24 cells (green). All cells were drop-dry deposited onto glass slides.
Figure 9.2: 50 spectra from each of the following datasets: (i) air dried T24 and RT112 cells;
(ii) formalin fixed T24 and RT112; and (iii) PreservCyt fixed T24 and RT112, corresponding to
the mean spectra shown in Figure 9.1.
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scores for PreservCyt cells are most similar to air dried cells; this shows that PreservCyt fixation
doesn’t alter the spectral differences that are seen between T24 and RT112 after air drying.
9.3.2 Urine exposure times
The mean spectra for T24 and RT112 cell lines following urine exposure for 5 h, 24 h, and 72 h,
with PreservCyt fixation, are shown in Figure 9.4, with individual cell spectra for each group
presented in Figure 9.5.
Figure 9.4: Mean spectrum of T24 and RT112 UC cells after exposure to urine and PreservCyt
for 5 h, 24 h, and 72 h; all cells were drop-dry deposited onto glass slides.
For each exposure time, a PC-LDA training model is implemented, and the corresponding
sensitivities and specificities are listed in Table 9.1, where it can be seen that it is still possible
to accurately differentiate between both cell lines after 72 h; corresponding PCA scores and
coefficients are shown in Figure 9.6. Interestingly, when the data from all three time durations
are combined, the classification accuracies remain above 90%, which indicates that PreservCyt
can preserve cells in urine for up to 3 days without significantly altering the cell biochemistry
or the diagnostic potential of the method.
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Figure 9.5: 50 T24 and RT112 spectra for each of the following time durations of urine expo-
sure: (i) 5 hours; (ii) 24 hours; and (iii) 72 hours.
Drop-dry method: Sens. Spec.
T24 - 5 h urine exposure 98% 94%
RT112 - 5 h urine exposure 94% 98%
T24 - 24 h urine exposure 98% 96%
RT112 - 24 h urine exposure 96% 98%
T24 - 72 h urine exposure 100% 100%
RT112 - 72 h urine exposure 100% 100%
T24 - Combined urine exposure times 92% 93%
RT112 - Combined urine exposure times 93% 92%
Table 9.1: Sensitivity and specificity values for T24 and RT112 cell lines after urine expo-
sure based on a PC-LDA model with leave-one-out cross validation (all cells were drop-dry
deposited).
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9.3.3 ThinPrep UroCyte
Figure 9.7 shows the mean spectra recorded from T24 and RT112 UC cells after exposure
to urine and PreservCyt for 24 h, with and without the addition of the red blood cell lysing
agent CytoLyt, followed by ThinPrep processing. Here, it can be seen that CytoLyt has no
significant impact on UC cells, and no spectral contributions are observed from cells that are
exposed to CytoLyt compared with those exposed to PreservCyt alone. The spectra recorded
from ThinPrep processed slides are more consistent than those measured with the drop-dry
method, i.e. a smaller standard deviation is measured across the spectra from both T24 and
RT112, as shown in Figure 9.8. It is possible that this is due to the uniform monolayer deposition
method employed by the T2 machine compared to the random distribution of cells that can
accumulate on the slide after the drop-dry method.
Figure 9.7: Mean spectra of T24 and RT112 UC cells after exposure to urine and PreservCyt
for 24 h, followed by ThinPrep processing with and without the addition of the red blood cell
lysing agent CytoLyt.
Figure 9.9 shows the images obtained from these slides after H&E staining (after Raman
spectral acquisition); distinct differences can be seen between both cell lines in terms of cellular
shape and size, along with more abnormal nuclei present in T24 UC cells, as expected. The cells
do not appear to have been photodamaged by the laser, which indicates that a cytopathologist
should still be able to perform standard urine cytology diagnostics on slides that have been
stained following Raman spectral acquisition, thus allowing for both Raman and standard urine
cytology to be performed on the same slide.
A PC-LDA model is generated based on a leave-one-out cross validation method for both
of these methods individually and combined, and the results are displayed in Table 9.2, with
PCA scores and loadings available in Figure 9.10. The sensitivities and specificities found are
greater than 88%.
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Figure 9.8: T24 and RT112 cell spectra recorded following cell deposition using the ThinPrep
UroCyte method, with (i) only PreservCyt, or (ii) with PreservCyt and CytoLyt.
ThinPrep method: Sens. Spec.
T24 - 24 h urine - PreservCyt only 94% 100%
RT112 - 24 h urine - PreservCyt only 100% 94%
T24 - 24 h urine - PreservCyt and CytoLyt 96% 96%
RT112 - 24 h urine - PreservCyt and CytoLyt 96% 96%
T24 - Both ThinPrep samples 88% 99%
RT112 - Both ThinPrep samples 99% 88%
Table 9.2: Sensitivity and specificity values for T24 and RT112 cell lines after urine exposure
based on a PC-LDA model with leave-one-out cross validation, following ThinPrep deposition.
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Figure 9.9: Images obtained from H&E stained UC cells after Raman spectral analysis, pre-
pared with the ThinPrep UroCyte method. (A) RT112 cells, and (B) T24 cells without CytoLyt;
(C) RT112, and (D) T24 cells with CytoLyt. Scale bar = 100 µm.
9.3. RESULTS 119
Fi
gu
re
9.
10
:
P
C
A
sc
or
es
an
d
th
e
fir
st
tw
o
P
C
lo
ad
in
gs
sh
ow
n
fo
r
T2
4
an
d
R
T1
12
ce
lls
fo
llo
w
in
g
ce
ll
de
po
si
tio
n
us
in
g
th
e
Th
in
P
re
p
U
ro
C
yt
e
m
et
ho
d,
w
ith
(i
)o
nl
y
P
re
se
rv
C
yt
,o
r
(i
i)
w
ith
P
re
se
rv
C
yt
an
d
C
yt
oL
yt
.
9.4. DISCUSSION OF RESULTS 120
9.3.4 Hematuria
Spectra recorded from cells obtained from ThinPrep processed urine samples replicating scant
and frank hematuria are shown in Figure 9.11. Here, it can be seen that cells obtained from a
urine sample with scant hematuria appear to be free from any contamination; this is due to the
effective removal of many of the red blood cells present in the sample using CytoLyt. However,
for the frank hematuria sample, several additional peaks have been observed that correspond to
the presence of residual blood cells, a further breakdown of the peaks associated with blood cells
can be found elsewhere. (186) This result indicates that samples that have relatively high blood
cell concentrations are not suitable for diagnostics with Raman micro-spectroscopy, although
further investigation into additional CytoLyt washes, or the use of H2O2 as suggested by Bonnier
et al. (78), could possibly help to further remove residual blood from these samples.
Figure 9.12 shows the H&E stained images obtained from both samples containing scant
and frank hematuria, respectively. Here, small regions of blood remain visible within the scant
hematuria sample, but the majority of UC cells in this sample appear to be isolated from the
blood regions. The frank hematuria sample, however, has a low UC cell yield, and contains large
regions of blood contamination. It is possible that this is due to large amounts of blood cells
gathering on the ThinPrep filter, resulting in less space for the UC cells. This demonstrates the
importance of removing blood cells with a lysing agent, as well as applying additional washes,
to further remove this contamination.
Figure 9.11: Mean spectra of T24 and RT112 UC cells after exposure to urine and PreservCyt
for 24 h with the addition of blood to replicate scant and frank hematuria. All samples were
ThinPrep processed with the red blood cell lysing agent CytoLyt.
9.4 Discussion of results
In this chapter the ability of Raman micro-spectroscopy to discriminate between low and high
grade bladder cancer cell lines with a high degree of accuracy has been demonstrated, even
within the practical constraints of a typical pathology laboratory. Four separate experiments
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Figure 9.12: H&E stained images of (A) RT112 cells from a scant hematuria urine sample, and
(B) T24 cells from a frank hematuria urine sample. Both samples were processed with CytoLyt
and the ThinPrep method. Scale bar = 100 µm.
are conducted that validate the performance of Raman based classification when applied as an
adjunct to the standard practice of urine cytology.
In the first experiment, it is concluded that the Raman spectra obtained from cells follow-
ing fixation, using the commercial methanol based fixative, PreservCyt, are not significantly
different to those recorded from air dried cells and formalin fixed cells, with negligible differ-
ences in statistical classification accuracies observed. This is an important result; not only does
it demonstrate that Raman micro-spectroscopy can easily be adopted into the standard urine
cytology protocol within a clinical setting, but it also provides an alternative to the use of for-
malin, a common fixative of choice in Raman based cell studies, (158; 180; 182) which is a
known carcinogen. (187) While it has been shown by Harvey et al. (55) that the alcohol based
fixative SurePath could be used as part of the BD SurePath liquid-based Pap test, SurePath pro-
duced a large signal within the fingerprint region, which makes PreservCyt a preferable fixative
for urine cytology samples.
In the second experiment, it is shown that UC cells can be exposed to urine for up to 3 days in
the presence of PreservCyt without significantly altering the cellular biochemistry. The ability
to accurately classify between two cell lines after exposure to urine for 5 h, 24 h, and 72 h has not
been significantly affected (see Table 9.1). Interestingly, the results in Table 9.1 indicate that the
sensitivities and specificities increase slightly with longer urine exposure times; however, this
is more likely to be related to minute changes in the system’s alignment or sample preparation
methods rather than an improved accuracy that corresponds directly to urine exposure times.
Therefore, the combined sensitivities and specificities (91.5% and 93.2% respectively) are a
better representation of this method. This result indicates that it may be possible to transport
urine samples from a clinic into a Raman lab within a realistic time frame. It is impractical
to consider analysing urine samples that have not been exposed to a preservative unless the
samples will be processed within a few hours of urine collection due to the rapid deterioration
of cells in urine. (188)
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In the third experiment, it is demonstrated that the ThinPrep UroCyte method can be applied
in combination with Raman micro-spectroscopy resulting in spectra that have a smaller standard
deviation than that obtained from cells deposited onto a slide via the drop-dry method. This
is most likely due to the uniform monolayer deposition method employed by ThinPrep, as
seen in Figure 9.9. ThinPrep also provides a cleaner background, increased cellularity, better
preservation, and facilitates easier and faster preparation. (123)
The two chemicals employed by the ThinPrep UroCyte method have little impact on the Ra-
man spectra obtained, and no significant impact in diagnostic classification results are observed.
Uniform cellular distribution results in smaller deviations in the background signal when com-
pared to the spectra obtained from cells deposited onto a slide via the drop-dry method. Cells do
not require any washing steps after fixation in PreservCyt with ThinPrep due to its filter based
properties, whereas drop-dried cells need further washing with PBS in order to avoid spectral
contamination from the PreservCyt solution. It should be noted that additional washing steps
could result in a reversal of the fixation process of PreservCyt.
The sensitivity and specificity values calculated for ThinPrep prepared samples, as shown in
Table 9.2, are greater than 88%. Whilst these results are slightly lower than those found for the
drop-dry method, ThinPrep offers many other advantages that make it a preferrable deposition
method for Raman micro-spectroscopy. These advantages include ease of preparation, which
is particularly important in a busy clinic, the inclusion of red blood cell lysing agents, and a
monolayer distribution of cells across the slide, where one focal depth is sufficient to analyse
most of the cells on the slide.
In the final experiment, the impact of hematuria on the spectra recorded from UC cells
obtained from a urine sample is investigated. Approximately 90% of patients diagnosed with
bladder cancer will present with hematuria. Therefore, it is inevitable that Raman spectra will
have to be recorded from patients with blood in their urine. The amount of blood will vary from
patient to patient, resulting in urine of a mild pink colour (scant hematuria) to deep red (frank
hematuria), with the most severe cases resembling the colour of coffee. In this experiment, it
is shown that urothelial cells can be easily separated from blood in scant hematuria samples
using ThinPrep with CytoLyt, as can be seen in Figure 9.12(A). However, it is more difficult to
fully remove red blood cells from frank hematuria samples, resulting in urothelial cells being
deposited onto the slide in very close proximity to regions of blood residue (Figure 9.12(B)).
The consequence of this is that the Raman spectra obtained from UC cells are contaminated
by spectral peaks associated with blood. Additional CytoLyt washes should help to further
eliminate this problem, but it may be necessary to wait for the patient to provide a sample at a
later date when their levels of hematuria have lowered, e.g. after an antibiotic for infection, or
medication for kidney stones, etc.
There are additional factors associated with urine cytology samples that have not been con-
sidered here, such as the ability to identify UC cells that are randomly distributed across a slide
containing healthy urothelial cells, squamous and glandular cells, renal tubular cells and casts,
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inflammation, or infection. It must also be noted that in this chapter, and in previous literature
on Raman based urine cytology described in Section 6.5, the number of cells to be recorded
from each slide have not been considered in great detail. Shapiro et al. reported recording
only five cells per slide; however, since it is possible for the majority of urothelial cells in a
typical sample to be non-cancerous, it is unknown how these five cells are chosen or identi-
fied. (151) An important problem with standard urine cytology is the inability to differentiate
between healthy cells and low grade cancer cells under a microscope, and this task becomes
more difficult when the cells are unstained, as required by Raman micro-spectroscopy. There-
fore, one reasonable approach may be to record spectra from every available urothelial cell on
the slide, and to monitor if any of these cells are classified as cancerous by the trained statistical
algorithm. If a cell is identified as such, the corresponding patient could then be flagged for
further investigation. Alternatively, it may be possible to train image processing algorithms to
identify cells of interest.
Similarly, the number of patients that should be used to accurately train a classifier needs to
be further examined. Beleites et al. reported that a sample size of 75–100 is typically needed
to verify the accuracy of a classifier. (189) However, it is difficult to train a classifier from urine
cytology samples due the low sensitivities associated with the standard urine cytology method;
thus, training of algorithms based on biopsy and tissue samples with a known pathological status
may be preferable.
9.5 Summary
In summary, the combination of Raman micro-spectroscopy and the ThinPrep UroCyte method
provides an ideal platform to replace cystoscopy for bladder cancer surveillance, particularly for
high-risk patients who otherwise would require frequent repeat cystoscopic procedures. A key
component of this involves the use of inexpensive glass slides, along with the EMSC algorithm
that was investigated in Chapter 8. Raman based urine cytology provides all of the advantages
associated with standard urine cytology, i.e. ease of procurement, non-invasive, and low cost,
as well as the advantages of high sensitivity and specificity that are typically associated with
cystoscopy. Additionally, Raman based urine cytology could help to significantly lower the
financial burden associated with bladder cancer surveillance for health care systems worldwide,
as well as improving the patient’s quality of life.
Chapter 10 investigates the potential of integrating the ThinPrep UroCyte method into FTIR
spectroscopy, as well as investigating the potential of Raman and FTIR for classifying prostate
cancer cells that are present in urine cytology samples.
Chapter 10
Detection of prostate cancer cells with
FTIR and Raman micro-spectroscopy
10.1 Introduction
FTIR and Raman micro-spectroscopy are both vibrational spectroscopic techniques, with the
physics involved previously discussed in Chapter 2. Both of these methods have been applied
extensively for the diagnosis of cancer of the genitourinary system (30; 56; 190; 191; 192; 193;
194); however, these techniques often involve preparing samples using non-traditional clinical
protocols, which has hindered their advancement into the cytopathology laboratory. Traditional
clinical protocols have been investigated in association with Raman micro-spectroscopy for
bladder cancer diagnostics in Chapter 9. This chapter expands upon this concept to include
prostate cancer cells as well as FTIR spectroscopy.
Prostate cancer affects one in seven men every year in the USA; however, there remains a
lack of modalities available for the accurate diagnosis of this disease. Monitoring of prostate
specific antigen (PSA) levels and/or digital rectal examination (DRE) form the first step of the
prostate diagnostics, but these techniques present with a high number of false positive results.
This study investigates the potential application of FTIR and Raman micro-spectroscopy to
identify prostate cancer cells that may be present in a urine sample. In a similar manner to that
described in the previous chapter, a simulated study is undertaken, in this case prostate and blad-
der cell lines are both added to an artificial urine solution, replicating a urine sample obtained
following prostatic massage. (195) The synthetic urine samples are prepared using the Thin-
Prep UroCyte method, as discussed in further detail in Section 5.5.1. This simulation includes
the cell lines PC3, PNT1A, and T24. PC3 represents an aggressive prostate cancer, PNT1A is
normal prostate epithelium, and T24 is high grade bladder cancer; these cell lines are chosen
as part of this proof of concept study in order to determine if it is possible to identify prostate
cancer cells from healthy prostate, and from bladder cancer cells which are morphologically
very similar to prostate cancer cells. (196) These three cell lines are exposed to urine and Pre-
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servCyt for 24 h, and deposited onto both glass and CaF2 substrates using the T2 machine, as
described in Chapter 5. Both methods are compared in terms of classification results, as well as
in terms of practical implementation and cost. Cells deposited on CaF2 substrates are analysed
with FTIR and Raman micro-spectroscopy, and cells on glass are analysed only with Raman
micro-spectroscopy due to the large glass signal present within the fingerprint region of FTIR
spectra. (37)
10.1.1 Prostate cancer diagnostics
There are over 230,000 new cases of prostate cancer every year across the United States. (2) This
disease has a high rate of recurrence, with 15-52% of prostate cancers progressing to a higher
stage. (197; 198) It is evident that the diagnosis, management, and surveillance of these patients
results is a significant burden for healthcare systems worldwide, with Sangar and colleagues
reporting annual estimated costs of £93 million for prostate cancer on the NHS in the UK. (2)
Detection of prostate cancer is primarily based on an abnormal DRE and/or increased PSA
levels; however, prostate biopsy is currently the only way to confirm the presence of clinically
localised prostate cancer. Despite its widespread use, 65-70% of males with elevated PSA levels
present with negative biopsy results. Importantly, when a patient presents with abnormal PSA
levels or DRE, their likelihood of having cancer is 20-25%, and with normal PSA levels and
DRE, the possibility of having missed cancer is 10%. (199) Furthermore, biopsies of the prostate
are not without significant risks, including infection, systemic sepsis, and hemorrhage, and are
known to inherently undersample the prostate, resulting in an estimated 34% false negative
rate. (200) Approximately 20-35% of patients that return for a repeat biopsy are diagnosed with
prostate cancer that was not detected with the initial biopsy. (200) Therefore, it is generally
recommended for patients with negative biopsy results to undergo repeat biopsies with the aim
of identifying patients at high risk of concealing prostate cancer. In order to avoid unnecessary
biopsies, and the associated risks involved for the patient, and the cost implications for the clinic,
it is imperative to develop a non-invasive, accurate test for the diagnosis of prostate cancer.
It is known that prostate cancer cells are shed into biological fluids, particularly after pro-
static massage, allowing for the non-invasive detection of these cells in urine or expressed pro-
static fluid. (196) Traditional cytology diagnostic methods (i.e. Pap stained slides analysed by
a cytopathologist) result in unacceptably low sensitivities for identifying prostate cancer cells.
These low sensitivities are a result of low numbers of prostate cancer cells found in urine sam-
ples, as well as the difficulty in differentiating between malignant prostate cells and high grade
bladder cancer cells, which are morphologically similar to each other. (196)
Cytology coupled with vibrational spectroscopy may prove useful in solving the clinical
dilemma of how best to proceed with men who are suspected of harboring prostate cancer.
This includes men whose initial biopsy was negative despite an abnormal DRE or PSA, for
primary cancer detection after DRE, or for monitoring disease progression in patients who opt
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for expectant management (e.g. “watchful waiting” or “active surveillance”).
Many studies have previously reported the application of Raman spectroscopy and/or FTIR
to classify bladder and prostate cancer cells, resulting in high sensitivities and specificities for
classification. (154; 193; 201; 202) However, to translate vibrational spectroscopy into a cy-
topathology lab, it is important to integrate these technologies with current clinical protocols.
Applications of Raman spectroscopy for classification of bladder and prostate cancer cells
from urine samples are reviewed in Section 6.5. FTIR has been extensively applied to both blad-
der and prostate cancer tissue samples (30; 192; 203; 204), resulting in sensitivities and speci-
ficities greater than 90%. However, applications of FTIR to cytology samples are less common.
In 2007, Harvey et al. (205) applied FTIR-photoacoustic spectroscopy to differentiate between
four formalin fixed prostate cancer cell lines. Bird and colleagues (206) (2008) applied FTIR
to discriminate between different cell groups found in voided urine samples. In 2009, Harvey
et al. (194) applied FTIR micro-spectroscopy, in transflection mode, to prostate cell lines and
primary cells grown on MirrIR slides, showing that classification was independent of the culture
medium used or the N/C ratio, indicating that FTIR based classification is explained mainly by
the cellular biochemical differences. However, recent studies have identified the presence of
electric field standing waves above the reflective MirrIR slides, resulting in unwanted spectral
perturbations, making these slides unreliable for FTIR based diagnostics. (37; 207) In 1998,
Cohenford et al (125) deposited cervical smear samples onto zinc selenide slides using the
ThinPrep method, and applied FTIR to identify the presence of abnormal cervical cells. To
the best of our knowledge, FTIR spectroscopy has not previously been applied for prostate or
bladder cancer diagnostics on cells obtained from a urine sample, prepared with a T2 machine,
and deposited onto CaF2 slides.
10.2 Methods
10.2.1 Sample preparation
* Note: the cell culturing methods discussed in this section were completed in collaboration
with Dr. Marion Butler (Institute of Immunology, Maynooth University, Ireland).
All cell lines are cultured in 1:1 mixture of DMEM and Hams-F12 medium supplemented
with 5% fetal bovine serum and 2 mM L-Glutamine. Flasks are maintained in a humidified at-
mosphere with 5% CO2 at 37oC. When the cell lines reach 80% confluency, the culture medium
is removed, and the cells are rinsed with sterile PBS. Trypsin-EDTA (0.5%) is added to the flask,
which is incubated at 37oC until the cells have completely detached (not exceeding 15 min). An
equal volume of 5% serum-containing medium is added to the flask in order to neutralise the
trypsin enzyme. The entire contents of the flask is transferred into a sterilin container, and
centrifuged. The supernatant is removed, and the cell pellet is resuspended in fresh medium.
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This solution is centrifuged, following which the medium is decanted, and resuspended in 1 ml
PBS. This step is repeated, the cell pellets are resuspended in 10 ml artifical urine and 5 ml
PreservCyt, and stored at room temperature for 24 h. The vial is then centrifuged, decanted,
and the cell pellet is resuspended in a 20 ml PreservCyt vial, and left at room temperature for
15 min. The vial is inserted into the T2 machine, and the cells are transferred onto either a glass
or Raman-grade CaF2 slide.
When operating the T2 machine with CaF2 substrates, it should be noted that the T2 only
accepts slides that are 1” x 3” x 1 mm, with all four corners removed, similar to that shown in
Figure 10.1. Raman-grade CaF2 slides of these dimensions are expensive to purchase, and due
to their fragile nature, the removal of the corners is a delicate and time consuming process. Fur-
thermore, due to the underlying cell deposition methods employed by the T2 machine, the cell
adherence numbers are lower for CaF2 substrates when compared to glass slides. It is believed
that this is due to the lack of impurities found in CaF2 substrates, resulting in fewer attrac-
tive forces, which are required for good cell adhesion. Nonetheless, adequate numbers of cells
are observed on the CaF2 substrates following ThinPrep deposition, allowing for vibrational
spectroscopic data to be recorded.
Figure 10.1: Substrate dimensions that are required in order to fit into the T2 machine.
10.2.2 Raman data acquisition and processing
Our custom-built Raman micro-spectroscopy system is employed for all measurements in this
study, as described in more detail in Section 3.6.1. Spectra are recorded within the 400–
1800 cm−1 region, with an acquisition time of 5 s each. Two spectra are recorded from the
same location within the nucleus of 50 cells from each slide, allowing for the subsequent re-
moval of cosmic rays. (72) All spectra are background corrected using the EMSC algorithm,
as described in Chapter 8. The chosen reference spectrum is based on the mean of T24 cells
recorded on CaF2; however, a number of different reference spectra were tested and found to
produce similar results. (79; 80; 85) For all data recorded from cells on CaF2, EMSC is applied
using only the reference spectrum, and a first order polynomial (i.e. a straight line). For spectra
recorded on glass slides, the glass signal contribution is removed as part of the EMSC process,
as well as a first order polynomial. All spectra are classified based on PC-LDA, with sensi-
tivity and specificity values determined using a leave-one-out cross validation, as described in
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Section 4.6.3.
10.2.3 FTIR data acquisition and processing
FTIR spectra are recorded using a Perkin Elmer Spotlight 400 FTIR imaging system (Perkin
Elmer Inc., USA; located in the Focas Institute, Dublin Institute of Technology, Ireland), with
collection of data in transmission mode. Spectra are recorded using the SpectrumIMAGE Spot-
light 400 software. Spectral measurements are acquired with a pixel size of 6.25 µm× 6.25 µm,
for 4 scans per pixel, with a spectral resolution of 4 cm−1. Background measurements are
recorded from a region on the slide free from any cells or specimen.
EMSC is applied to all FTIR spectra to correct for resonant Mie scattering contributions
based on the Matrigel spectrum, as developed by Bassan et al. (81; 83; 82; 32) This algorithm is
operated over 5 iterations per spectrum. Following this, spectra are smoothed with a Savitzky-
Golay filter (w = 3, k = 41), and area normalised. Spectra are classified based on PC-LDA,
with sensitivity and specificity values determined using a k-fold cross validation approach (k =
10).
10.3 Results
10.3.1 Raman results
Figure 10.2: (a) Raw spectra of PNT1A, PC3, and T24 cells, recorded on CaF2 slides; (b) ref-
erence spectrum and EMSC corrected PNT1A, PC3, and T24 datasets.
Figure 10.2(a) shows the raw Raman spectra recorded from PC3, PNT1A, and T24 cells
on CaF2 slides, and Figure 10.2(b) shows the reference spectrum, which is input to the EMSC
algorithm, as well as the corresponding Raman spectral datasets after background correction
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with EMSC. This figure demonstrates a significant reduction in the variance both within and
across datasets.
Figure 10.3: (a) Raw spectra of PNT1A, PC3, and T24 cells, recorded on glass slides; (b) refer-
ence spectrum and glass signal input to EMSC, and corrected PNT1A, PC3, and T24 datasets.
Figure 10.3(a) shows the raw Raman spectra recorded from PC3, PNT1A, and T24 cells
on glass slides. The glass signal is evident in the raw spectra within the 500–600 cm−1 and
1050–1150 cm−1 regions. Figure 10.3(b) displays the reference spectrum and the smoothed
glass signal (using a Savitzky-Golay filter; w = 3, k = 41) both of which are input to the
EMSC algorithm. Also shown in the figure are the corresponding Raman spectral datasets after
background correction using the EMSC algorithm, as described in Chapter 8. A reduction in
the signal intensity can be seen within 500–600 cm−1 and 1050–1150 cm−1 regions that is
associated with the removal of the glass component. Similar to the data shown in Figure 10.2,
a significant reduction in variance can be seen across all three datasets following background
correction.
PCA and LDA scores are shown in Figure 10.4 for PC3, PNT1A, and T24, with (a) and
(b) representing the data recorded on CaF2, (c) and (d) the data recorded on glass, and (e) and
(f) representing a combination of the data recorded on both CaF2 and glass. These PCA results
show poor separation, although it is possible to separate T24 from both prostate cell lines across
the second PC for Raman data recorded on CaF2. Good separation across the three groups can
be seen following LDA, as shown in Figure 10.4(b), (d), and (f).
Table 10.1 provides the sensitivities and specificities that are calculated following PC-LDA
classification, based on a leave-one-out cross validation for the results shown in Figure 10.4.
The results achieved are greater than 92% across both substrates. Interestingly, good classi-
fication results can still be achieved when spectra from both substrates are combined. This
result shows that it may be possible to record Raman spectra from either substrate, and EMSC
background correction can allow for these datasets to be combined when training a multivariate
10.3. RESULTS 130
Figure 10.4: (a) PCA scores and (b) LDA scores for Raman data of PNT1A, PC3, and T24 cells
recorded on CaF2; (c) PCA scores and (d) LDA scores for PNT1A, PC3, and T24 Raman cell
spectra recorded on glass; (e) PCA scores and (f) LDA scores for PNT1A, PC3, and T24 cells
that were recorded on both CaF2 and glass.
Raman micro-spectroscopy: FTIR:
CaF2: Glass: CaF2 & glass: CaF2:
Sens.: Spec.: Sens.: Spec.: Sens.: Spec.: Sens.: Spec.:
PC3 96% 97% 96% 98% 92% 99% 93% 99%
PNT1A 96% 97% 96% 97% 95% 95% 98% 99%
T24 94% 97% 92% 96% 95% 98% 97% 96%
Table 10.1: PC-LDA results of Raman spectra recorded on CaF2 and glass slides, based on a
leave-one-out cross validation, and for FTIR spectra recorded on CaF2 based on a k-fold cross
validation approach (K = 10).
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Figure 10.5: The first and second PC coefficients, (a) and (b) respectively, obtained from Raman
spectra of PNT1A, PC3, and T24 cells recorded on CaF2; (c) and (d) represent the first and
second PC coefficients obtained from Raman spectra of PNT1A, PC3, and T24 cells recorded
on glass; and (e) and (f) are the first and second PC coefficients obtained from PNT1A, PC3,
and T24 cells recorded from both on CaF2 and glass. PC coefficients correspond to the PCA
scores shown in Figure 10.4(a), (c), and (e), respectively.
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statistical classifier.
The first two PC coefficients from each analysis can be found in Figure 10.5(a) and (b) for
CaF2 slides, (c) and (d) for glass slides, and a combination of CaF2 and glass are shown in (e)
and (f). Similar features appear across the first two PC coefficients for all three cases, with
common peaks observed at 782 (DNA), 1243 (amide III), 1304 (nucleic acids), 1340 (colla-
gen), 1437 (lipids), 1485 (nucleic acids), 1573 (nucleic acids), and 1681 cm−1 (amide I) for the
first PC, and at 915 (RNA), 1336 (DNA), 1401 (collagen), and 1663 cm−1 (DNA) for the sec-
ond PC. (163; 208) Importantly, there are no prominent features associated with the glass signal
appearing in any of these coefficients. This result indicates that spectra recorded on glass slides
could be directly compared to Raman spectra recorded on CaF2 slides (assuming adequate sys-
tem calibration has been achieved, see Section 4.2 for further information). This is an important
result for research groups, or clinics, that would like to alter their current protocols to include
glass slides, but would like to retain retrospective Raman datasets that have been recorded on
CaF2 substrates in their lab for inclusion in ongoing studies.
10.3.2 FTIR results
Figure 10.6 shows the fingerprint region (1000–2000 cm−1) of the FTIR spectra recorded from
PNT1A, PC3, and T24 cells on CaF2, with the raw spectra shown in Figure 10.6(a), and spectra
following EMSC resonant Mie scatter correction shown in Figure 10.6(b). Similar to Raman
data (as shown in Figures 10.2 and 10.3), the variance has been reduced across each FTIR
dataset following EMSC, along with a reduction of any spectral shifting that may have been
present in the raw spectra due to Mie scattering artifacts. (81)
Figure 10.6: FTIR spectra of PNT1A, PC3, and T24 cells, recorded on CaF2 slides, with (a) rep-
resenting the raw spectra, and (b) shows the corresponding spectra following EMSC resonant
Mie scattering correction.
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(a)
(b)
Figure 10.7: (a) PCA scores for FTIR spectra of PNT1A, PC3, and T24 cells, and (b) shows the
first three corresponding PC coefficients.
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Table 10.1 shows the PC-LDA classification results obtained for the data shown in Fig-
ure 10.6(b), based on a k−fold cross validation (k = 10). These results are similar to those
obtained with Raman micro-spectroscopy, in terms of the ability to classify across all three cell
lines, with sensitivities and specificities obtained of greater than 93%.
Based on the PCA scores shown in Figure 10.7(a), it can be seen that the FTIR spectra are
separable based on PCA alone, whereas all three Raman spectral datasets are only separable
following PC-LDA. Interestingly, PC3 and T24 cells are grouped closer together relative to
PNT1A cells, allowing for complete separation between cancerous and healthy cells, similar
to the separation observed between cancerous and healthy cells across the first LD for Raman
spectra recorded on CaF2, as shown in Figure 10.4(b).
As shown in Figure 10.7(a), most of the separation across the FTIR spectral datasets oc-
curs over the second PC. Figure 10.7(b) shows the first three PCs, with the main peak differ-
ences seen in the second PC at 1060 (glycogen), 1220 (PO2 asymmetric stretching, Amide III),
1400 (Amide III), 1470 (CH3 asymmetric stretching, proteins, lipids), and 1580 cm−1 (Amide
III). (30; 191; 202)
10.4 Summary
The results presented in this chapter suggest that Raman and FTIR spectroscopy have the poten-
tial to identify prostate cancer cells that are present in a urine cytology sample prepared using
the ThinPrep UroCyte method, which is commonly used in clinical cytopathology laboratories.
The results presented here show that Raman micro-spectroscopy can be applied to both CaF2
and glass slides, and that these recordings can be carried out somewhat interchangeably, as well
as showing that FTIR spectroscopy can be applied to CaF2 slides that have been processed using
the ThinPrep method. These results reinforce previous studies that have suggested that vibra-
tional spectroscopy could be applied to slides obtained directly from the clinic. (78) However, it
is important to highlight some of the incompatibility issues that have been observed with CaF2
and the T2 machine, as discussed in Section 10.2.1, as well as acknowledging the financial
burden associated with operating a diagnostic technique using expensive CaF2 substrates.
In order to overcome any issues with CaF2 and the T2 machine, it may be possible to in-
corporate glass slides into FTIR based cytology studies in a similar manner as Raman micro-
spectroscopy. Bassan et al (37) recently showed the ability to classify between paraffin embed-
ded breast cancer tissue samples in the higher wavenumber region. However, the combination
of glass slides and FTIR have not been considered here as this study focused only on the finger-
print region of the FTIR spectrum. Furthermore, the complex resonant Mie scattering signals
that are inherent in FTIR cytology spectra may prove problematic to remove using EMSC due
to the varying levels of the glass signal present across each spectrum. Nonetheless, this may
prove interesting for future studies, and it may be possible to expand the resonant Mie scattering
EMSC algorithm to incorporate the glass signal, similar to that presented in Chapter 8.
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Similar classification results have been achieved within this study for both vibrational spec-
troscopy methods, as shown in Table 10.1. However, it is also important to consider other
aspects of both these techniques in terms of the practical implementation in the clinic. For this
study, Raman spectra are recorded from 50 cells on each slide, with a total acquisition time of
10 s per cell. With the inclusion of additional time required to locate cellular nuclei and the
correct z-focal depth position, the overall time required to analyse one Raman cytology slide
is on the order of 1-2 h, with longer times required for inexperienced users. FTIR on the other
hand allows for the analysis of large regions of a slide, and therefore larger numbers of cells,
within the order of 10-15 min, even when operated by an inexperienced user. Whilst the times
required for both techniques could be improved by automating the systems involved, Raman
micro-spectroscopy remains a much slower technique than FTIR. However, pre-processing of
both groups of spectral datasets shows that Raman algorithms are significantly faster to run than
the complex algorithms required to remove Mie scattering artifacts from FTIR spectra, resulting
in similar time frames overall for the application of either technique.
Given the degree of accuracy obtained here, which is significantly higher than that achieved
with PSA or DRE, there is a good argument for the possible introduction of vibrational spec-
troscopic techniques into the clinic to assist cytopathologists in accurately identifying the pres-
ence of prostate cancer cells. Prior to the widespread application of core biopsy, many prostate
cancers were diagnosed with fine needle aspiration (FNA); however, core biopsy samples pro-
duced higher accuracies in determining the presence of prostate carcinoma. With the ThinPrep
method, it is also possible to prepare FNA samples to produce similar cytology slides as that
achieved with urine cytology, with the added benefit of larger numbers of prostate cells. This
study has shown that Raman and FTIR micro-spectroscopy may have the potential to improve
upon the diagnostic capabilities of FNA samples. FNA carries the additional benefits of being
quicker, less expensive to perform, and safer for the patient. (209) FNA samples are routinely
obtained from patients suspected of harbouring breast cancer; Chapter 11 investigates the appli-
cation of Raman micro-spectroscopy for the analysis of such simulated breast cytology samples.
Chapter 11
Monitoring of changes in cellular
biochemistry associated with hypoxia and
exosomal communication
11.1 Introduction
Exosomes are microvesicles (40–100 nm in diameter) of endocytic origin released into the ex-
tracellular environment by most cell types, as briefly discussed in Section 5.4. It is believed
that they play a significant role in cell signalling and communication by virtue of their capac-
ity to traffic miRNA, mRNA, and proteins to recipient target cells. (112) Furthermore, it has
previously been shown that the levels of exosomes in patients with cancer are significantly
higher than those in normal plasma, with hypoxic tumours producing even more exosomes
when compared to the levels observed from normoxic tumours. (119) This chapter investigates
the application of Raman micro-spectroscopy for (i) identifying the differences between cells
growing in normoxia versus cells growing in hypoxia, and (ii) monitoring of any changes in
cellular biochemistry upon exposure to exosomes. These measurements are based on MDA-
MB-231 triple negative breast cancer (TNBC) cells, although it is believed that similar changes
could be induced in cells within the urinary bladder under these conditions. TNBC is a specific
subtype of epithelial tumour which lacks protein expressions for the estrogen receptor (ER), the
progesterone receptor (PR), or the human EGF receptor 2 (HER2), and is often associated with
a high occurrence rate of hypoxia. (210) Approximately 15% of all breast cancers are TNBC,
although it accounts for 30% of breast cancers amongst African-American women. (211)
Hypoxia is a key feature of many tumours throughout the body, and whilst this chapter
focuses on TNBC, it is believed that similar physiological changes would be observed within
bladder and prostate tumours. Hypoxia has previously been observed in bladder (212; 213; 214)
and prostate (215; 216) tumours, as well as investigations on the release of their associated ex-
osomes (113; 217; 218). This chapter reports the application of Raman micro-spectroscopy to
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identify any biomolecular changes that occur due to either the presence of hypoxia or interac-
tions with exosomes.
11.1.1 Hypoxic TNBC tumours
TNBC is associated with advanced disease stage, BRCA1 gene mutations, a younger age at pre-
sentation, and has a poorer prognosis compared to other breast cancer subtypes. TNBC tumours
are innately hypoxic, a tumour micro-environment integral to aggressive tumour behaviours
such as increased invasion. Tumour hypoxia (reduced levels of O2 availability) occurs when
rapid cancer cell proliferation leads to the growth of cells that are too far away from a blood ves-
sel, and therefore these cells become structurally and functionally abnormal. (211) Hypoxia ex-
erts significant effects on the tumour micro-environment with profound consequences for cancer
progression, often leading to patient mortality. Additionally, hypoxia has been linked with inva-
sion, angiogenesis, apoptosis, metastasis, chemoresistance, and radiation resistance. (210; 219)
Knowledge of the degree and extent of hypoxia is invaluable for patient treatment planning.
Current techniques for measuring hypoxia include polarographic needle electrodes, 19F mag-
netic resonance imaging (MRI), and phosphorescence imaging. (219) However, there remains
a clinical need for a technique to measure hypoxia on a cellular level in a reliable and repro-
ducible manner. The first experiment within this chapter is based on investigating the ability of
Raman micro-spectroscopy to classify between normoxic and hypoxic TNBC cells, as well as
identifying the main biomolecular differences between both groups.
11.1.2 Exosomes
It has previously been shown that breast cancer cells release greater levels of exosomes upon
exposure to hypoxia (220); the impact of such exosomes on the surrounding tumour micro-
environment is an ongoing subject of interest, with increasing evidence showing that tumour
cell-derived exosomes play an important role in angiogenesis, metastasis, and tumour progres-
sion. (220)
Exosomes are defined as extracellular vesicles that are released from cells upon fusion of
the MVEs with the plasma membrane, as previously shown in Figure 5.4. Over the last decade,
there has been significant interest into the understanding of exosomes, and their role in cell
communication, disease transmission, and their potential application for drug delivery. (113;
221; 222; 223) However, despite research efforts, little is known of the basic biology involved in
these processes, or how exosomes affect normal cellular physiology. Furthermore, it is difficult
to isolate exosomes from other similar sized extracellular vesicles, with many studies using the
terms interchangeably, resulting in great scepticism amongst the research community.
The second aim of this chapter is to monitor any changes within the cellular biochemistry of
TNBC cells upon exposure to exosomes. To achieve this, exosomes are isolated from normoxic
and hypoxic cells respectively, across three different batches, and are introduced to separate
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batches of cells for 48 h, following which Raman micro-spectroscopy is applied for cellular
analysis.
11.1.3 Fine needle aspiration
All cytology samples within this chapter are prepared for Raman micro-spectroscopic analysis
using the ThinPrep method, as previously discussed in Section 5.5.1. Throughout this thesis,
the ThinPrep UroCyte method has been applied to urine cytology specimen; however, with this
study, the cell pellets are placed in a vial of PreservCyt, representing FNA breast specimen.
As discussed in Section 10.5, FNA samples are often prepared with ThinPrep method in the
clinic (224), resulting in cytology slides that can be analysed using Raman micro-spectroscopy.
Breast FNA is a relatively simple procedure, which removes cells from a breast lesion or cyst
with a needle that is thinner than that used to obtain a standard blood sample. FNA is safer
for the patient, and relatively inexpensive to process, when compared with core needle biop-
sies. (225) In contrast to prostate diagnostics, FNA analysis is currently a popular technique
employed in the clinic for the analysis of suspicious breast lesions.
11.2 Materials and methods
11.2.1 Sample preparation
Raman micro-spectroscopy is sensitive to minute changes across samples and experimental
protocols, batch-to-batch cellular variations, and daily variations of the Raman system. These
changes can result in small differences in the Raman spectra that can lead to irreproducible
results. (226) Therefore, in order to optimise the reproducibility and reliability of the results
presented in this study, the first experiment consists of three batches of cells grown in normoxia
(21% O2) and hypoxia (1% O2), respectively. Similarly, the second experiment consists of three
batches of normoxic cells grown in the presence of exosomes that have been released from nor-
moxic cells (NEx), and three batches grown with exosomes released by hypoxic cells (HEx).
Furthermore, Raman spectral measurements are recorded randomly across each cytology sam-
ple in order to further reduce any experimental variability.
Cell culture
∗ Note: The work outlined in the following cell culture subsection was completed by our collab-
orator Luke Gubbins (Conway Institute, University College Dublin, Ireland).
MDA-MB-231 cells are grown in RPMI 1640 culture medium, in either normoxic conditions
(21% O2) or hypoxic conditions (1% O2) for 48 h, until 70–80% confluency is reached. For
parent cell analysis in the first experiment, the cells are trypsinised, and centrifuged into a cell
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pellet, as described in Section 10.2.1. The cell pellet is suspended in a 20 ml vial of PreservCyt,
and left at room temperature for 15 min.
Exosome isolation
∗ Note: The work outlined in the following exosome isolation subsection was completed by our
collaborator Luke Gubbins (Conway Institute, University College Dublin, Ireland).
Cells grown to 70-80% confluency are cultivated for a further 48 h in medium supplemented
with exosome depleted fetal calf serum. The supernatants are collected and centrifuged at 300g
for 10 min, following by 2,000g for 20 min to remove cellular debris. Supernatants are filtered
using a 0.22 µm filter (Millex; Merck Millipore, Ireland), transferred into fresh ultracentrifuge
tubes, and centrifuged at 120,000g for 80 min at 40C in a Beckman Coulter Optima LE-80K
ultracentrifuge (Beckman Coulter Inc., USA). The supernatant is completely removed, and the
pellet in each tube is resuspended in 1 ml of PBS. The resuspended pellets from the same cell
line are pooled in a single ultracentrifuge tube, and PBS is added. The sample is centrifuged
again at 120,000g for 80 min at 40C. The supernatant is removed, and the exosomal pellet is
resuspended in 50-100 µl PBS, and stored at -800C. The presence of exosomes is verified with
western blotting, NanoSight measurements (Malvern, USA), and mass spectrometry (results
not shown here).
Co-culture cells with exosomes
∗ Note: The work outlined in the following co-culture subsection was completed by our collab-
orator Luke Gubbins (Conway Institute, University College Dublin, Ireland).
MDA-MB-231 cells are trypsinised and counted, and seeded at an initial density of 180,000
cells per well in six well plates. The cells are allowed to adhere for approximately 12 h. The
medium is changed, and replaced with RPMI 1640 supplemented with 10% v/v exosome de-
pleted fetal calf serum, 1% penicillin/streptomysin (Gibco, ThermoFisher Scientific, Ireland).
The exosomes (either derived from normoxic or hypoxic cells) are added, and the cells are
grown for a further 48 h in normoxic conditions. For co-culture cell analysis in the second
experiment, the cells are trypsinised, and centrifuged into a cell pellet, as described in Sec-
tion 10.2.1. The cell pellet is suspended in a 20 ml vial of PreservCyt, and left at room temper-
ature for 15 min.
ThinPrep preparation
The vials containing PreservCyt and the cell pellets are inserted into the T2 machine, along with
ThinPrep glass slides and filter tubes. The cells are transferred onto the glass slide based on the
T2 fluid/FNA setting.
11.3. RESULTS 140
11.2.2 Raman spectral acquisition
Our custom-built Raman micro-spectroscopy system is employed for all measurements in this
study, as described in further detail in Section 3.6.1. Spectra are recorded within the 600–
1800 cm−1 range with an acquisition time of 5 s each; two spectra are recorded from the same
location within the nucleus, and are averaged together using an algorithm that simultaneously
removes cosmic rays (72), with 60 cells recorded from each slide. Spectra are wavenumber
calibrated, and background corrected using the EMSC algorithm to remove both the slowly
varying baseline signal, and the unwanted glass signal, as described in Chapter 8. The EMSC
algorithm is operated with a reference spectrum recorded from MDA-MB-231 cells on CaF2
and a fifth order polynomial.
PC-LDA is applied to the datasets in order to classify between cells that are grown in a
normoxic environment compared to those grown in an hypoxic environment. Further PC-LDA
classifications are applied to identify cells that have been exposed to either NEx or HEx. All
classifications are based on a leave-one-out cross validation approach.
11.3 Results
Figure 11.1 shows all of the Raman spectra recorded from normoxic and hypoxic parent cells,
across all three batches, following EMSC background correction. Similar to the spectra shown
in previous chapters, the glass signal has been removed from these spectra.
Following PCA analysis, Figure 11.2(a) shows the PCA scores for normoxic and hypoxic
parent cells (all batches combined), with most separation occurring across a combination of
PC1 and PC2. Further PCA analysis is applied across each batch individually, resulting in
the PC coefficients shown in Figure 11.2, with (b) and (c) representing PC1 and PC2 for the
first batch of parent cells, respectively, (d) and (e) representing PC1 and PC2 for the second
batch of parent cells, and (f) and (g) representing PC1 and PC2 for the third batch of par-
ent cells. Focusing on the first PC coefficient, tentative peak assignments are provided for
the compositional differences that can be seen across all three batches relating to DNA (782,
1098, 1336, 1373 cm−1), nucleic acids (1485, 1577 cm−1), lipids (1064, 1128, 1299, 1437,
1744 cm−1), amino acids (869 cm−1), phenylalanine (1002 cm−1), amide III (1243 cm−1),
and amide I (1676 cm−1). Biomolecular differences across the second PC coefficient relate
to DNA (725, 782, 1098 cm−1), amino acids (928, 1548, 1622 cm−1), lipids (1064, 1294,
1434 cm−1), proteins (1152, 1573 cm−1), ribose (996 cm−1), amide III (1243 cm−1), colla-
gen (1401), nucleic acids (1485 cm−1), and amide I (1652 cm−1), with peak assignments ob-
tained from the following references: (163; 202; 208; 227; 228; 229). Observation of consistent
peak differences across all three batches for both PCs allows for the identification of the bio-
chemical changes that occur as cells are exposed to hypoxic environments. Interestingly, the
majority of these peak differences relate to DNA, nucleic acids, and lipid content, which is in
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Figure 11.1: Raman spectra of normoxic and hypoxic MDA-MB-231 cells, recorded from all
three batches, following EMSC background correction.
agreement with previous reports that have linked cell growth dependence on unsaturated fatty
acids for survival under O2 deprivation. (230)
Table 11.1 provides the sensitivities and specificities obtained following PC-LDA classi-
fication for each batch, and for all batches combined. These results show a good ability to
differentiate between cells growing under normoxic conditions compared to those in hypoxia
using Raman micro-spectroscopy. The clinical relevance of such results allows for FNA cy-
tology samples to be identified as originating from a tumour with or without hypoxic regions,
which could allow for improved patient treatment planning. This also raises the possibility of
applying Raman fiberoptic probes within a surgical procedure for identifying hypoxic regions
within a tumour, as well as identifying the borders between normoxic and hypoxic regions. The
best results are achieved for the second and third batches, which may relate to batch-to-batch
variations, or small differences within the Raman system during the recording of the first batch
of cells. This highlights the importance of repeating experiments across multiple batches and
recording of spectra across different days in order to combine the results to provide a more
realistic classifier.
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Figure 11.2: (a) PCA scores for normoxic and hypoxic parent cells (all batches combined),
(b) PC1 coefficient and (c) PC2 coefficient for normoxic and hypoxic parent cells (Batch 1),
(d) PC1 coefficient and (e) PC2 coefficient for normoxic and hypoxic parent cells (Batch 2),
and (f) PC1 coefficient and (g) PC2 coefficient for normoxic and hypoxic parent cells (Batch 3).
Consistent peak differences across all three batches are highlighted in blue.
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Sensitivity: Specificity:
Batch 1:
Normoxic parent cells 72% 68%
Hypoxic parent cells 68% 72%
Batch 2:
Normoxic parent cells 95% 87%
Hypoxic parent cells 87% 95%
Batch 3:
Normoxic parent cells 98% 97%
Hypoxic parent cells 97% 98%
All batches:
Normoxic parent cells 84% 88%
Hypoxic parent cells 88% 84%
Table 11.1: PC-LDA classification results of Raman parent cell spectra recorded across each
individual batch, and for all batches combined.
Figure 11.3 shows the Raman spectra recorded from MDA-MB-231 cells grown in the pres-
ence of either NEx or HEx, for each of the three batches, following EMSC background sub-
traction. Figure 11.4(a) shows the PCA scores for normoxic parent cells and normoxic cells
exposed to NEx; poor separation is seen across the first three PCs for both of these groups.
Figure 11.4(b) shows the PCA scores for normoxic parent cells and normoxic cells exposed to
HEx; both of these cell groups are separable across a combination of PC2 and PC3.
Figure 11.5 shows the first PC coefficients for each batch of normoxic parent cells when
compared with normoxic cells exposed to either NEx or HEx, with (a) and (b) representing
the results from the first batch, (c) and (d) correspond to the second batch, and (e) and (f)
relate to the third batch. The first PC coefficients are similar for all batches, with consistent
peak differences observed for DNA (782, 1098, 1334 cm−1), lipids (1297, 1437 cm−1), nucleic
acids (1484, 1575 cm−1), phenylalanine (1002 cm−1), amide III (1243 cm−1), and amide I
(1676 cm−1), with peak assignments obtained from the following references: (163; 202; 208;
227; 228; 229).. Interestingly, these peak differences are also observed in PC1 coefficients for
PCA analysis of the normoxic and hypoxic parent cells (see Figure 11.2(b), (d), and (f)).
Similar to Figure 11.5, Figure 11.6 shows the second PC coefficients for each batch of co-
cultured measurements, with (a) and (b) corresponding to the first batch of cells, (c) and (d)
corresponding to the second batch, and (e) and (f) representing the third batch. The second
PC coefficients show less correlation across each batch, with three major peak differences ob-
served across each batch relating to lipids (1294 cm−1), collagen (1401 cm−1), and amide I
(1655 cm−1), as highlighted in yellow in Figure 11.6. Consistent peaks observed across batch
one and batch three correspond to DNA (724, 785, 1132 cm−1), and nucleic acids (1180,
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Figure 11.3: Raman spectra of MDA-MB-231 cells growing in normoxic after exposure to either
NEx or HEx, recorded across all three batches, following EMSC background correction.
Figure 11.4: (a) PCA scores for normoxic parent cells and normoxic cells exposed to NEx,
(b) PCA scores for normoxic parent cells and normoxic cells exposed to HEx. These scatter
plots represent the Raman data recorded across all three batches.
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Sensitivity: Specificity:
Batch 1:
Normoxic parent cells 92% 88%
Normoxic cells with NEx 88% 92%
Batch 2:
Normoxic parent cells 95% 75%
Normoxic cells with NEx 75% 95%
Batch 3:
Normoxic parent cells 95% 73%
Normoxic cells with NEx 73% 95%
All batches:
Normoxic parent cells 87% 78%
Normoxic cells with NEx 78% 87%
Batch 1:
Normoxic parent cells 100% 98%
Normoxic cells with HEx 88% 92%
Batch 2:
Normoxic parent cells 97% 87%
Normoxic cells with HEx 87% 97%
Batch 3:
Normoxic parent cells 80% 80%
Normoxic cells with HEx 80% 80%
All batches:
Normoxic parent cells 87% 81%
Normoxic cells with HEx 81% 87%
Table 11.2: PC-LDA classification results of Raman spectra recorded from normoxic cells and
normoxic cells exposed to either NEx or HEx, across each individual batch and for all batches
combined.
1571 cm−1), as highlighted in green, and across batch two and batch three correspond to colla-
gen (915-935 cm−1), nucleic acids (1327 cm−1), and DNA (1457 cm−1), highlighted in pink in
Figure 11.6. The PC coefficients are most consistent across batches two and three with respect
to each other. Further peak differences that relate to phenylalanine (1002 cm−1), DNA (1338,
1375 cm−1), and nucleic acids (1483 cm−1) are observed within batch one that correspond to
cells exposed to either NEx or HEx, as shown in Figure 11.6(a) and (b) respectively, with spe-
cific peaks highlighted in purple. Overall, these results show that there is good consistency
across batches two and three, however, there is poor consistency with batch one, which might
correspond to differences in exosomal composition within each batch, therefore resulting in
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Figure 11.7: LDA scores for normoxic and hypoxic parent cells, and normoxic cells exposed to
either NEx or HEx.
Sensitivity: Specificity:
Batch 1:
Normoxic parent cells 71% 88%
Hypoxic parent cells 58% 89%
Normoxic cells with NEx 83% 96%
Normoxic cells with HEx 95% 99%
Batch 2:
Normoxic parent cells 88% 90%
Hypoxic parent cells 88% 96%
Normoxic cells with NEx 55% 93%
Normoxic cells with HEx 68% 88%
Batch 3:
Normoxic parent cells 75% 86%
Hypoxic parent cells 87% 97%
Normoxic cells with NEx 57% 91%
Normoxic cells with HEx 58% 85%
All batches:
Normoxic parent cells 72% 87%
Hypoxic parent cells 83% 94%
Normoxic cells with NEx 61% 86%
Normoxic cells with HEx 63% 91%
Table 11.3: PC-LDA classification results of Raman spectra recorded from normoxic and hy-
poxic parent cells, and normoxic cells exposed to either NEx or HEx, across each individual
batch and for all batches combined.
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slightly different physiological changes. However, these results also show that the changes in-
duced in normoxic cells upon exposure to exosomes is somewhat independent on whether those
exosomes were released by either normoxic or hypoxic parent cells. Nonetheless, the major-
ity of peak assignments relate to changes in DNA and nucleic acid content, a trait commonly
observed with cancer cell progression.
Table 11.2 presents the sensitivities and specificities obtained following PC-LDA classifi-
cation for normoxic cells and normoxic cells exposed to either NEx or HEx, across each batch,
and for all batches combined. For NEx, it is possible to separate cells that have been exposed
to NEx compared to those that have not, with greater than 73% accuracy, and despite the dif-
ferences seen across the second PC coefficient for each batch, the results show a good ability to
identify both cell groups, even when all batches are combined. Greater classification accuracies
are obtained for cells exposed to HEx, with results achieved greater than 80%. Similarly, it is
possible to identify cells when spectra recorded across all batches are combined for PC-LDA
classification.
By combining all of the data recorded across this study, it is possible to apply PC-LDA
for whole group classification. Figure 11.7 shows the LDA scatter plot obtained, with good
separation observed across normoxic and hypoxic parent cells based on LD2. Hypoxic cells
can be separated from normoxic cells that are co-cultured with either NEx or HEx based on
LD1. Interestingly, there is a significant amount of overlap between cells exposed to either NEx
or HEx, which reinforces the results shown in Figure 11.6, whereby the oxygen conditions of
the cells that exosomes are secreted from has little impact on the biomolecular changes that they
induce in other cells.
Table 11.3 shows the sensitivities and specificities obtained for classification when all four
cell subtypes are combined. The results presented here vary from batch to batch, with sensitivity
values ranging from 55-95%. Nonetheless, specificity values remained above 86%.
11.4 Summary
This study consists of two main experiments, with the first focusing on the ability of Raman
micro-spectroscopy and multivariate statistical algorithms to classify between TNBC cells that
are growing in normal oxygen conditions compared to those growing in hypoxia, and the second
aims to identify any differences that are induced in cells upon exposure to exosomes obtained
from either normoxic or hypoxic cells. Clinically, TNBC is recognised as an innately hypoxic
cancer type, and the ability to identify the presence of hypoxia has significant implications for
the patient involved. The results presented here show that consistent biomolecular changes
occur within TNBC cells when they are growing in hypoxia, as shown in the PC coefficients
presented for all three batches in Figure 11.2. Additionally, most of these changes relate to
DNA content, nucleic acids, and lipids, which is in agreement with previous publications that
link hypoxic cell growth with changes in lipid content. (230)
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The combination of Raman micro-spectroscopy and PC-LDA shows the ability to classify
between normoxic and hypoxic cells that are prepared with the ThinPrep method. Clinically,
hypoxic tumour cells can become radiation and chemotherapy resistant, requiring specific treat-
ment plans in order to improve patient survival rates. (210; 219) However, current diagnostic
modalities do not always provide reliable or reproducible detection of hypoxic regions. There-
fore, it may be possible to integrate Raman micro-spectroscopy into current clinical protocols
for the analysis of FNA cytology samples, in order to identify patients harbouring hypoxic
tumours, such that alternative treatment plans can be implemented to target these cells. Ad-
ditionally, it may be possible to include Raman based fiberoptic probes, via endoscopes or
hypodermic needles, into a surgical procedure to assist in the identification of hypoxic tumour
regions. (231; 232)
Focusing on the results presented in the second study, it has been shown that exosomes
can induce biomolecular changes within cells growing in normoxic conditions. These changes
are independent of the source of the exosomes, i.e. the same changes are induced for NEx
and HEx. However, the peak differences observed in Figure 11.6 show that the biomolecular
changes are dependent upon the cell batch that the exosomes are isolated from. In order to
fully understand the reasoning behind this, further analysis of the exosomal content across each
batch is required; such analyses could form part of a future study involving the application of
mass spectrometry or SERS (surface enhanced Raman spectroscopy) to investigate if different
batches of cells produce exosomes containing different levels of proteins, mRNA, or miRNA,
which might be responsible for the communication of different signals with recipient cells.
Despite these inconsistencies, this study has shown that exposing cells to exosomes results in
a change in cellular biomolecular composition. Further research is required to determine the
impact of exosomes released by cancerous cells on neighbouring healthy cells, and whether this
can result in the spreading of cancerous tumours.
PC-LDA based classification of normoxic cells and cells exposed to either NEx or HEx
shows a good ability to identify both cell groups. This is an interesting result, as despite the
biomolecular differences seen across the second PC coefficient, the combination of PCA and
LDA can separate both groups, even when all three batches are combined. With further research,
this combination of Raman micro-spectroscopy and PC-LDA could provide the clinician with
information on the presence of cancer cells within a tumour if an FNA cytology sample shows
the presence of healthy cells that have been exposed to cancerous exosomes.
Chapter 12
Conclusion
12.1 Summary of thesis contributions
The primary objective of this thesis is for the development of Raman based urine cytology for
bladder cancer detection and surveillance, with a key emphasis on the translation of Raman
micro-spectroscopy into the clinic. This PhD project began with the publication of a detailed
literature review (L.T. Kerr et al., Photon. Lasers Med., 3(3), 193-224, 2014), which identified
a variety of source wavelengths, sample substrates, fixation agents, and cell deposition methods
that have been applied for Raman based urine cytology to date. Therefore, within this thesis, a
range of traditional protocols and consumables have been systematically examined in terms of
their compatibility with Raman micro-spectroscopy. Compatibility of some of these methodolo-
gies with FTIR spectroscopy has also been examined, along with an extension of the approach
in order to detect prostate cancer cells.
The first achievement within this thesis involves the design and building of a confocal Ra-
man micro-spectrometer, as described in Section 3.6.1. In order to design a Raman system, it
is necessary to determine the impact of different source wavelengths on the associated Raman
spectrum, and to choose the optimum laser for this application. Five source wavelengths rang-
ing from 473-830 nm are investigated, showing that NIR lasers result in less sample damage, but
the Raman signal obtained has a significantly lower intensity than that achieved with a source
in the visible wavelength region.
Another important consideration is the compatibility of the sample substrate with the cho-
sen source wavelength, as published in the following paper: L.T. Kerr et al., Anal. Methods,
7(12), 5041-5052, 2015. This thesis compared ten different substrates for Raman cytology in
terms of the associated background signals, cost, the ability to re-use such slides, and their bio-
compatibility. The best results, in terms of the quality of the Raman spectra obtained, along
with the lowest background signals, are shown for Raman-grade CaF2 and aluminium thin film
substrates. However, CaF2 is expensive, particularly for routine applications within the cy-
topathology clinic. Aluminium thin film substrates, whilst cheaper than CaF2, are still more
151
12.1. SUMMARY OF THESIS CONTRIBUTIONS 152
expensive than glass slides, and the thin film surface can be easily damaged or scratched, poten-
tially altering the Raman spectra due to Mie scattering. Glass slides are cheap, readily available
in the clinic, and are biocompatible, making them an ideal substrate for large scale clinical
applications; however, they produce a large background signal within the Raman fingerprint
region. Additionally, this signal varies, in terms of location, shape, and intensity, depending on
the source wavelength.
Following from the conclusion that glass slides are a necessary consumable from a clinical
perspective due to their low cost, three background correction algorithms are investigated within
this thesis for the removal of the glass signal from Raman spectra recorded from cells with a
532 nm laser (as published in L.T. Kerr et al., Chemometr. Intell. Lab., 158, 61-68, 2016).
Results show that the EMSC algorithm is the best choice for the removal of the glass signal in
conjunction with the inherent slowly varying baseline signal. Furthermore, the application of
PCA to spectra corrected using this algorithm shows that the results obtained are independent
of the choice of reference spectrum used. This indicates that the reference spectrum does not
introduce any biasing of PCA based classification.
In order to move Raman micro-spectroscopy a step closer to the clinic, various protocols and
consumables are examined in terms of their impact on Raman cell spectra. In the absence of pa-
tient samples, simulated urine samples are created in order to replicate the stringent conditions
present within the cytopathology clinic (published in L.T. Kerr et al., Anal. Methods, 25(8),
4991-5000, 2016). The use of glass slides, traditional fixation agents, and the ThinPrep cell
deposition method are investigated, along with lengthy exposure to urine, and the application
of red blood cell lysing agents to remove residual blood present from patients suffering with
hematuria. Results show that the combination of the ThinPrep UroCyte method with Raman
micro-spectroscopy provides an ideal platform for the identification of bladder cancer cells. It
has also been shown that these cytology samples can be stained post-Raman acquisition, and
that the cells do not appear to have been photodamaged by the laser, thus indicating that a cy-
topathologist should still be able to perform standard urine cytology diagnostics on the slides if
desired.
The integration of the ThinPrep UroCyte method with CaF2 substrates is investigated, al-
lowing for the integration of this cell preparation technique with FTIR spectroscopy. However,
poorer cell adhesion is observed with CaF2 samples that are prepared in this manner compared
to the use of glass slides; nonetheless, adequate numbers of cells are observed across CaF2 for
vibrational spectroscopic analysis. As a direct comparison between FTIR and Raman micro-
spectroscopies, similar classification results are achieved from both methods for the identifica-
tion of prostate cancer cells within a urine sample that also contains bladder cancer and healthy
prostate epithelium. FTIR is a significantly faster, and easier, technique for the acquisition of
spectra, however, Raman requires less numerical pre-processing due to the lack of complex
resonant Mie scattering artifacts. These results also showed the ability to obtain similar PCA
coefficients from cells recorded on CaF2 and glass substrates following EMSC background sub-
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traction. With further development of this algorithm, and acquisition of larger datasets across
a variety of cell types, it may be possible to use either substrate interchangeably throughout an
experiment, provided a robust calibration tool has been used.
The final component of this thesis focuses on the application of Raman micro-spectroscopy
for the identification of cells growing in hypoxic conditions. Hypoxia is a feature of many forms
of cancer throughout the body, including both the bladder and the prostate. Analysis of breast
cancer cells growing in both normoxia and hypoxia shows that the main biomolecular differ-
ences associated with both oxygen conditions relate to DNA, nucleic acids, and lipid content. A
triplicate experiment, using a combination of Raman micro-spectroscopy and PC-LDA shows
the ability to classify between normoxic and hypoxic cells, which may allow for the applica-
tion of this technique to identify patients requiring more intensive treatment plans. The second
part of this study involves the analysis of cells that are grown in the presence of exosomes
(nano-sized vesicles that have been hypothesized to play a role in cellular communication and
disease transmission), and whilst the results observed are not reproducible across each batch,
biomolecular changes are observed upon exposure to exosomes, indicating that some form of
communication may be taking place. In order to fully understand the role of exosomes in cancer
communication, further experimentation is required, with the inclusion of a larger number of
cancerous and non-cancerous cell lines.
12.2 Clinical translation
When designing a diagnostic device, it is important to acknowledge its place within the market,
whether it is needed by the clinician, and how much value it would have if sold commercially.
Within this section, the potential for the future commercialisation, and clinical translation, of
Raman based urine cytology for bladder cancer surveillance is discussed. In order to bring such
a device to the market, it would be necessary to develop a university spin-out company. The
company should be focused on the following objectives:
• Develop its technologies to final product and approval stage, and apply for technology
patenting,
• Establish a full medical advisory board,
• Conduct clinical trials with a large cohort of patients,
• Apply for regulatory approval (FDA, 510k, CE mark of medical device regulation (Na-
tional Standards Authority of Ireland), 98/79/EC in vitro diagnostic medical device direc-
tive, and S.I. No. 304 of European Communities Regulations 2001),
• Establish corporate identity, brand names, and trademarks.
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Another important consideration is to assess the current technologies available on the mar-
ket, and to determine what advantages Raman based urine cytology can provide. A brief anal-
ysis of the urine cytology market shows that the UroVysion test (Abbott Molecular Inc., USA)
can be used as an aid to identify bladder cancer cells based on the presence of chromosomal
abnormalities. (233) Similarly, the BTA Stat test (Polymedco Inc., USA) can identify specific
antigens associated with bladder cancer. (234) A similar Raman based device is currently avail-
able for cervical cytology (CervAssist, Raman Diagnostics Ltd., Ireland); however, there are
no such devices available for urine cytology. Raman based urine cytology offers three distinct
advantages over these technologies:
• As demonstrated within this thesis, there is no additional sample preparation required;
urine cytology samples prepared using standard clinical protocols and consumables are
compatible with Raman micro-spectroscopy,
• The Raman system can become fully automated (235), allowing for clinical staff to sim-
ply place the cytology slide onto the microscope stage; such a system could potentially
identify cells, record spectra, and apply statistical algorithms for classification,
• This device could potentially offer clinicians a tool to identify patients with early-stage
bladder cancer, which would result in better treatment planning and patient survival rates.
It is believed that there is a pre-existing market for a highly accurate, non-invasive device
for the diagnosis of urothelial carcinoma via urine cytology. The target market for a Raman
based urine cytology device would initially be hospitals and health care systems that currently
spend a large percentage of their annual budget on the surveillance of patients suspected of har-
bouring bladder cancer; these patients are typically aged between 60 and 85 years, and current
cystoscopic surveillance can result in significant anxiety and morbidity for these patients. With
further development, it may become possible to develop a Raman device that is suitable for use
within a general practitioners office, further easing patient anxiety.
On a broader scale, knowledge of medical regulations, the need for adequate clinic trials,
and the patenting process are essential for research groups worldwide who are developing tech-
nologies that are suitable for commercialisation. Scientists and engineers within universities
often strive to make a significant contribution to human knowledge; however, it is important
to remember to connect with businesses, and to aim to translate research from the lab into the
commercial world. In recent years, the gap between university research and industry has nar-
rowed, and with government funded grants being aimed towards research with a large potential
for commercialisation (e.g. Enterprise Partnership Scheme, Ireland), it is imperative that re-
searchers are aware of the selling potential of their work, as having customers who are willing
to invest in your product or ideas is often more significant than the peer review process.
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12.3 Future work
It is expected that the application of Raman based urine cytology for bladder cancer diagnostics
will continue to expand and develop over the next decade, and it is hoped that the investigations
and results presented within this thesis will aid and enhance the work of future researchers in
this area. With more time, this project could have been developed further to include:
• More comprehensive cell line/urine simulation studies, with the inclusion of healthy blad-
der cells, different subtypes/grades of bladder cancer, as well as the presence of other cells
found in a typical urine sample (i.e. urethral, ureter, and kidney cells).
• A clinical study, with urine cytology samples obtained from patients currently undergoing
cystoscopic procedures for bladder cancer detection or surveillance.
• Development of a tool for a fully calibrated Raman micro-spectroscopy system, allowing
for the comparison of spectra recorded across a large time frame, or across different
Raman systems.
• Development of larger training and testing datasets for classification would provide a
more accurate representation of the diagnostic capabilities of Raman micro-spectroscopy.
• Further optimisation of the EMSC background correction algorithm to include a “univer-
sal” Raman reference spectrum that could be used by research groups worldwide, similar
to the Matrigel spectrum applied to FTIR spectra.
• A greater understanding of the biochemistry associated with specific peak assignments;
further work is required to allow for accurate, and reliable, peak assignments to be made
for Raman spectra. Whilst many studies have previously investigated the biochemistry
and physical chemistry involved, there are many instances of where peaks have multiple
assignments in the literature, related to different biomolecules, resulting in great scepti-
cism amongst the research community.
• Further investigations into the impact of cellular morphology on the associated Raman
spectra obtained, and how Mie scattering can impact upon the recorded Raman signal.
• Monitoring of biomolecular changes observed when non-cancerous cells are exposed to
exosomes derived from cancerous cells using Raman micro-spectroscopy.
• Analysis of other cell types growing in normoxia, hypoxia, and anoxia (severe hypoxia);
these results may prove useful for cancer diagnostics, but also for understanding brain
injuries associated with a lack of oxygen.
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